<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="pmc-domain-id">1692</journal-id><journal-id journal-id-type="pmc-domain">nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10140991</article-id><article-id pub-id-type="pmcid-ver">PMC10140991.1</article-id><article-id pub-id-type="pmcaid">10140991</article-id><article-id pub-id-type="pmcaiid">10140991</article-id><article-id pub-id-type="pmid">37111209</article-id><article-id pub-id-type="doi">10.3390/nu15081990</article-id><article-id pub-id-type="publisher-id">nutrients-15-01990</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Nutritional and Lifestyle Therapy for NAFLD in People with HIV</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cinque</surname><given-names initials="F">Felice</given-names></name><xref rid="af1-nutrients-15-01990" ref-type="aff">1</xref><xref rid="af2-nutrients-15-01990" ref-type="aff">2</xref><xref rid="af3-nutrients-15-01990" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8116-9307</contrib-id><name name-style="western"><surname>Cespiati</surname><given-names initials="A">Annalisa</given-names></name><xref rid="af2-nutrients-15-01990" ref-type="aff">2</xref><xref rid="af3-nutrients-15-01990" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6958-927X</contrib-id><name name-style="western"><surname>Lombardi</surname><given-names initials="R">Rosa</given-names></name><xref rid="af2-nutrients-15-01990" ref-type="aff">2</xref><xref rid="af3-nutrients-15-01990" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names initials="G">Giovanni</given-names></name><xref rid="af4-nutrients-15-01990" ref-type="aff">4</xref><xref rid="af5-nutrients-15-01990" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2655-8283</contrib-id><name name-style="western"><surname>Sebastiani</surname><given-names initials="G">Giada</given-names></name><xref rid="af1-nutrients-15-01990" ref-type="aff">1</xref><xref rid="c1-nutrients-15-01990" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Ferri</surname><given-names initials="S">Silvia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-nutrients-15-01990"><label>1</label>Division of Gastroenterology and Hepatology, and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada; <email>felice.cinque@mail.mcgill.ca</email></aff><aff id="af2-nutrients-15-01990"><label>2</label>Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy</aff><aff id="af3-nutrients-15-01990"><label>3</label>Medicine and Metabolic Disease Unit, Fondazione IRCCS C&#224; Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy</aff><aff id="af4-nutrients-15-01990"><label>4</label>Modena HIV Metabolic Clinic, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy</aff><aff id="af5-nutrients-15-01990"><label>5</label>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy</aff><author-notes><corresp id="c1-nutrients-15-01990"><label>*</label>Correspondence: <email>giada.sebastiani@mcgill.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>15</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">434550</issue-id><elocation-id>1990</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>17</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>19</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-14 17:25:29.763"><day>14</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nutrients-15-01990.pdf"/><abstract><p>HIV infection and nonalcoholic fatty liver disease (NAFLD) are two major epidemics affecting millions of people worldwide. As people with HIV (PWH) age, there is an increased prevalence of metabolic comorbidities, along with unique HIV factors, such as HIV chronic inflammation and life-long exposure to antiretroviral therapy, which leads to a high prevalence of NAFLD. An unhealthy lifestyle, with a high dietary intake of refined carbohydrates, saturated fatty acids, fructose added beverages, and processed red meat, as well as physical inactivity, are known to trigger and promote the progression of NAFLD to nonalcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma. Furthermore, with no currently approved pharmacotherapy and a lack of clinical trials that are inclusive of HIV, nutritional and lifestyle approaches still represent the most recommended treatments for PWH with NAFLD. While sharing common features with the general population, NAFLD in PWH displays its own peculiarities that may also reflect different impacts of nutrition and exercise on its onset and treatment. Therefore, in this narrative review, we aimed to explore the role of nutrients in the development of NAFLD in PWH. In addition, we discussed the nutritional and lifestyle approaches to managing NAFLD in the setting of HIV, with insights into the role of gut microbiota and lean NAFLD.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>fatty liver</kwd><kwd>MAFLD</kwd><kwd>NAFLD therapy</kwd><kwd>nutrients</kwd><kwd>lifestyle</kwd><kwd>diet</kwd><kwd>exercise</kwd><kwd>food insecurity</kwd><kwd>lean NASH</kwd><kwd>microbiota</kwd></kwd-group><funding-group><award-group><funding-source>Fonds de Recherche du Quebec&#8212;Sante (FRQS)</funding-source><award-id>#296306</award-id></award-group><funding-statement>The study was not funded. G.S. is supported by a Senior Salary Award from Fonds de Recherche du Quebec&#8212;Sante (FRQS) (#296306).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nutrients-15-01990"><title>1. Introduction</title><p>The global human immunodeficiency virus (HIV) epidemic is still a major health concern, with 38.4 million people having HIV (PWH) in 2021, according to the World Health Organization [<xref rid="B1-nutrients-15-01990" ref-type="bibr">1</xref>]. Tremendous scientific advances have been made, and luckily, the revolution of combined antiretroviral therapy (cART) has turned HIV infection from a fatal disease into a chronic yet treatable condition [<xref rid="B2-nutrients-15-01990" ref-type="bibr">2</xref>]. Despite its narrowing, we still witness a gap in the life expectancy between PWH and the general population [<xref rid="B3-nutrients-15-01990" ref-type="bibr">3</xref>]. Acquired immunodeficiency syndrome (AIDS) still accounts for the highest number of deaths, especially in developing countries, while the burden of non-AIDS comorbidities is increasingly growing over the time [<xref rid="B4-nutrients-15-01990" ref-type="bibr">4</xref>]. In fact, aging with HIV also leads to a higher mortality related to non-communicable diseases, mainly cancer, cardiovascular disease, and liver disease [<xref rid="B5-nutrients-15-01990" ref-type="bibr">5</xref>]. Of note is that PWH experience a higher and anticipated prevalence of noninfectious comorbidities compared to the uninfected population, making the management of non-AIDS comorbidities a priority [<xref rid="B6-nutrients-15-01990" ref-type="bibr">6</xref>]. Furthermore, liver-related diseases in PWH have risen over the years, becoming one of the most common comorbidities and among the leading causes of non-AIDS-related deaths [<xref rid="B7-nutrients-15-01990" ref-type="bibr">7</xref>]. In the setting of HIV, a variety of factors, including coinfection with hepatitis C (HCV) and hepatitis B (HBV) viruses, alcohol, the hepatotoxicity of cART, and nonalcoholic fatty liver disease (NAFLD), contribute to liver injury [<xref rid="B8-nutrients-15-01990" ref-type="bibr">8</xref>]. Notably, NAFLD is currently the leading cause of liver disease worldwide and its burden keeps increasing over time [<xref rid="B9-nutrients-15-01990" ref-type="bibr">9</xref>]. NAFLD is defined by the accumulation of fat in more than 5% of hepatocytes, detected either by imaging or histology, with no evidence of other causes of underlying liver diseases such as alcohol abuse, viral hepatitis, or genetic disorders [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>]. The spectrum of this condition is wide, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), where inflammation and hepatocyte injury coexist, possibly evolving to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [<xref rid="B11-nutrients-15-01990" ref-type="bibr">11</xref>]. NAFLD affects approximately 25&#8211;30% of the global population, with a much higher prevalence in high-risk groups such as patients with type 2 diabetes mellitus or obesity, where it rises to 50% and 90%, respectively [<xref rid="B12-nutrients-15-01990" ref-type="bibr">12</xref>]. Given the high prevalence of NAFLD in the context of metabolic syndrome, and considering that individuals with hepatic steatosis show a high risk of cardiovascular complications and mortality, a new definition for metabolic-dysfunction-associated fatty liver disease (MAFLD) has been proposed [<xref rid="B13-nutrients-15-01990" ref-type="bibr">13</xref>,<xref rid="B14-nutrients-15-01990" ref-type="bibr">14</xref>]. MAFLD is diagnosed by the presence of fatty liver with one of the following metabolic dysfunctions: overweight, obesity, the presence of type 2 diabetes, or a normal weight with evidence of metabolic dysregulation [<xref rid="B14-nutrients-15-01990" ref-type="bibr">14</xref>]. This term seems to better account for the strong and bidirectional association between NAFLD and metabolic syndrome [<xref rid="B15-nutrients-15-01990" ref-type="bibr">15</xref>]. Like obesity and diabetes, a growing body of evidence shows that HIV is a risk factor for hepatic steatosis. Indeed, the prevalence of NAFLD in PWH ranges from 13 to 65% [<xref rid="B16-nutrients-15-01990" ref-type="bibr">16</xref>], with two meta-analyses based on imaging studies reporting that around 35% of HIV mono-infected patients had NAFLD [<xref rid="B17-nutrients-15-01990" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-15-01990" ref-type="bibr">18</xref>]. Notably, NAFLD is not only more common, but also seems to be more severe in the setting of HIV [<xref rid="B19-nutrients-15-01990" ref-type="bibr">19</xref>], with a pooled prevalence of biopsy-proven NASH and significant liver fibrosis of up to 49% and 23%, respectively [<xref rid="B18-nutrients-15-01990" ref-type="bibr">18</xref>]. Furthermore, NAFLD pathogenesis is likely more complex within PWH compared to the general population. First, classic metabolic risk factors, such as type 2 diabetes, dyslipidemia, and hypertension, are more frequent in the context of HIV [<xref rid="B20-nutrients-15-01990" ref-type="bibr">20</xref>]. Moreover, unique determinants, including HIV chronic inflammation and a lifelong exposure to cART, especially old nucleoside reverse transcriptase inhibitors (NRTIs) and ritonavir-boosted protease inhibitors (PIs), also contribute to the causative pathway towards NAFLD [<xref rid="B16-nutrients-15-01990" ref-type="bibr">16</xref>]. Among PWH, the recently introduced definition of MAFLD seems very promising, because unlike NAFLD, it does not exclude patients with alcohol abuse and an HBV or HCV coinfection, which are conditions commonly associated with HIV. In addition, the literature highlights the pivotal roles of nutrition and lifestyle in both the pathogenesis and management of NAFLD. First of all, an unhealthy diet rich in polyunsaturated fat, sugar-sweetened beverages, red and processed meat, and an excessive carbohydrates intake, along with a sedentary lifestyle and a lack of physical activity, are known risk factors for NAFLD [<xref rid="B21-nutrients-15-01990" ref-type="bibr">21</xref>]. Moreover, although this is being attempted in many randomized clinical trials (RCT), there are currently no NASH-targeted therapies that have been approved by the Food and Drug Administration (FDA), with lifestyle intervention being the cornerstone and only available treatment [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>]. While strong evidence is available for the uninfected population, studies tailored to the HIV population are much fewer, and the roles of macronutrients and lifestyle habits in NAFLD in PWH are still unclear. Therefore, the aim of the current narrative review is to provide insight into the available literature on the roles of nutrition and lifestyle in the pathogenesis and treatment of NAFLD in PWH.</p></sec><sec sec-type="methods" id="sec2-nutrients-15-01990"><title>2. Methods</title><p>We performed a comprehensive literature search for this narrative review by screening peer-reviewed articles regarding nutrition and lifestyle in the setting of NAFLD in PWH, using the electronic database PubMed. Studies from 1996&#8212;when cART was introduced&#8212;to February 2023 and only English papers were included. The following search terms were matched to &#8220;Non-alcoholic fatty liver disease&#8221; or &#8220;Non-alcoholic steatohepatitis&#8221; and &#8220;&#8220;HIV&#8221; or &#8220;HIV infection&#8221;, or related acronyms were used: &#8220;nutrition&#8221;, &#8220;diet&#8221;, &#8220;carbohydrates&#8221;, &#8220;lipids&#8221;, &#8220;fatty acids&#8221;, &#8220;proteins&#8221;, &#8220;vitamins&#8221;, &#8220;alcohol&#8221;, &#8220;coffee&#8221;, &#8220;cannabinoids&#8221;, &#8220;food insecurity&#8221;, &#8220;lifestyle&#8221;, &#8220;exercise&#8221;, &#8220;physical activity&#8221;, &#8220;lean NAFLD&#8221;, and &#8220;gut microbiota&#8221;. We included experimental and observational studies, clinical trials, systematic reviews, meta-analyses, editorials, and commentaries reporting data about nutritional and lifestyle approaches to NAFLD in PWH. We excluded studies that did not meet the selection criteria, meeting abstracts and duplicate publications.</p></sec><sec id="sec3-nutrients-15-01990"><title>3. The Role of Nutrients in NAFLD in People with HIV</title><sec id="sec3dot1-nutrients-15-01990"><title>3.1. Nutrients in NAFLD </title><sec id="sec3dot1dot1-nutrients-15-01990"><title>3.1.1. Macronutrients</title><p>Macronutrients have an impact on the multifactorial pathogenesis of NAFLD, being able to alter hepatic fat storage and liver inflammation [<xref rid="B23-nutrients-15-01990" ref-type="bibr">23</xref>]. In this section, we will discuss the roles of carbohydrates, lipids, proteins, alcohol, and coffee in NAFLD.</p><sec><title>Carbohydrates</title><p>Overfeeding with refined carbohydrates leads to an intrahepatic triglycerides accumulation, supporting the role of excessive carbohydrates consumption in hepatic de novo lipogenesis [<xref rid="B24-nutrients-15-01990" ref-type="bibr">24</xref>]. Special attention should be paid to soft drinks, which are beverages made with great amounts of high fructose (corn syrup) or sucrose, having been shown to be a risk factor for NAFLD independently of metabolic syndrome [<xref rid="B25-nutrients-15-01990" ref-type="bibr">25</xref>,<xref rid="B26-nutrients-15-01990" ref-type="bibr">26</xref>]. In contrast, the consumption of whole grains, oatmeal, and quinoa, which are very rich in vitamins, minerals, and fibers, shows a strong inverse correlation with NAFLD [<xref rid="B27-nutrients-15-01990" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-15-01990" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-15-01990" ref-type="bibr">29</xref>] and improves insulin sensitivity, with proven benefits for metabolic disease [<xref rid="B30-nutrients-15-01990" ref-type="bibr">30</xref>,<xref rid="B31-nutrients-15-01990" ref-type="bibr">31</xref>].</p></sec><sec><title>Lipids</title><p>As for carbohydrates, the type of fat being ingested has a great impact on the NAFLD pathophysiology, more so than the total amount consumed [<xref rid="B32-nutrients-15-01990" ref-type="bibr">32</xref>]. On the one hand, the dietary abuse of saturated long-chain fatty acids (FAs), which are commonly found in animal products, promotes hepatic oxidative stress and the impairment of insulin signaling, leading to fatty liver, insulin resistance, and NASH [<xref rid="B23-nutrients-15-01990" ref-type="bibr">23</xref>]. On the other hand, plant-based food, especially nuts, olive oil, and avocados, are good sources of dietary monounsaturated FAs and polyunsaturated FAs, which are both associated with the amelioration of hepatic steatosis and liver inflammation [<xref rid="B33-nutrients-15-01990" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-15-01990" ref-type="bibr">34</xref>]. In addition, among polyunsaturated FAs, there is evidence of a more harmful effect of <italic toggle="yes">n</italic>-6 FA (linoleic acid) than <italic toggle="yes">n</italic>-3 FA (alpha-linolenic acid) on the accumulation of intrahepatic triglycerides, with a higher intake of <italic toggle="yes">n</italic>-6 FAs and an increased <italic toggle="yes">n</italic>-6/<italic toggle="yes">n</italic>-3 ratio in NASH patients compared to controls [<xref rid="B35-nutrients-15-01990" ref-type="bibr">35</xref>].</p></sec><sec><title>Proteins</title><p>Finally, there is conflicting evidence regarding the association between protein consumption and NAFLD. Although a high protein intake seems to reduce intrahepatic fat, it may also negatively impact insulin sensitivity [<xref rid="B23-nutrients-15-01990" ref-type="bibr">23</xref>]. Again, the source of the protein is critical. In fact, a moderately high protein intake from white meats and legumes seems to be beneficial, lowering the hepatic fat content and markers of liver damage [<xref rid="B36-nutrients-15-01990" ref-type="bibr">36</xref>]. Conversely, eating a large amount of red and processed meat is associated with NAFLD and insulin resistance, independently of saturated fat intake [<xref rid="B37-nutrients-15-01990" ref-type="bibr">37</xref>,<xref rid="B38-nutrients-15-01990" ref-type="bibr">38</xref>].</p></sec><sec><title>Alcohol</title><p>Another macronutrient relevant to NAFLD is alcohol. By definition, the alcohol intake in NAFLD is either absent or low to mild (less than 20 g/day for women and less than 30 g/day for men) [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>], but its effects on this population are still debated. Among NAFLD patients, while some old retrospective studies pointing to a favorable association between moderate alcohol use and less severe histological liver damage [<xref rid="B39-nutrients-15-01990" ref-type="bibr">39</xref>,<xref rid="B40-nutrients-15-01990" ref-type="bibr">40</xref>], more recent research has shown that even mild drinking might lead to liver fibrosis progression [<xref rid="B41-nutrients-15-01990" ref-type="bibr">41</xref>,<xref rid="B42-nutrients-15-01990" ref-type="bibr">42</xref>]. Furthermore, in a prospective cohort of NASH patients, alcohol consumption was identified as the major risk factor for HCC [<xref rid="B43-nutrients-15-01990" ref-type="bibr">43</xref>]. Evidence from longitudinal cohorts is accumulating, with a recent systematic review concluding that, in patients with NAFLD, any amount of alcohol intake, even at low concentrations, seems to be harmful to the liver&#8217;s health [<xref rid="B44-nutrients-15-01990" ref-type="bibr">44</xref>]. As for cardiovascular outcomes, limited data are available about the effects of small alcohol consumption on the cardiovascular risk in NAFLD. In fact, one study has shown a protective effect of moderate alcohol intake on cardiovascular outcomes [<xref rid="B45-nutrients-15-01990" ref-type="bibr">45</xref>], while others have found no difference [<xref rid="B41-nutrients-15-01990" ref-type="bibr">41</xref>,<xref rid="B46-nutrients-15-01990" ref-type="bibr">46</xref>]. Finally, aligned with the latest evidence, the most recent American Association for the Study of Liver Diseases (AASLD) guidance states that alcohol abstinence may lower the risk of fibrosis progression and hepatic and extrahepatic cancers in patients with NAFLD [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>].</p></sec><sec><title>Coffee</title><p>Coffee is the second most consumed beverage in the world after water [<xref rid="B47-nutrients-15-01990" ref-type="bibr">47</xref>]. Coffee contains several compounds with known antioxidant effects, such as caffeine, chlorogenic acid, cafestol, kahweol, trigenolline, and tocopherols. These antioxidants are known to improve a number of liver conditions, ranging from fibrosis to cirrhosis and HCC [<xref rid="B48-nutrients-15-01990" ref-type="bibr">48</xref>]. In the setting of NAFLD, a recent meta-analysis of five cross-sectional studies showed a positive correlation between a high coffee consumption and a lower liver fibrosis, although no clear agreement was reached on the required dose [<xref rid="B49-nutrients-15-01990" ref-type="bibr">49</xref>]. However, not all forms and methods of coffee preparation show the same beneficial effects on NAFLD. Anty et al. reported that regular filtered coffee intake was associated with a lower liver fibrosis, while espresso was not [<xref rid="B50-nutrients-15-01990" ref-type="bibr">50</xref>]. In fact, antioxidant compounds seem to be better preserved in filtered coffee than in espresso [<xref rid="B51-nutrients-15-01990" ref-type="bibr">51</xref>]. In addition, espresso, as well as Turkish or Scandinavian boiled coffee, are often consumed with refined sugar, which is harmful for NAFLD, as it is highly rich in fructose [<xref rid="B49-nutrients-15-01990" ref-type="bibr">49</xref>]. Similarly, consuming a latte or cappuccino, in which the coffee is added to milk, which is rich in saturated fat, can also be detrimental [<xref rid="B52-nutrients-15-01990" ref-type="bibr">52</xref>]. Finally, in a recent RCT evaluating the administration of coffee components to treat NAFLD in diabetic patients, a supplementation with caffeine and/or chlorogenic acid did not improve hepatic steatosis or liver stiffness [<xref rid="B53-nutrients-15-01990" ref-type="bibr">53</xref>].</p></sec></sec><sec id="sec3dot1dot2-nutrients-15-01990"><title>3.1.2. Micronutrients</title><p>In addition to macronutrients, micronutrients also play a role in the complex pathogenesis of fatty liver; thus, expert opinions recommend the consumption of micronutrients with proven antioxidant and anti-inflammatory effects to prevent and treat NAFLD [<xref rid="B54-nutrients-15-01990" ref-type="bibr">54</xref>].</p><sec><title>Vitamin E</title><p>Vitamin E, which similarly to polyunsaturated FAs can be found in olive oil, nuts, and green vegetables, is a lipophilic antioxidant engaged in cellular signaling and gene expression regulation, showing anti-inflammatory and anti-apoptotic properties [<xref rid="B55-nutrients-15-01990" ref-type="bibr">55</xref>]. In total, two RCTs, the PIVENS trial in adults with NASH [<xref rid="B56-nutrients-15-01990" ref-type="bibr">56</xref>] and the PIVOT trial in the pediatric population [<xref rid="B57-nutrients-15-01990" ref-type="bibr">57</xref>], showed that a vitamin E supplementation resulted in a significant resolution of NASH compared to a placebo. Although these trials were not able to demonstrate that a vitamin E supplementation reduces liver fibrosis, a recent retrospective study on 236 individuals with severe liver fibrosis and NASH found a positive correlation between vitamin E consumption and both a longer transplant-free survival and reduced rates of hepatic decompensation [<xref rid="B58-nutrients-15-01990" ref-type="bibr">58</xref>]. In line with these promising results, the administration of vitamin E is acknowledged in both the AASLD and the European Association for the Study of the Liver guidelines as a short-term therapeutic option for non-diabetic NASH patients with liver fibrosis or with a high necroinflammation and a risk of fast histologic progression [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>].</p></sec><sec><title>Vitamin D</title><p>Vitamin D may play a role in NAFLD development, as its deficiency is able to activate Toll-like receptors, induce oxidative stress, and finally, increase liver inflammation [<xref rid="B59-nutrients-15-01990" ref-type="bibr">59</xref>]. In mouse models, low serum vitamin D promotes the progression of simple steatosis to NASH [<xref rid="B60-nutrients-15-01990" ref-type="bibr">60</xref>], while vitamin D receptor ligands prevent hepatic stellate cells activation and liver fibrosis [<xref rid="B61-nutrients-15-01990" ref-type="bibr">61</xref>]. Consistently, human studies have shown that having decreased serum vitamin D concentrations is common among NAFLD patients [<xref rid="B62-nutrients-15-01990" ref-type="bibr">62</xref>], with a recent meta-analysis reporting an inverse correlation between vitamin D serum levels and an increased risk of NAFLD [<xref rid="B63-nutrients-15-01990" ref-type="bibr">63</xref>]. While several preclinical studies have shown a beneficial role for vitamin D in fatty liver [<xref rid="B64-nutrients-15-01990" ref-type="bibr">64</xref>], so far, interventional human studies have failed to demonstrate that a vitamin D administration improves the histologic severity of NAFLD [<xref rid="B65-nutrients-15-01990" ref-type="bibr">65</xref>], although it is significantly associated with a reduced fasting glucose and insulin resistance [<xref rid="B66-nutrients-15-01990" ref-type="bibr">66</xref>]. This may be explained by the limited number of trials examining the role of vitamin D replacement in NAFLD and by the variability of the levels and methodologies used to detect serum vitamin D levels [<xref rid="B67-nutrients-15-01990" ref-type="bibr">67</xref>].</p></sec><sec><title>Polyphenols</title><p>Polyphenols, commonly found in fruits, vegetables, olive oil, coffee, red wine, and dark chocolate, might be involved in the pathophysiology of NAFLD by preventing oxidative stress and inflammation, promoting FA beta-oxidation, and modulating insulin resistance [<xref rid="B68-nutrients-15-01990" ref-type="bibr">68</xref>]. Several clinical trials have revealed intriguing early findings on the safety and efficacy of polyphenols administration for the treatment of NAFLD. Specifically, a supplementation with curcumin [<xref rid="B69-nutrients-15-01990" ref-type="bibr">69</xref>,<xref rid="B70-nutrients-15-01990" ref-type="bibr">70</xref>], Silymarin [<xref rid="B71-nutrients-15-01990" ref-type="bibr">71</xref>], or hesperidin [<xref rid="B72-nutrients-15-01990" ref-type="bibr">72</xref>] seems to improve the different features of NAFLD with a good safety profile, whereas the available evidence on resveratrol is conflicting [<xref rid="B73-nutrients-15-01990" ref-type="bibr">73</xref>]. However, despite the encouraging preliminary data, further well-designed RCTs are warranted to address the use of polyphenols in NAFLD management.</p></sec><sec><title>Cannabinoid</title><p>Another natural plant-based compound whose role is being studied in chronic liver diseases is cannabinoid. Evidence from pre-clinical models shows that a cannabinoid receptors 1 overexpression leads to de novo hepatic lipogenesis, along with an intrahepatic monounsaturated FAs accumulation. Oppositely, a cannabinoid receptors 1 blockage inhibits insulin resistance and hepatic steatosis [<xref rid="B74-nutrients-15-01990" ref-type="bibr">74</xref>]. Similarly, cannabinoid receptors 2 are known to contribute both directly&#8212;by inducing liver inflammation&#8212;and indirectly&#8212;by increasing the hepatic cannabinoid receptors 1 expression&#8212;to NAFLD, NASH, and liver fibrosis [<xref rid="B74-nutrients-15-01990" ref-type="bibr">74</xref>]. Aligned with these findings, human studies have confirmed an inverse association of cannabis consumption with NAFLD [<xref rid="B75-nutrients-15-01990" ref-type="bibr">75</xref>,<xref rid="B76-nutrients-15-01990" ref-type="bibr">76</xref>], as well as with its metabolic risk factors, namely obesity [<xref rid="B77-nutrients-15-01990" ref-type="bibr">77</xref>], diabetes [<xref rid="B78-nutrients-15-01990" ref-type="bibr">78</xref>], and metabolic syndrome [<xref rid="B79-nutrients-15-01990" ref-type="bibr">79</xref>]. However, although several preclinical studies have suggested cannabinoids as a potential treatment for NAFLD, so far, no RCTs have been able to demonstrate their effective role in reducing hepatic steatosis or fibrosis [<xref rid="B80-nutrients-15-01990" ref-type="bibr">80</xref>].</p></sec></sec></sec><sec id="sec3dot2-nutrients-15-01990"><title>3.2. Nutrients in NAFLD in People with HIV</title><sec id="sec3dot2dot1-nutrients-15-01990"><title>3.2.1. Macronutrients</title><p>Limited data are available on the role of nutrients in the setting of NAFLD in PWH, with no studies specifically addressing the roles of carbohydrates and proteins. Studies evaluating the impact of lipids, alcohol, and coffee on hepatic steatosis and/or liver fibrosis in PWH are shown in <xref rid="nutrients-15-01990-t001" ref-type="table">Table 1</xref>.</p><sec><title>Lipids</title><p>As for the uninfected population, fat consumption plays a role in NAFLD pathogenesis in PWH. An altered hepatic FA composition was associated with NAFLD in PWH in a Canadian study comparing 20 PWH with NAFLD to 21 NAFLD uninfected subjects and 7 healthy controls [<xref rid="B81-nutrients-15-01990" ref-type="bibr">81</xref>]. The PWH with NAFLD showed a higher hepatic <italic toggle="yes">n</italic>-6/<italic toggle="yes">n</italic>-3 ratio, with a lower <italic toggle="yes">n</italic>-3 erythrocytes polyunsaturated FAs concentration (which reflects a lower polyunsaturated FAs dietary intake), and lower levels of the indirect markers of enzymatic FA desaturation and elongation compared to the controls. Interestingly, the altered FA composition was more impaired in the PWH with NAFLD compared to the uninfected NAFLD population [<xref rid="B81-nutrients-15-01990" ref-type="bibr">81</xref>]. Based on these results, FA imbalances, which are known to be major drivers of NAFLD, seem even more prominent in NAFLD in PWH. Indeed, the association between lipid imbalances and HIV infection is well established, with a high prevalence of dyslipidemia in PWH [<xref rid="B90-nutrients-15-01990" ref-type="bibr">90</xref>]. This might be caused both by HIV chronic inflammation, since lipid alterations were already reported before the use of cART [<xref rid="B91-nutrients-15-01990" ref-type="bibr">91</xref>], and a lifelong exposure to cART, especially to old PIs boosted with ritonavir and certain NRTIs [<xref rid="B92-nutrients-15-01990" ref-type="bibr">92</xref>]. Another recent study evaluated the changes in the plasma FAs profiles between 31 HIV-positive and 22 HIV-negative subjects with NAFLD [<xref rid="B82-nutrients-15-01990" ref-type="bibr">82</xref>]. Although they didn&#8217;t report any significant differences in the overall FA compositions, the authors showed higher concentrations of &#945;-Linolenic, trans-palmitoleic, and behenic acids, all of which have been previously associated with metabolic alterations, in the PWH compared to the uninfected population. Additionally, the PWH had a lower activity of the elongases ELOVL1 and ELOVL6 (enzymes regulating the elongation of FAs), which have previously been found to be reduced in other chronic inflammatory diseases such as psoriasis. Interestingly, despite showing a similar hepatic steatosis severity, the PWH were significantly younger, with a lower body mass index (BMI) and a lower prevalence of metabolic syndrome compared to the controls [<xref rid="B82-nutrients-15-01990" ref-type="bibr">82</xref>], suggesting that an FA imbalance might occur earlier and at a lower BMI in the context of NAFLD in PWH. Larger studies assessing the differences in the FA compositions between HIV-positive and HIV-negative NAFLD patients are required. In a well-characterized cohort of 451 HIV mono-infected patients in Brazil, De Almeida et al. showed that the odds of developing NAFLD were 91% higher in the subjects with a high usual fat consumption compared to those with a lower fat intake [<xref rid="B83-nutrients-15-01990" ref-type="bibr">83</xref>]. As expected, a moderate monounsaturated FAs ingestion was linked to lower odds of liver steatosis and fibrosis, and a moderate n-6 polyunsaturated FAs intake was associated with lower odds of NAFLD. Surprisingly, as opposed to the evidence for the general population, no association between the total saturated fat consumption and NAFLD was found. Instead, a moderate intake of saturated FA seemed to be protective against NAFLD, with lower odds of liver fibrosis compared to a lower saturated FA consumption. Moreover, unexpectedly, the odds of liver fibrosis appeared to increase with a higher <italic toggle="yes">n</italic>-6 polyunsaturated FAs intake [<xref rid="B83-nutrients-15-01990" ref-type="bibr">83</xref>]. These results might reflect the methodology of the study, which relied on the 24 h dietary recall method, which is a self-assessment tool performed only on two non-consecutive days, to define the habitual fat intake. In addition, evidence about the role of polyunsaturated FAs in the liver health of PWH is mixed. A first study comparing 216 PWH with 1604 uninfected subjects found that polyunsaturated FAs intake, <italic toggle="yes">n</italic>-6 polyunsaturated FAs, and the ratio of polyunsaturated FAs to saturated FAs were associated with liver damage, which was measured by transaminases levels [<xref rid="B93-nutrients-15-01990" ref-type="bibr">93</xref>]. Conversely, in a case-control study comparing 305 PWH to 301 healthy controls, Stonehouse and colleagues showed an inverse correlation between the plasma total omega-6 polyunsaturated FAs concentrations and liver enzymes in both HIV-infected and HIV-uninfected subjects [<xref rid="B94-nutrients-15-01990" ref-type="bibr">94</xref>]. Surprisingly, De Almeida et al. found a direct association between a higher usual intake of total carbohydrates and lower odds of NAFLD [<xref rid="B83-nutrients-15-01990" ref-type="bibr">83</xref>]. This finding is in disagreement with the large body of evidence for the uninfected population showing that high intakes of dietary sugar increase the risk of NAFLD [<xref rid="B24-nutrients-15-01990" ref-type="bibr">24</xref>]. However, although a description of the subtypes of carbohydrates ingested was not available, the authors suggested that the cohort had a high dietary intake of beans and cereals, which provide fiber and polysaccharides instead of the more harmful fructose [<xref rid="B83-nutrients-15-01990" ref-type="bibr">83</xref>]. Overall, based on the strong evidence for the general NAFLD population [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>], PWH with NAFLD should avoid a high intake of refined carbohydrates and fructose-supplemented beverages. Finally, De Almeida and colleagues revealed that a moderate consumption of dietary fibers was associated with lower odds of NAFLD, which is in line with the evidence for the general population [<xref rid="B27-nutrients-15-01990" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-15-01990" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-15-01990" ref-type="bibr">29</xref>]. Focusing on omega 3 supplementation, although no study has specifically addressed NAFLD in PWH, in a meta-analysis of nine RCTs performed on PWH with hypertriglyceridemia, a diet supplementation with polyunsaturated FAs significantly improved triglycerides and high-density lipoprotein cholesterol, with a favorable safety profile [<xref rid="B95-nutrients-15-01990" ref-type="bibr">95</xref>]. Additionally, an omega-3 administration seemed to be also able to decrease systemic HIV-related inflammation, as measured by serum C-reactive protein [<xref rid="B96-nutrients-15-01990" ref-type="bibr">96</xref>]. Therefore, a dietary supplementation with omega-3 polyunsaturated FAs is recommended for PWH with hypertriglyceridemia, although further studies are warranted to evaluate its impact on NAFLD. Finally, we feel that the evidence on macronutrients for NAFLD in PWH, especially on carbohydrates and lipids, is scarce and conflicting, calling for future research.</p></sec><sec><title>Alcohol</title><p>Alcohol consumption is common among PWH and its abuse is known to be associated with unfavorable clinical outcomes [<xref rid="B97-nutrients-15-01990" ref-type="bibr">97</xref>]. In fact, in the setting of HIV, drinking alcohol may lead to a low medication adherence, as well as to poor HIV control, with decreased CD4+ cells and elevated HIV-RNA levels, regardless of cART use [<xref rid="B98-nutrients-15-01990" ref-type="bibr">98</xref>,<xref rid="B99-nutrients-15-01990" ref-type="bibr">99</xref>]. In addition, by suppressing the innate and acquired immune system and causing a disruption in the gut barrier, alcohol intake seems to increase the susceptibility to HIV infection and accelerate the disease&#8217;s progression [<xref rid="B100-nutrients-15-01990" ref-type="bibr">100</xref>,<xref rid="B101-nutrients-15-01990" ref-type="bibr">101</xref>]. As for the liver&#8217;s health, alcohol metabolism may potentiate the effects of HIV-induced hepatotoxicity, because alcohol and HIV infection act on common targets to cause liver damage [<xref rid="B102-nutrients-15-01990" ref-type="bibr">102</xref>]. Ganesan et al., in a preclinical study, demonstrated that ethanol metabolism promotes an accumulation of HIV components in hepatocytes, causing oxidative stress and apoptotic cell death [<xref rid="B103-nutrients-15-01990" ref-type="bibr">103</xref>]. The underlying mechanism is potentially related to acetaldehyde-induced lysosomes damage, which enhances this HIV-induced hepatotoxicity [<xref rid="B104-nutrients-15-01990" ref-type="bibr">104</xref>]. Of note is that the removal of these HIV-infected apoptotic bodies by nonparenchymal liver cells triggers their activation, contributing to liver disease progression [<xref rid="B103-nutrients-15-01990" ref-type="bibr">103</xref>]. Our literature search shows a lack of clinical studies evaluating the impact of light to moderate alcohol intake on the liver outcomes among PWH, especially in the setting of NAFLD. In a large prospective cohort of 686 HIV/HCV-coinfected women, with a median follow-up of 10 years, light (1&#8211;3 drinks/week) or moderate (4&#8211;7 drinks/week) alcohol consumption was not associated with liver fibrosis progression, whereas drinking more than 14 drinks per week showed increased rates of fibrosis progression [<xref rid="B84-nutrients-15-01990" ref-type="bibr">84</xref>]. Therefore, Kelly and colleagues concluded that, although heavy alcohol consumption should be strongly discouraged in this population, complete abstinence might not be necessary [<xref rid="B84-nutrients-15-01990" ref-type="bibr">84</xref>]. Interestingly, a Danish study comparing 453 PWH without viral hepatitis and an excessive alcohol consumption to 765 healthy controls, showed that, in the HIV population, a moderate alcohol consumption (defined as &lt;14 alcoholic units per week for men and &lt;7 alcoholic units per week for women) was associated with lower odds of moderate-to-severe hepatic steatosis, in a multivariate analysis adjusted for age, sex, ethnicity, BMI, and physical activity level [<xref rid="B85-nutrients-15-01990" ref-type="bibr">85</xref>]. In addition, although a weekly consumption of beer was associated with lower odds of moderate-to-severe hepatic steatosis, no association was found with wine, liquor, sugar-sweetened beverages, coffee, fast food, and type of meat products [<xref rid="B85-nutrients-15-01990" ref-type="bibr">85</xref>]. However, in this study, the prevalence of moderate-to-severe hepatic steatosis (assessed by computed tomography) was only 8.6%, which is very low compared to the previous evidence on NAFLD in PWH and may have led to an underestimation of the alcohol effect. Further studies assessing the role of mild alcohol intake in NAFLD in PWH are needed.</p></sec><sec><title>Coffee</title><p>The anti-inflammatory and hepato-protective properties of coffee have also been studied in the setting of HIV. Evidence on this topic comes from a national multicenter prospective cohort of PWH coinfected with HCV in France (ANRS CO13 HEPAVIH) [<xref rid="B86-nutrients-15-01990" ref-type="bibr">86</xref>]. Firstly, in a subset of 990 subjects, Carrieri et al. showed that a higher coffee intake (&#8805;three cups/day) was associated with a lower risk of impaired transaminases, with similar results for chocolate consumption [<xref rid="B86-nutrients-15-01990" ref-type="bibr">86</xref>]. Notably, combining a high intake of the two macronutrients together reduced the risk of abnormal liver enzymes by about 40% [<xref rid="B86-nutrients-15-01990" ref-type="bibr">86</xref>]. In 1028 HIV/HCV-coinfected patients with a median follow-up of 5 years, the same authors observed that a baseline high daily coffee intake of three or more cups was significantly associated with a 50% reduced risk in all-cause mortality [<xref rid="B87-nutrients-15-01990" ref-type="bibr">87</xref>]. Interestingly, looking at the baseline characteristics of the study cohort, the patients with a high coffee consumption were also less likely to present an advanced liver fibrosis in their Fibrosis-4 score (FIB-4) than the subjects with a moderate (i.e., two cups/day) or low (i.e., one cup/day, occasional consumption, or no consumption) coffee intake (10.7% vs. 14.3% vs. 19.7% respectively, <italic toggle="yes">p</italic> = 0.002) [<xref rid="B87-nutrients-15-01990" ref-type="bibr">87</xref>]. However, in this cohort, the effect of HCV infection may have been greater than that of HIV, being that HCV-related mortality was the first cause of death (42.8%), followed by non-HIV and non-HCV-related cancer (11.7%), AIDS (10.8%), and cardiovascular disease (3.9%) [<xref rid="B87-nutrients-15-01990" ref-type="bibr">87</xref>]. In a recent editorial, the same team further investigated the impact of coffee intake on significant liver steatosis and fibrosis among the patients of the ANRS CO13 HEPAVIH cohort [<xref rid="B88-nutrients-15-01990" ref-type="bibr">88</xref>]. Despite the lack of an association with hepatic steatosis, coffee intake was confirmed to have a significant protective effect on liver fibrosis, with a dose&#8211;response relationship for both the FIB-4 and liver stiffness measurements taken by transient elastography [<xref rid="B88-nutrients-15-01990" ref-type="bibr">88</xref>]. Finally, in a longitudinal observational study on 1019 subjects from the same cohort, Yaya et al. not only confirmed a strong inverse association between a high coffee consumption (i.e., &#8805; three cups/day) and advanced liver fibrosis, but also showed a role for coffee in mitigating alcohol&#8217;s negative effect on liver damage [<xref rid="B89-nutrients-15-01990" ref-type="bibr">89</xref>]. Indeed, a higher coffee intake was associated with a lower risk of liver fibrosis, even in HIV/HCV-coinfected patients with a high-risk alcohol consumption (i.e., &gt;four alcoholic units/day for men and &gt;three alcoholic units/day for women). Although no data regarding hepatic steatosis were available, patients with a high coffee intake and low-risk alcohol consumption (i.e., &#8804;four alcoholic units/day for men and &#8804;three alcoholic units/day for women) had a significantly lower prevalence of advanced liver fibrosis (FIB-4 &#8805; 3.25) compared to subjects with a low coffee intake and low-risk alcohol consumption (11.4% vs. 77.3% respectively, <italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B89-nutrients-15-01990" ref-type="bibr">89</xref>], possibly suggesting a beneficial role of drinking coffee in NAFLD in PWH. However, since all these studies addressed a population of HIV/HCV coinfected subjects, there is still a need for evidence specifically assessing the link between coffee and NAFLD in HIV monoinfection. <xref rid="nutrients-15-01990-f001" ref-type="fig">Figure 1</xref> shows the role of nutrients in NAFLD in PWH.</p></sec></sec><sec id="sec3dot2dot2-nutrients-15-01990"><title>3.2.2. Micronutrients</title><p>As for the uninfected population, the roles of several micronutrients have been investigated among PWH with NAFLD. Studies addressing the role of micronutrients in hepatic steatosis and/or liver fibrosis in PWH are shown in <xref rid="nutrients-15-01990-t002" ref-type="table">Table 2</xref>.</p><sec><title>Vitamin E</title><p>Vitamin E deficiency seems to be common among PWH. For instance, in a cohort of 107 PWH in Ghana, a high prevalence (82.5%) of serum vitamin E insufficiency was detected, with a low dietary intake of this vitamin and other antioxidant micronutrients [<xref rid="B117-nutrients-15-01990" ref-type="bibr">117</xref>]. In addition, whether high vitamin E levels reduce the progression of HIV infection to AIDS is still under debate. In a study of 311 HIV-positive men in Baltimore, patients in the highest quartile of serum vitamin E levels showed a decreased risk of developing AIDS compared to those in the lowest quartile [<xref rid="B118-nutrients-15-01990" ref-type="bibr">118</xref>]. Oppositely, Graham and colleagues reported that higher vitamin E levels pre-infection were associated with a higher mortality among 67 Kenyan women with HIV [<xref rid="B119-nutrients-15-01990" ref-type="bibr">119</xref>]. More research is required on the clinical impact of vitamin E on the immunologic features of HIV. Focusing on the liver&#8217;s health, vitamin E is recommended for NASH treatment in the general population [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>]. One of us designed a clinical trial to specifically investigate the effect of vitamin E supplementation on NASH in PWH [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. This Canadian open-label phase 4 single-arm trial included 27 HIV mono-infected patients with non-invasive diagnoses of NASH, defined by a controlled attenuation parameter (CAP) of at least 248 dB/m and a serum cytokeratin 18 (marker of hepatocyte apoptosis) greater than 130.5 U/l. The daily administration of vitamin E 800 IU over 24 weeks led to a decrease in alanine transaminase levels and improvements in hepatic steatosis and hepatocyte apoptosis [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. In addition, no major side effects were registered, confirming a good safety profile [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. However, consistent with the findings for the general NAFLD population [<xref rid="B56-nutrients-15-01990" ref-type="bibr">56</xref>,<xref rid="B57-nutrients-15-01990" ref-type="bibr">57</xref>], no improvement in liver fibrosis was reported, possibly also due to the relatively short study duration [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. Therefore, vitamin E may serve as a &#8220;bridge therapy&#8221; while awaiting novel drugs that will comprehensively treat all the features of NASH [<xref rid="B120-nutrients-15-01990" ref-type="bibr">120</xref>].</p></sec><sec><title>Vitamin D</title><p>Vitamin D seems to also play a role in NAFLD in PWH. Importantly, serum vitamin D deficiency is common among PWH, with a higher prevalence than that in the general population [<xref rid="B121-nutrients-15-01990" ref-type="bibr">121</xref>,<xref rid="B122-nutrients-15-01990" ref-type="bibr">122</xref>]. In fact, other than the traditional risk factors, such as a lack of exposure to UVB radiation, age, and a darker skin pigmentation, HIV chronic infection and the lifelong use of cART seem to exacerbate vitamin D deficiency in the setting of HIV [<xref rid="B122-nutrients-15-01990" ref-type="bibr">122</xref>]. Screening PWH for vitamin D insufficiency is clinically relevant due to the higher prevalence of osteopenia/osteoporosis and fractures in PWH and cART-treated individuals compared to controls [<xref rid="B123-nutrients-15-01990" ref-type="bibr">123</xref>]. Focusing on liver outcomes, in the setting of HIV/HCV coinfection, several studies have shown an association between vitamin D deficiency and increased biopsy-proven liver fibrosis [<xref rid="B106-nutrients-15-01990" ref-type="bibr">106</xref>,<xref rid="B107-nutrients-15-01990" ref-type="bibr">107</xref>,<xref rid="B108-nutrients-15-01990" ref-type="bibr">108</xref>]. Similarly, in a study evaluating 86 people with HIV/HCV coinfection, Mandorfer et al. reported that a vitamin D deficiency and low CD4+ nadir were independently associated with a higher portal pressure (assessed by a hepatic venous pressure gradient) and fibrosis progression rate (computed by dividing the METAVIR fibrosis score at liver biopsy by the duration of HCV infection expressed in years) [<xref rid="B109-nutrients-15-01990" ref-type="bibr">109</xref>]. Moreover, in a cohort of 139 PWH with advanced liver disease, who were candidates for liver transplantation, Branch et al. found a very high prevalence of vitamin D deficiency (90%), which was also independently associated with cirrhosis [<xref rid="B124-nutrients-15-01990" ref-type="bibr">124</xref>]. Conversely, El-Maouche and colleagues, in a cohort of 116 HIV/HCV-coinfected patients, although vitamin D deficiency was highly prevalent, there was no reported association between low vitamin D levels and liver fibrosis severity (by liver biopsy) or low bone mineral density (by dual-energy X-ray absorptiometry) [<xref rid="B110-nutrients-15-01990" ref-type="bibr">110</xref>]. Of note is that the study&#8217;s participants were predominantly African-American (87%) [<xref rid="B110-nutrients-15-01990" ref-type="bibr">110</xref>], raising questions about the role of ethnicity in the association between vitamin D deficiency and liver damage. As for NAFLD in PWH, in a cross-sectional study of 707 PWH without alcohol abuse and viral hepatitis, Milic et al. found an association between low serum vitamin D levels and liver fibrosis among the NAFLD subjects (odds ratio 1.94, 95% CI 1.18&#8211;3.24) [<xref rid="B111-nutrients-15-01990" ref-type="bibr">111</xref>]. Finally, in a cross-sectional study of 94 HIV patients, Moreno-Perez and colleagues found that vitamin D insufficiency was associated with an impaired insulin sensitivity [<xref rid="B125-nutrients-15-01990" ref-type="bibr">125</xref>], which has a well-known pathogenetic role in NAFLD [<xref rid="B126-nutrients-15-01990" ref-type="bibr">126</xref>]. Future RCTs are warranted to better clarify the role of vitamin D in NAFLD pathogenesis among PWH. These studies would also address the need to screen for vitamin D deficiency, as well as to detect and possibly manage osteoporosis in the setting of NAFLD in PWH.</p></sec><sec><title>Cannabinoids</title><p>In HIV infection, preliminary evidence has shown that cannabinoid intake may have a beneficial impact on its clinical outcomes. In fact, cannabis usage seems to be associated with lower levels of T-cell activation, inflammatory monocytes, and pro-inflammatory cytokine secretion, all of which correlate with both HIV progression and its comorbidities [<xref rid="B127-nutrients-15-01990" ref-type="bibr">127</xref>]. A few studies have investigated the role of cannabinoids in the liver&#8217;s health among PWH, with mixed results. The investigators of the ANRS CO13 HEPAVIH cohort demonstrated that, in the setting of HIV/HCV coinfection, daily cannabis use was negatively associated with being overweight [<xref rid="B128-nutrients-15-01990" ref-type="bibr">128</xref>], insulin resistance [<xref rid="B129-nutrients-15-01990" ref-type="bibr">129</xref>], and fatty liver, diagnosed by abdominal ultrasound [<xref rid="B112-nutrients-15-01990" ref-type="bibr">112</xref>] or the fatty liver index [<xref rid="B113-nutrients-15-01990" ref-type="bibr">113</xref>]. Oppositely, in 248 Russian PWH with heavy alcohol consumption, who were mostly male (72.6%), young (median age of 33.9 years), and coinfected with HCV (87.9%), Fuster et al. did not report any association between cannabis use and advanced liver fibrosis (detected by FIB-4, aminotransferase-to-platelet ratio (APRI), or transient elastography) [<xref rid="B114-nutrients-15-01990" ref-type="bibr">114</xref>]. Along the same lines, in a large longitudinal cohort of 575 HIV/HCV-coinfected women who were followed for a median of 11 years, marijuana usage was not associated with a progression to significant liver fibrosis (diagnosed by FIB-4 or APRI) [<xref rid="B115-nutrients-15-01990" ref-type="bibr">115</xref>]. Similar results were also shown by Brunet and colleagues, who detected no evidence that marijuana smoking accelerated significant liver fibrosis progression (detected by APRI) or cirrhosis in a prospective cohort of 690 Canadian HIV/HCV-coinfected individuals [<xref rid="B116-nutrients-15-01990" ref-type="bibr">116</xref>]. However, a longer follow-up than that of this study (2.7 years, interquartile range 0.8&#8211;3.8) may be needed to detect a significant rate of liver fibrosis and cirrhosis progression [<xref rid="B116-nutrients-15-01990" ref-type="bibr">116</xref>]. Of note is that recreational and medical cannabis use is also associated with negative cardiovascular, respiratory, cognitive, and psychological effects, although a definitive causal relationship between cannabis use and these adverse effects is lacking [<xref rid="B130-nutrients-15-01990" ref-type="bibr">130</xref>]. Therefore, these risks should be carefully considered before suggesting the use of cannabinoids. In addition, despite preclinical studies that have focused on isolated phytocannabinoids as therapeutic options for NAFLD showing promising results, preliminary human trials have failed to confirm them [<xref rid="B74-nutrients-15-01990" ref-type="bibr">74</xref>]. We believe that further evidence on safety and tolerability is needed before conducting large-scale efficacy human trials. In fact, as recently reported by one of us in a randomized interventional pilot study investigating the safety and tolerability of oral cannabinoids in 10 PWH, 2 patients developed elevated transaminases when receiving high doses of cannabinoids (800 mg per day) [<xref rid="B131-nutrients-15-01990" ref-type="bibr">131</xref>]. Therefore, it is still unclear what the optimal dose of cannabinoids is to determine their anti-inflammatory properties without causing hepatotoxicity.</p></sec></sec></sec><sec id="sec3dot3-nutrients-15-01990"><title>3.3. Food Insecurity</title><p>When discussing nutrition and chronic diseases, in addition to the type and amount of nutrients consumed, it is relevant to mention food insecurity. Food insecurity is defined as the inability to acquire or consume an adequate diet quality or a sufficient quantity of food in socially acceptable ways, or the uncertainty that one will be able to do so [<xref rid="B132-nutrients-15-01990" ref-type="bibr">132</xref>]. Notably, it is not only a concern for low-income countries, but also for high-income ones, as it affects more than 12% of households in the United States [<xref rid="B133-nutrients-15-01990" ref-type="bibr">133</xref>]. As shown in <xref rid="app1-nutrients-15-01990" ref-type="app">Figure S1</xref> (<xref rid="app1-nutrients-15-01990" ref-type="app">Supplementary Materials</xref>), a growing body of evidence shows an association between food insecurity and cardio-metabolic risk [<xref rid="B134-nutrients-15-01990" ref-type="bibr">134</xref>]. In fact, facing food shortages leads people to engage in compensatory behaviors, such as a lower fruit and vegetable intake, skipping meals, and cycling food restrictions, along with a higher consumption of inexpensive junk foods with poor nutritional values [<xref rid="B135-nutrients-15-01990" ref-type="bibr">135</xref>]. Indeed, all these poverty-related unhealthy habits can lead to an increase in metabolic syndrome, obesity, hypertension, and diabetes [<xref rid="B136-nutrients-15-01990" ref-type="bibr">136</xref>]. The liver&#8217;s health is also dramatically affected by health disparities, with social determinants being crucial to the development and management of chronic liver diseases [<xref rid="B137-nutrients-15-01990" ref-type="bibr">137</xref>]. Focusing on hepatic steatosis, Golovaty et al., in a large cohort of 2627 adults in the United States, reported that food-insecure subjects were more likely to have NAFLD (assessed by the fatty liver index) and advanced liver fibrosis (assessed by NAFLD fibrosis score) compared to food-secure adults [<xref rid="B138-nutrients-15-01990" ref-type="bibr">138</xref>]. Of note is that in another, even larger population-based study, including 4816 subjects with NAFLD (diagnosed by fatty liver index) and 1654 patients with advanced liver fibrosis (diagnosed by NAFLD fibrosis score, APRI, or FIB-4), food insecurity was an independent predictor of a higher mortality rate for both groups, also being significantly associated with a greater outpatient health care utilization among the NAFLD subjects [<xref rid="B139-nutrients-15-01990" ref-type="bibr">139</xref>]. In addition, PWH seem to be even more vulnerable to food insecurity than the general population, being that HIV infection is disproportionately affected by economic disadvantages and social stigmas [<xref rid="B140-nutrients-15-01990" ref-type="bibr">140</xref>]. Consistent with the findings for the general population, Muhammad et al. reported that food-insecure PWH had a poor diet quality, with a low dietary intake of fiber, vitamin E, folate, magnesium, and copper [<xref rid="B141-nutrients-15-01990" ref-type="bibr">141</xref>]. Among 603 subjects of the Miami Adult Studies on HIV cohort (43.6% HIV-positive), who were screened for NAFLD and liver fibrosis with magnetic resonance imaging, Tamargo and colleagues showed that food insecurity was linked to increased odds for NAFLD at a higher BMI, and that it was independently associated with a higher risk of liver fibrosis [<xref rid="B142-nutrients-15-01990" ref-type="bibr">142</xref>]. Finally, we would like to emphasize that the health promotion of PWH with NAFLD cannot be limited to nutritional advice alone. In fact, it is a matter of human rights to ensure that all patients, even the most underprivileged and those with the lowest incomes, have equal access to quality food. It is critical that health policies take action to remove the socioeconomic barriers that force these vulnerable patients into food insecurity, exposing them to an increased risk of serious illness and death.</p></sec></sec><sec id="sec4-nutrients-15-01990"><title>4. Nutrition, Lifestyle and Pharmacotherapy in the Treatment of NAFLD in People with HIV</title><sec id="sec4dot1-nutrients-15-01990"><title>4.1. Lifestyle Interventions in NAFLD in People with HIV</title><sec id="sec4dot1dot1-nutrients-15-01990"><title>4.1.1. Lifestyle Treatment of NAFLD</title><p>Lifestyle interventions are structured programs that help patients to change their nutritional habits and exercise routines, and to learn behavioral strategies aimed at improving a range of health outcomes [<xref rid="B143-nutrients-15-01990" ref-type="bibr">143</xref>]. Current international guidelines state that, in overweight or obese NAFLD patients, the primary goal of lifestyle intervention is a 7&#8211;10% reduction in their body weight [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>]. In fact, it is well-proven that losing weight has favorable effects on hepatic steatosis, liver inflammation, and fibrosis [<xref rid="B144-nutrients-15-01990" ref-type="bibr">144</xref>]. Weight loss can be achieved through diet, physical activity, or, even better, a combination of them [<xref rid="B145-nutrients-15-01990" ref-type="bibr">145</xref>]. Whether or not there is an ideal diet for NAFLD is still a debated issue [<xref rid="B146-nutrients-15-01990" ref-type="bibr">146</xref>]. Certainly, the Mediterranean diet has been the most widely studied in the context of NAFLD, with consistent effects on the improvement of liver disease [<xref rid="B147-nutrients-15-01990" ref-type="bibr">147</xref>,<xref rid="B148-nutrients-15-01990" ref-type="bibr">148</xref>] and a known beneficial impact on cardiovascular disease and diabetes prevention [<xref rid="B149-nutrients-15-01990" ref-type="bibr">149</xref>]. Recent clinical studies comparing the Mediterranean diet with other nutritional strategies in the setting of NAFLD have shown comparable positive effects for different diets on hepatic and metabolic outcomes [<xref rid="B150-nutrients-15-01990" ref-type="bibr">150</xref>,<xref rid="B151-nutrients-15-01990" ref-type="bibr">151</xref>]. Similarly, a low free sugar diet, characterized by the avoidance of foods with added monosaccharides and disaccharides, has emerged as a successful strategy for improving hepatic steatosis and fibrosis, as well as glycemic control and inflammation, in NAFLD patients [<xref rid="B152-nutrients-15-01990" ref-type="bibr">152</xref>]. Therefore, the latest AASLD guidance recommends a patient-tailored nutritional approach, stating that different calorie restriction strategies (a Mediterranean diet, low-carbohydrate and low-fat diets, saturated vs. unsaturated fat diets, and intermittent fasting) have a similar ability to improve NAFLD [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>]. As for physical activity, international hepatologic societies, aligned with the guidelines for cardiovascular disease prevention [<xref rid="B153-nutrients-15-01990" ref-type="bibr">153</xref>], recommend that NAFLD patients engage in at least 150 min of exercise per week, with possibly a minimum of three&#8211;five training sessions [<xref rid="B10-nutrients-15-01990" ref-type="bibr">10</xref>,<xref rid="B22-nutrients-15-01990" ref-type="bibr">22</xref>]. Indeed, exercise shows a dose&#8211;effect relationship with NAFLD remission, with vigorous physical activity showing the most valuable impact [<xref rid="B154-nutrients-15-01990" ref-type="bibr">154</xref>]. However, any level of physical activity is proven to be useful, and even a small amount of exercise is better than continuing with inactivity [<xref rid="B155-nutrients-15-01990" ref-type="bibr">155</xref>]. Aerobic workouts are generally preferred, although resistance training has shown equally positive outcomes, representing a viable option for NAFLD treatment [<xref rid="B156-nutrients-15-01990" ref-type="bibr">156</xref>,<xref rid="B157-nutrients-15-01990" ref-type="bibr">157</xref>,<xref rid="B158-nutrients-15-01990" ref-type="bibr">158</xref>]. Therefore, patients should be provided with an individually tailored exercise plan, advising them to choose the activity that suits them the most. This seems to be the best strategy for improving long-term adherence, which is essential to avoiding losing the benefits that have been achieved [<xref rid="B159-nutrients-15-01990" ref-type="bibr">159</xref>]. In addition, another very effective therapy for losing weight and maintaining it in morbid obese patients is bariatric surgery, including sleeve gastrectomy and a Roux-en-Y gastric bypass, which act by reducing the volume of food that can be ingested and causing malabsorption, or a combination of these [<xref rid="B160-nutrients-15-01990" ref-type="bibr">160</xref>]. Notably, lifestyle treatment of NAFLD is associated with a reduction in liver fat and other metabolic benefits independently of weight loss [<xref rid="B161-nutrients-15-01990" ref-type="bibr">161</xref>,<xref rid="B162-nutrients-15-01990" ref-type="bibr">162</xref>,<xref rid="B163-nutrients-15-01990" ref-type="bibr">163</xref>]. In fact, following a healthy diet and engaging in physical activity promotes biological changes such as modifications in energy balance, circulating lipids, and insulin sensitivity, which can lead to NAFLD remission even without losing weight [<xref rid="B164-nutrients-15-01990" ref-type="bibr">164</xref>]. Although highly relevant, lifestyle intervention should be prescribed more cautiously in liver cirrhosis than in the earlier stages of NAFLD. As for diet, cirrhotic patients should receive nutritional counseling tailored to their current nutritional status, following a comprehensive screening for malnutrition, sarcopenia, and frailty [<xref rid="B165-nutrients-15-01990" ref-type="bibr">165</xref>]. Weight loss should be prescribed with extreme caution in overweight/obese cirrhotic patients, especially if they have decompensated cirrhosis or sarcopenic obesity [<xref rid="B166-nutrients-15-01990" ref-type="bibr">166</xref>], possibly through a multidisciplinary approach to ensure an adequate protein intake (1.2&#8211;1.5 g/kg/day). Similarly, despite exercise having been shown to improve cardiopulmonary performance, muscle mass, contractile function, and the quality of life in cirrhotic patients, it should be carefully monitored by experienced physical therapists after a precise assessment of the patient&#8217;s needs [<xref rid="B165-nutrients-15-01990" ref-type="bibr">165</xref>].</p></sec><sec id="sec4dot1dot2-nutrients-15-01990"><title>4.1.2. Lifestyle Treatment of NAFLD in People with HIV</title><p><xref rid="nutrients-15-01990-f002" ref-type="fig">Figure 2</xref> summarizes the lifestyle treatment of NAFLD in PWH. Providing good lifestyle counselling to PWH with NAFLD can be challenging. As already mentioned, PWH seem to have a poorer nutritional quality, greater rates of food insecurity, and a reduced likelihood of fulfilling their global physical activity recommendations compared to the uninfected population [<xref rid="B167-nutrients-15-01990" ref-type="bibr">167</xref>,<xref rid="B168-nutrients-15-01990" ref-type="bibr">168</xref>,<xref rid="B169-nutrients-15-01990" ref-type="bibr">169</xref>]. Furthermore, in the context of HIV, more intense physical activity may be required to achieve similar metabolic improvements to those of HIV-negative subjects [<xref rid="B170-nutrients-15-01990" ref-type="bibr">170</xref>]. Indeed, weight loss strategies of a proven efficacy for the uninfected population might not be generalizable to PWH, in whom ectopic adipose tissue, dysfunctional subcutaneous fat, and immune activation play a key role [<xref rid="B171-nutrients-15-01990" ref-type="bibr">171</xref>]. However, this should not discourage physicians, who are recommended to provide PWH with lifestyle intervention, since several studies showed that structured behavioral programs lead to weight loss and a reduction in abdominal obesity among obese PWH [<xref rid="B172-nutrients-15-01990" ref-type="bibr">172</xref>,<xref rid="B173-nutrients-15-01990" ref-type="bibr">173</xref>,<xref rid="B174-nutrients-15-01990" ref-type="bibr">174</xref>,<xref rid="B175-nutrients-15-01990" ref-type="bibr">175</xref>,<xref rid="B176-nutrients-15-01990" ref-type="bibr">176</xref>,<xref rid="B177-nutrients-15-01990" ref-type="bibr">177</xref>]. Focusing on NAFLD in PWH, evidence from the few pharmacological RTCs available reports that PWH struggle to achieve a healthy lifestyle, even when they receive comprehensive counselling [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>,<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]. For instance, in a trial evaluating the vitamin E effect on NASH in PWH, lifestyle changes, provided by a dedicated counseling approach, were ineffective, with no BMI improvement observed in the 21 overweight patients of the cohort after 48 months of follow-up [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. Similarly, in the study evaluating the effects of tesamorelin on NAFLD in HIV, although all the patients were given nutritional counselling from nutritionists at baseline, 6 months, and 12 months, they did not significantly lose either weight or waist circumference by the end of the trial, with no change in their daily caloric, macronutrient, alcohol intakes or hours of physical activity [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]. It should be noted that these studies were not designed to assess the impact of lifestyle interventions, so it is possible that the participants relied on the novel drug as a cure for NAFLD, while regarding the behavioral advice as less important. Nevertheless, a lack of lifestyle changes may also lie in the peculiarities of the HIV population, such as their socio-economic vulnerability, with a low access to quality food and structured training sessions, and in the lipodystrophy and HIV-related stigma that may prevent their participation in traditional weight management programs [<xref rid="B120-nutrients-15-01990" ref-type="bibr">120</xref>,<xref rid="B179-nutrients-15-01990" ref-type="bibr">179</xref>]. A recent study tailored to NAFLD in PWH showed the benefits of a structured lifestyle intervention on weight loss [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]. In this Portuguese trial, 55 PWH with ultrasound-proven NAFLD were allocated to dietary interventions based on the Mediterranean diet (intervention group, 27 patients) or to the standard of care (control group, 28 patients), and after a 5-month follow-up, the standard of care group had gained a median of 0.65 kg, while the intervention group had lost a median of 1.5 kg (<italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]. Right after that, the 3-month period of the Coronavirus disease 2019 (COVID-19) national lockdown started, and both groups started to gain weight [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]. In fact, the COVID-19 lockdown posed a threat to healthy lifestyles, as proven by several studies reporting weight gains and the worsening of the disease control in the overall NAFLD population [<xref rid="B181-nutrients-15-01990" ref-type="bibr">181</xref>,<xref rid="B182-nutrients-15-01990" ref-type="bibr">182</xref>,<xref rid="B183-nutrients-15-01990" ref-type="bibr">183</xref>]. However, patients in the intervention group experienced less weight gain (3.1 &#177; 1.6 kg vs. 0.7 &#177; 1.7 kg, <italic toggle="yes">p</italic> &lt; 0.001) and lower alterations in their dietary habit patterns compared to the controls, also being more likely to maintain their physical activity levels [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]. This study suggests that a structured nutritional intervention can mitigate the negative impact of lockdown on NAFLD in PWH. Another interesting aspect of this paper was the use of telemedicine to provide dietary interventions, with follow-up consultations performed by video and/or phone during lockdown [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]. Studies addressing the role of telemedicine in the NAFLD-uninfected population are accumulating, emphasizing the beneficial effects of e-Health in reducing body weight, BMI, and transaminases levels, as it increases patients&#8217; adherence to diet and physical activity recommendations [<xref rid="B184-nutrients-15-01990" ref-type="bibr">184</xref>]. Similarly, in the setting of NAFLD in PWH, digital health seems to be a promising strategy for delivering lifestyle interventions [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>], although further studies are needed. Focusing on the role of physical activity, Yarasheski and colleagues randomly assigned 44 PWH with a baseline insulin resistance and central adiposity to either pioglitazone (30 mg/day) alone or pioglitazone with supervised, progressive aerobic, and resistance exercise training (1.5&#8211;2 h/day, 3 days/week) [<xref rid="B185-nutrients-15-01990" ref-type="bibr">185</xref>]. Combining pioglitazone with a physical activity intervention resulted in further improvements in peripheral insulin sensitivity compared to pioglitazone administration alone [<xref rid="B185-nutrients-15-01990" ref-type="bibr">185</xref>]. Notably, although it did not reach statistical significance, pioglitazone plus exercise reduced the liver lipid content (measured by liver proton magnetic resonance spectroscopy) more than pioglitazone alone (&#8722;2.6 &#177; 1.4% vs. &#8722;1.5 &#177; 1.3, <italic toggle="yes">p</italic> = 0.6), hinting at a potential beneficial role of exercise training in NAFLD in PWH [<xref rid="B185-nutrients-15-01990" ref-type="bibr">185</xref>]. <xref rid="nutrients-15-01990-t003" ref-type="table">Table 3</xref> summarizes the studies evaluating the role of lifestyle intervention in weight loss in hepatic steatosis in PWH. Future RCTs are warranted to specifically address the impact of a structured and tailored lifestyle intervention on PWH with NAFLD.</p></sec></sec><sec id="sec4dot2-nutrients-15-01990"><title>4.2. The State of the Art NAFLD Pharmacotherapy in People with HIV</title><p>A few pilot studies have assessed NAFLD pharmacotherapy in PWH (<xref rid="nutrients-15-01990-t004" ref-type="table">Table 4</xref>). We have already discussed the role of vitamin E supplementation as a NASH treatment in the setting of HIV [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]. A total of two trials have assessed the role of pioglitazone, a thiazolidinedione agent able to improve insulin sensitivity, in the management of NAFLD in PWH [<xref rid="B186-nutrients-15-01990" ref-type="bibr">186</xref>,<xref rid="B187-nutrients-15-01990" ref-type="bibr">187</xref>]. In a 48-week double-blind RCT, the administration of pioglitazone (45 mg/day) to 13 HIV/HCV-coinfected patients with hepatic steatosis led to a significant reduction in their intrahepatic fat content, which was assessed by magnetic resonance spectroscopy, in comparison to those who received a placebo, with no improvement in biopsy-proven NASH [<xref rid="B186-nutrients-15-01990" ref-type="bibr">186</xref>]. In a second trial, 98 HIV-positive individuals with prediabetes, who had evidence of fatty liver assessed by abdominal ultrasound or CAP &#8805; 238 dB/m, were randomly assigned to pioglitazone (30 mg/day) or a placebo and followed for 48 weeks [<xref rid="B187-nutrients-15-01990" ref-type="bibr">187</xref>]. The pioglitazone administration led to a significant reduction in the CAP and liver stiffness measured by transient elastography [<xref rid="B187-nutrients-15-01990" ref-type="bibr">187</xref>]. However, in the pioglitazone group, although they were statistically significant, the mean changes in both the CAP and liver stiffness were small (&#8722;23.5 dB/m and &#8722;0.184 kPa, respectively), raising doubts about the clinical relevance of these results. In addition, no information about the changes in the prevalence of clinically significant or advanced fibrosis were provided by the authors [<xref rid="B187-nutrients-15-01990" ref-type="bibr">187</xref>]. The ARRIVE trial evaluated the effect of Aramchol (600 mg/day) an oral stearoyl-coenzyme-A-desaturase-1, an inhibitor known to reduce hepatic steatosis in the uninfected NAFLD population, among 25 PWH with NAFLD, defined by magnetic resonance imaging-proton density fat fraction vs. a placebo [<xref rid="B188-nutrients-15-01990" ref-type="bibr">188</xref>]. During a follow-up of 12 weeks, Aramchol did not reduce either hepatic steatosis nor the liver stiffness measured by magnetic resonance elastography or transient elastography [<xref rid="B188-nutrients-15-01990" ref-type="bibr">188</xref>]. Similarly, it did not change their body fat and muscle compositions, as assessed by magnetic resonance imaging and bone densitometry [<xref rid="B188-nutrients-15-01990" ref-type="bibr">188</xref>]. Another trial evaluated the therapeutic effect of tesamorelin (2 mg/day), a growth-hormone-releasing hormone analog approved by the FDA for HIV-associated lipodystrophy, among 61 PWH with NAFLD diagnosed via magnetic resonance spectroscopy [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]. After 12 months of follow-up, tesamorelin reduced the hepatic fat content by 37% and showed a lower rate of biopsy-proven liver fibrosis progression in the interventional group compared to the placebo group (10.5% vs. 37.5%, <italic toggle="yes">p</italic> = 0.04) [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]. However, no changes in the histologic NAFLD activity scores, lobular inflammation, or hepatocellular ballooning were observed [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]. Finally, in a maraviroc add-on for steatohepatitis in HIV-infected patients study, 13 PWH with biopsy-proven NASH were invited to add maraviroc, an antiretroviral agent with promising effects on NAFLD remission, to their existing suppressive cART regimen [<xref rid="B189-nutrients-15-01990" ref-type="bibr">189</xref>]. In this trial, after 48 weeks of follow-up, the liver biopsies did not show any changes in the hepatic steatosis, liver fibrosis, or NASH features in the study cohort [<xref rid="B189-nutrients-15-01990" ref-type="bibr">189</xref>]. Unfortunately, the number of trials addressing NAFLD pharmacotherapy for PWH is much fewer than that of the RCTs for the HIV-uninfected NAFLD population. In fact, any novel drug trial for NASH still considers HIV infection to be an exclusion criterion, raising the ethical issue of preventing a vulnerable group from receiving potentially beneficial treatments. Although regulatory agencies justify this decision by the concern of interactions between cART and the experimental drug, experts in the field of NASH in PWH advocate for the design of more inclusive trials [<xref rid="B190-nutrients-15-01990" ref-type="bibr">190</xref>]. A good strategy would be to incorporate a priori subanalyses to investigate HIV-unique features, especially drug&#8211;drug interactions, while keeping the same therapeutic targets, as this will prevent a protracted delay in the release of new medications for PWH [<xref rid="B191-nutrients-15-01990" ref-type="bibr">191</xref>]. For all these reasons, as is the case for the uninfected population, lifestyle intervention remains as the cornerstone treatment for NAFLD in PWH [<xref rid="B192-nutrients-15-01990" ref-type="bibr">192</xref>].</p></sec><sec id="sec4dot3-nutrients-15-01990"><title>4.3. Lifestyle Treatment of Lean NAFLD in People with HIV</title><p>Lean NAFLD, defined as NAFLD with a BMI of &lt;25 Kg/m<sup>2</sup> among non-Asian subjects and &lt;23 Kg/m<sup>2</sup> among Asian ones, is a relevant condition in the setting of HIV. In fact, in a study from one of the authors, up to 35% of PWH with NAFLD were lean, and 24% of HIV patients presented with hepatic steatosis [<xref rid="B193-nutrients-15-01990" ref-type="bibr">193</xref>]. An even higher prevalence of lean NAFLD (45%) was reported in a cohort of Indian PWH [<xref rid="B194-nutrients-15-01990" ref-type="bibr">194</xref>]. These rates are much higher compared to the general NAFLD population, in which 7 to 20% of individuals have a normal body weight [<xref rid="B195-nutrients-15-01990" ref-type="bibr">195</xref>]. Indeed, PWH with NAFLD may be leaner than HIV-negative ones, with a case-control study that compared 26 PWH and 25 HIV-uninfected people with biopsy-proven NAFLD reporting that the PWH had a lower BMI, lower percentage of fat mass, and higher physical activity level compared to the controls [<xref rid="B196-nutrients-15-01990" ref-type="bibr">196</xref>]. Therefore, when discussing lifestyle treatment for NAFLD in PWH, the specifics of the lean population should be addressed. The recent American Gastroenterological Association guidelines recommend a modest weight loss of 3&#8211;5% in lean subjects with NAFLD, achieved through diet, exercise, and an avoidance of fructose-added drinks [<xref rid="B195-nutrients-15-01990" ref-type="bibr">195</xref>]. In fact, a lower weight loss is necessary for lean patients in the treatment of NAFLD, with an RCT showing that non-obese patients achieved NAFLD remission with a weight reduction of 3&#8211;5%, while obese participants needed at least 7&#8211;10% [<xref rid="B197-nutrients-15-01990" ref-type="bibr">197</xref>]. The pharmacotherapy of lean NASH is still an unknown field. Not only are there no specific pharmacological RTCs addressing this population, but also most of the existing NASH trials exclude non-overweight patients by protocol. Since PWH with NAFLD are denied the opportunity to be enrolled in drug RCTs, unsurprisingly, our literature search showed a lack of studies assessing the therapy for NAFLD in normal-weight PWH, which deserves future investigations.</p></sec><sec id="sec4dot4-nutrients-15-01990"><title>4.4. The Role of Gut Microbiota in Lifestyle Treatment of NAFLD in People with HIV</title><p>Understanding the relationship between intestinal microbiota and the nutritional approaches to NAFLD in PWH is critical. The gut microbiota are an ecosystem of bacteria that coexist in dynamic balance with the host and each other, and are involved in a range of interactions that influence the host&#8217;s health across their lifespan [<xref rid="B198-nutrients-15-01990" ref-type="bibr">198</xref>]. The main contributors to the intestinal flora of healthy adults are four phyla, namely Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria [<xref rid="B199-nutrients-15-01990" ref-type="bibr">199</xref>]. Recently, gut microbiota have been shown to play a key role in metabolic diseases, with a strong association between intestinal dysbiosis and obesity [<xref rid="B200-nutrients-15-01990" ref-type="bibr">200</xref>,<xref rid="B201-nutrients-15-01990" ref-type="bibr">201</xref>], metabolic syndrome [<xref rid="B202-nutrients-15-01990" ref-type="bibr">202</xref>], diabetes [<xref rid="B203-nutrients-15-01990" ref-type="bibr">203</xref>], and cardiovascular disease [<xref rid="B204-nutrients-15-01990" ref-type="bibr">204</xref>]. As the hepatic manifestation of metabolic syndrome, NAFLD is also strictly linked to gut microbiota disruption, with both animal and human studies clearly showing its correlation with NAFLD onset and progression [<xref rid="B205-nutrients-15-01990" ref-type="bibr">205</xref>,<xref rid="B206-nutrients-15-01990" ref-type="bibr">206</xref>,<xref rid="B207-nutrients-15-01990" ref-type="bibr">207</xref>]. Furthermore, intestinal flora play a central role in the nutritional therapy for NAFLD, as they influence the energy uptake, nutrient absorption, and fat storage from the food consumed [<xref rid="B208-nutrients-15-01990" ref-type="bibr">208</xref>]. In fact, gut bacteria profiles have been shown to differ between normal-weight and overweight individuals, with an obese microbiome harvesting more energy from the food eaten compared to a lean microbiome [<xref rid="B200-nutrients-15-01990" ref-type="bibr">200</xref>]. In more detail, weight gain and metabolic syndrome are associated with a low richness in the intestinal microorganisms [<xref rid="B209-nutrients-15-01990" ref-type="bibr">209</xref>], and the same has also been reported among NAFLD patients [<xref rid="B210-nutrients-15-01990" ref-type="bibr">210</xref>]. In addition, an obese dysbiosis is characterized by higher levels of Firmicutes and lower proportions of Bacteroidetes [<xref rid="B201-nutrients-15-01990" ref-type="bibr">201</xref>,<xref rid="B211-nutrients-15-01990" ref-type="bibr">211</xref>]. Similarly, many efforts are being made to identify a specific NAFLD microbiome signature, still with mixed results. Loomba et al. built a metagenomic-based model to detect advanced liver fibrosis among NASH patients, based on increased Proteobacteria levels and a decrease in Firmicutes [<xref rid="B212-nutrients-15-01990" ref-type="bibr">212</xref>]. This approach is promising, because identifying unique microbiome signatures for NAFLD, NAFLD fibrosis, and cirrhosis could serve as future noninvasive diagnostic or prognostic biomarkers [<xref rid="B213-nutrients-15-01990" ref-type="bibr">213</xref>]. Targeting the microbiota might also be an effective strategy for NAFLD treatment, as it could lead to the recovery of intestinal inflammation and restoration of gut permeability. Although preliminary data show that antidiabetic medications, such as biguanides/metformin, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors, may achieve metabolic improvements by healing microbiota dysbiosis, no drugs are currently approved [<xref rid="B214-nutrients-15-01990" ref-type="bibr">214</xref>]. Therefore, once again, a nutritional approach is recommended, as dietary fiber intake has been shown to significantly change the gut microbiota by decreasing the pathogenic bacteria and increasing the bifidobacteria, with a beneficial metabolite production and an improved barrier permeability [<xref rid="B215-nutrients-15-01990" ref-type="bibr">215</xref>]. Notably, HIV infection itself is linked to intestinal flora alterations [<xref rid="B216-nutrients-15-01990" ref-type="bibr">216</xref>,<xref rid="B217-nutrients-15-01990" ref-type="bibr">217</xref>]. Early after infection, PWH develop gut dysbiosis, characterized by a reduced diversity within the microbiome, similar to the findings for obese and diabetic patients [<xref rid="B218-nutrients-15-01990" ref-type="bibr">218</xref>]. Microbiota disruption persists in chronic HIV infection, and unexpectedly, it is not only reported in untreated subjects [<xref rid="B219-nutrients-15-01990" ref-type="bibr">219</xref>], but also in patients undergoing cART [<xref rid="B220-nutrients-15-01990" ref-type="bibr">220</xref>]. Of note is that cART initiation could further reduce the diversity of intestinal flora [<xref rid="B219-nutrients-15-01990" ref-type="bibr">219</xref>,<xref rid="B221-nutrients-15-01990" ref-type="bibr">221</xref>]. Interestingly, the similarities in the gut dysbiosis between PWH and obese or diabetic subjects may partly explain the high prevalence of metabolic comorbidities, as well as NAFLD, in the setting of HIV. Another clue about the close relationships between HIV, metabolic diseases, and the microbiome lies in the pharmacodynamics of maraviroc. Maraviroc is a CCR5 antagonist currently approved for HIV treatment that also shows anti-inflammatory properties and beneficial effects on glucose and lipid metabolism [<xref rid="B222-nutrients-15-01990" ref-type="bibr">222</xref>]. In a preclinical study, P&#233;rez-Matute and colleagues demonstrated that a maraviroc treatment significantly changed the microbiomes of mice by reducing Enterobacteriales, a bacterial order that, in the same cohort, was positively associated with weight gain, insulin resistance, and fatty liver [<xref rid="B223-nutrients-15-01990" ref-type="bibr">223</xref>]. Under these assumptions, maraviroc could also be a valuable treatment for NAFLD in PWH, although a clinical trial failed to demonstrate its efficacy [<xref rid="B189-nutrients-15-01990" ref-type="bibr">189</xref>]. Focusing on the role of microbiota in the nutritional approaches to NAFLD in PWH, Yanavich et al. revealed a distinct microbiome profile for liver steatosis and fibrosis among 82 HIV monoinfected patients divided into a steatosis group, fibrosis group, and normal group, according to transient elastography results [<xref rid="B224-nutrients-15-01990" ref-type="bibr">224</xref>]. Some microbial perturbations were previously identified in other cohorts of NAFLD-uninfected patients, including increases in <italic toggle="yes">P. copri</italic>, while others, such as <italic toggle="yes">E. rectale</italic>, <italic toggle="yes">F. magna</italic>, <italic toggle="yes">F. prausnitzii</italic>, <italic toggle="yes">A. muciniphila</italic>, <italic toggle="yes">B. fragilis</italic>, <italic toggle="yes">B. dorei,</italic> and various species of Prevotella, were specific to this study population [<xref rid="B224-nutrients-15-01990" ref-type="bibr">224</xref>]. Surprisingly, the authors reported no significant differences in the macronutrient intakes between the normal, steatosis, and fibrosis groups, suggesting a lack of association between diet and gut dysbiosis [<xref rid="B224-nutrients-15-01990" ref-type="bibr">224</xref>]. This result is in contrast with the large body of evidence for the uninfected population, which identifies diet as a strong modulator of the microbiome composition [<xref rid="B225-nutrients-15-01990" ref-type="bibr">225</xref>,<xref rid="B226-nutrients-15-01990" ref-type="bibr">226</xref>,<xref rid="B227-nutrients-15-01990" ref-type="bibr">227</xref>,<xref rid="B228-nutrients-15-01990" ref-type="bibr">228</xref>]. In another study of 33 biopsy-proven PWH with NAFLD, Maurice et al. did not find any association between NAFLD or liver fibrosis and a distinct gut microbial signature, although they reported significant differences in the intestinal flora compositions between the PWH and an age- and sex-matched healthy control group [<xref rid="B229-nutrients-15-01990" ref-type="bibr">229</xref>]. This might be ascribed to methodological limitations, such as the small sample size or the use of markers of bacterial translocation (lipopolysaccharide-binding protein, bacterial DNA, and lipopolysaccharide), lacking robust and reproducible assays. Nevertheless, discordances among the studies examining the role of the gut microbiome in liver diseases are significant, and associations of specific bacterial populations with NAFLD are rarely replicated in subsequent research. This may be due to the extreme heterogeneity of microbiome sequencing methods, liver disease diagnostic techniques, and disease severity, as well as the clinical and demographic features among the different studies. We feel that further investigations are required to better elucidate the role of gut microbiota in PWH with NAFLD, together with the impact of dietary pattern changes on the intestinal dysbiosis of PWH.</p></sec></sec><sec sec-type="conclusions" id="sec5-nutrients-15-01990"><title>5. Conclusions</title><p>Our review shows a lack of studies specifically addressing nutritional and lifestyle therapies for NAFLD in the setting of HIV. A fatty acids imbalance seems to be associated with hepatic steatosis in PWH and, in line with evidence for the uninfected population, PWH with NAFLD should avoid a diet that is rich in saturated fatty acids, refined carbohydrates, fructose-added beverages, and red processed meat. Although strict alcohol abstinence is recommended for patients with liver cirrhosis [<xref rid="B165-nutrients-15-01990" ref-type="bibr">165</xref>,<xref rid="B230-nutrients-15-01990" ref-type="bibr">230</xref>], future research on PWH with NAFLD will investigate whether a light alcohol consumption should also be completely avoided. Conversely, black coffee seems to have a beneficial impact on liver fibrosis in HIV/HCV coinfection, with a need for confirmation in HIV monoinfection. Moreover, vitamin E administration has a proven efficacy for NASH in PWH, while the roles of vitamin D supplementation and oral cannabinoids need to be further explored. Indeed, with no current approved medication and novel pharmacological NASH trials still excluding PWH, diet and exercise remain the cornerstones of NAFLD treatment in PWH, with weight loss targets of 7&#8211;10% and 3&#8211;5% in overweight/obese and lean individuals, respectively. Importantly, any successful nutritional intervention should also address food insecurity, which has been shown to worsen liver and cardiovascular diseases in PWH. Future research should focus on tailoring lifestyle therapy for NALFD to the specific needs of PWH, possibly using telemedicine and the engagement of PWH to increase patients&#8217; awareness and adherence.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-nutrients-15-01990"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/nu15081990/s1">https://www.mdpi.com/article/10.3390/nu15081990/s1</uri>, Figure S1: The role of food insecurity on health outcomes. </p><supplementary-material id="nutrients-15-01990-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutrients-15-01990-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Writing&#8212;original draft preparation, F.C. and G.S.; writing&#8212;review and editing, F.C., A.C., R.L., G.G. and G.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>G.S. acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Pfizer, served as an advisory board member for Pfizer, Merck, Novonordisk, Gilead, and has received unrestricted research funding from Theratechnologies Inc. G.G. received a research grant and speaker honoraria from Gilead, ViiV, Merck and Jansen and attended advisory boards of Gilead, ViiV and Merck. F.C., A.C. and R.L. declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-15-01990"><label>1.</label><element-citation publication-type="webpage"><article-title>Global HIV &amp; AIDS Statistics&#8212;Fact Sheet</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unaids.org/en/resources/fact-sheet" ext-link-type="uri">https://www.unaids.org/en/resources/fact-sheet</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-28">(accessed on 28 January 2023)</date-in-citation></element-citation></ref><ref id="B2-nutrients-15-01990"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palella</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Loveless</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Holmberg</surname><given-names>S.D.</given-names></name></person-group><article-title>Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection</article-title><source>N. Engl. J. Med.</source><year>1998</year><volume>383</volume><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1056/NEJM199803263381301</pub-id><pub-id pub-id-type="pmid">9516219</pub-id></element-citation></ref><ref id="B3-nutrients-15-01990"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Maduro</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torian</surname><given-names>L.V.</given-names></name></person-group><article-title>Life Expectancy Among People with HIV in New York City, 2009&#8211;2018</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>2022</year><volume>91</volume><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000003095</pub-id><pub-id pub-id-type="pmid">36084201</pub-id></element-citation></ref><ref id="B4-nutrients-15-01990"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croxford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kitching</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kall</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edelstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skingsley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>F.</given-names></name><name name-style="western"><surname>Copas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Mortality and Causes of Death in People Diagnosed with HIV in the Era of Highly Active Antiretroviral Therapy Compared with the General Population: An Analysis of a National Observational Cohort</article-title><source>Lancet Public Health</source><year>2017</year><volume>2</volume><fpage>e35</fpage><lpage>e46</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(16)30020-2</pub-id><pub-id pub-id-type="pmid">29249478</pub-id></element-citation></ref><ref id="B5-nutrients-15-01990"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Milic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mussini</surname><given-names>C.</given-names></name></person-group><article-title>Aging with HIV</article-title><source>Curr. HIV/AIDS Rep.</source><year>2019</year><volume>16</volume><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1007/s11904-019-00464-3</pub-id><pub-id pub-id-type="pmid">31823125</pub-id></element-citation></ref><ref id="B6-nutrients-15-01990"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Orlando</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zona</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menozzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garlassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roverato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palella</surname><given-names>F.</given-names></name></person-group><article-title>Premature Age-Related Comorbidities Among HIV-Infected Persons Compared with the General Population</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>53</volume><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1093/cid/cir627</pub-id><pub-id pub-id-type="pmid">21998278</pub-id></element-citation></ref><ref id="B7-nutrients-15-01990"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taiwo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seedat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Autran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Katlama</surname><given-names>C.</given-names></name></person-group><article-title>HIV</article-title><source>The Lancet</source><year>2018</year><volume>392</volume><fpage>685</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31311-4</pub-id><pub-id pub-id-type="pmid">30049419</pub-id></element-citation></ref><ref id="B8-nutrients-15-01990"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaspar</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>R.K.</given-names></name></person-group><article-title>Mechanisms of Liver Disease in Patients Infected with HIV</article-title><source>BMJ Open Gastroenterol.</source><year>2017</year><volume>4</volume><fpage>e000166</fpage><pub-id pub-id-type="doi">10.1136/bmjgast-2017-000166</pub-id><pub-id pub-id-type="pmcid">PMC5663263</pub-id><pub-id pub-id-type="pmid">29119002</pub-id></element-citation></ref><ref id="B9-nutrients-15-01990"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Marietti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eslam</surname><given-names>M.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bugianesi</surname><given-names>E.</given-names></name></person-group><article-title>Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2018</year><volume>15</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2017.109</pub-id><pub-id pub-id-type="pmid">28930295</pub-id></element-citation></ref><ref id="B10-nutrients-15-01990"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinella</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Neuschwander-Tetri</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Abdelmalek</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barb</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R.</given-names></name></person-group><article-title>AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease</article-title><source>Hepatology</source><year>2023</year><pub-id pub-id-type="doi">10.1097/HEP.0000000000000323</pub-id><pub-id pub-id-type="pmcid">PMC10735173</pub-id><pub-id pub-id-type="pmid">36727674</pub-id></element-citation></ref><ref id="B11-nutrients-15-01990"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>T.</given-names></name></person-group><article-title>Natural History of NAFLD</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>1161</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10061161</pub-id><pub-id pub-id-type="pmid">33802047</pub-id><pub-id pub-id-type="pmcid">PMC8000279</pub-id></element-citation></ref><ref id="B12-nutrients-15-01990"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Golabi</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Avila</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Srishord</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>L.</given-names></name><name name-style="western"><surname>Afendy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nader</surname><given-names>F.</given-names></name></person-group><article-title>The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis</article-title><source>J. Hepatol.</source><year>2019</year><volume>71</volume><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.021</pub-id><pub-id pub-id-type="pmid">31279902</pub-id></element-citation></ref><ref id="B13-nutrients-15-01990"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eslam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neuschwander-Tetri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tiribelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bugianesi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yki-J&#228;rvinen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>1999</fpage><lpage>2014.e1</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.11.312</pub-id><pub-id pub-id-type="pmid">32044314</pub-id></element-citation></ref><ref id="B14-nutrients-15-01990"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eslam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Newsome</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Sarin</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Romero-Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zelber-Sagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wai-Sun Wong</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Schattenberg</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement</article-title><source>J. Hepatol.</source><year>2020</year><volume>73</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.03.039</pub-id><pub-id pub-id-type="pmid">32278004</pub-id></element-citation></ref><ref id="B15-nutrients-15-01990"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leoni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alswat</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Fouad</surname><given-names>Y.</given-names></name></person-group><article-title>History of Nonalcoholic Fatty Liver Disease</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>5888</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21165888</pub-id><pub-id pub-id-type="pmid">32824337</pub-id><pub-id pub-id-type="pmcid">PMC7460697</pub-id></element-citation></ref><ref id="B16-nutrients-15-01990"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shengir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>G.</given-names></name></person-group><article-title>NASH in HIV</article-title><source>Curr. HIV/AIDS Rep.</source><year>2020</year><volume>17</volume><fpage>601</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1007/s11904-020-00531-0</pub-id><pub-id pub-id-type="pmid">32984925</pub-id></element-citation></ref><ref id="B17-nutrients-15-01990"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thursz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemoine</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in HIV-Monoinfection</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>1621</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001504</pub-id><pub-id pub-id-type="pmid">28398960</pub-id></element-citation></ref><ref id="B18-nutrients-15-01990"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalligeros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vassilopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shehadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vassilopoulos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lazaridou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mylonakis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Promrat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wands</surname><given-names>J.R.</given-names></name></person-group><article-title>Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living with HIV Monoinfection: A Systematic Review and Meta-Analysis</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.cgh.2023.01.001</pub-id><pub-id pub-id-type="pmid">36642292</pub-id></element-citation></ref><ref id="B19-nutrients-15-01990"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verna</surname><given-names>E.C.</given-names></name></person-group><article-title>Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Patients with HIV</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2017</year><volume>2</volume><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(16)30120-0</pub-id><pub-id pub-id-type="pmid">28404136</pub-id></element-citation></ref><ref id="B20-nutrients-15-01990"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lonardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Palella</surname><given-names>F.J.</given-names></name></person-group><article-title>Metabolic Concerns in Aging HIV-Infected Persons: From Serum Lipid Phenotype to Fatty Liver</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>S147</fpage><lpage>S156</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001483</pub-id><pub-id pub-id-type="pmid">28471945</pub-id></element-citation></ref><ref id="B21-nutrients-15-01990"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelber-Sagi</surname><given-names>S.</given-names></name></person-group><article-title>Nutrition and Physical Activity in NAFLD: An Overview of the Epidemiological Evidence</article-title><source>WJG</source><year>2011</year><volume>17</volume><fpage>3377</fpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i29.3377</pub-id><pub-id pub-id-type="pmid">21876630</pub-id><pub-id pub-id-type="pmcid">PMC3160564</pub-id></element-citation></ref><ref id="B22-nutrients-15-01990"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EASL&#8211;EASD&#8211;EASO</collab></person-group><article-title>Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease</article-title><source>J. Hepatol.</source><year>2016</year><volume>64</volume><fpage>1388</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.11.004</pub-id><pub-id pub-id-type="pmid">27062661</pub-id></element-citation></ref><ref id="B23-nutrients-15-01990"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarthy</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Waddell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guess</surname><given-names>N.</given-names></name></person-group><article-title>Nutrition and Nonalcoholic Fatty Liver Disease</article-title><source>Gastroenterol. Clin. North Am.</source><year>2020</year><volume>49</volume><fpage>63</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.gtc.2019.09.003</pub-id><pub-id pub-id-type="pmid">32033765</pub-id></element-citation></ref><ref id="B24-nutrients-15-01990"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevastianova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kotronen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hakkarainen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Makkonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silander</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peltonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lundbom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lundbom</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Effect of Short-Term Carbohydrate Overfeeding and Long-Term Weight Loss on Liver Fat in Overweight Humans</article-title><source>Am. J. Clin. Nutr.</source><year>2012</year><volume>96</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.038695</pub-id><pub-id pub-id-type="pmid">22952180</pub-id></element-citation></ref><ref id="B25-nutrients-15-01990"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nseir</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Assy</surname><given-names>N.</given-names></name></person-group><article-title>Soft Drinks Consumption and Nonalcoholic Fatty Liver Disease</article-title><source>World J. Gastroenterol.</source><year>2010</year><volume>16</volume><fpage>2579</fpage><lpage>2588</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i21.2579</pub-id><pub-id pub-id-type="pmid">20518077</pub-id><pub-id pub-id-type="pmcid">PMC2880768</pub-id></element-citation></ref><ref id="B26-nutrients-15-01990"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nseir</surname><given-names>W.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grosovski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Assy</surname><given-names>N.</given-names></name></person-group><article-title>Soft Drink Consumption Is Associated with Fatty Liver Disease Independent of Metabolic Syndrome</article-title><source>J. Hepatol.</source><year>2009</year><volume>51</volume><fpage>918</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.05.033</pub-id><pub-id pub-id-type="pmid">19765850</pub-id></element-citation></ref><ref id="B27-nutrients-15-01990"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Association Between Dietary Fiber Intake and Non-Alcoholic Fatty Liver Disease in Adults</article-title><source>Front. Nutr.</source><year>2020</year><volume>7</volume><fpage>593735</fpage><pub-id pub-id-type="doi">10.3389/fnut.2020.593735</pub-id><pub-id pub-id-type="pmid">33330594</pub-id><pub-id pub-id-type="pmcid">PMC7710900</pub-id></element-citation></ref><ref id="B28-nutrients-15-01990"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zolfaghari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Askari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Siassi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sotoudeh</surname><given-names>G.</given-names></name></person-group><article-title>Intake of Nutrients, Fiber, and Sugar in Patients with Nonalcoholic Fatty Liver Disease in Comparison to Healthy Individuals</article-title><source>Int. J. Prev. Med.</source><year>2016</year><volume>7</volume><fpage>98</fpage><pub-id pub-id-type="doi">10.4103/2008-7802.188083</pub-id><pub-id pub-id-type="pmid">27625763</pub-id><pub-id pub-id-type="pmcid">PMC4995850</pub-id></element-citation></ref><ref id="B29-nutrients-15-01990"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maciejewska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ryterska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Czerwi&#324;ka-Rogowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jamio&#322;-Milc</surname><given-names>D.</given-names></name><name name-style="western"><surname>Skonieczna-&#379;ydecka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Milkiewicz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raszeja-Wyszomirska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stachowska</surname><given-names>E.</given-names></name></person-group><article-title>Gut Permeability Might Be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1793</elocation-id><pub-id pub-id-type="doi">10.3390/nu10111793</pub-id><pub-id pub-id-type="pmid">30453660</pub-id><pub-id pub-id-type="pmcid">PMC6266494</pub-id></element-citation></ref><ref id="B30-nutrients-15-01990"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barber</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Kabisch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>A.F.H.</given-names></name><name name-style="western"><surname>Weickert</surname><given-names>M.O.</given-names></name></person-group><article-title>The Health Benefits of Dietary Fibre</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>3209</elocation-id><pub-id pub-id-type="doi">10.3390/nu12103209</pub-id><pub-id pub-id-type="pmid">33096647</pub-id><pub-id pub-id-type="pmcid">PMC7589116</pub-id></element-citation></ref><ref id="B31-nutrients-15-01990"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mainali</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nagpal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sheikh-Zeinoddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soleimanian-Zad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deep</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kumar Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>H.</given-names></name></person-group><article-title>Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases</article-title><source>Obes. Control Ther.</source><year>2017</year><volume>4</volume><fpage>7058</fpage><lpage>7069</lpage><pub-id pub-id-type="doi">10.15226/2374-8354/4/2/00140</pub-id><pub-id pub-id-type="pmcid">PMC6249025</pub-id><pub-id pub-id-type="pmid">30474051</pub-id></element-citation></ref><ref id="B32-nutrients-15-01990"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parry</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hodson</surname><given-names>L.</given-names></name></person-group><article-title>Influence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism</article-title><source>J. Investig. Med.</source><year>2017</year><volume>65</volume><fpage>1102</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1136/jim-2017-000524</pub-id><pub-id pub-id-type="pmcid">PMC5749316</pub-id><pub-id pub-id-type="pmid">28947639</pub-id></element-citation></ref><ref id="B33-nutrients-15-01990"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Errazuriz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dube</surname><given-names>S.</given-names></name><name name-style="western"><surname>Slama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Visentin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nayar</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cobelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kremers</surname><given-names>W.K.</given-names></name><etal/></person-group><article-title>Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2017</year><volume>102</volume><fpage>1765</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1210/jc.2016-3722</pub-id><pub-id pub-id-type="pmid">28323952</pub-id><pub-id pub-id-type="pmcid">PMC5443322</pub-id></element-citation></ref><ref id="B34-nutrients-15-01990"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capanni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Biagini</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Genise</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bedogni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Svegliati-Baroni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sofi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Milani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abbate</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Prolonged N-3 Polyunsaturated Fatty Acid Supplementation Ameliorates Hepatic Steatosis in Patients with Non-Alcoholic Fatty Liver Disease: A Pilot Study</article-title><source>Aliment. Pharmacol. Ther.</source><year>2006</year><volume>23</volume><fpage>1143</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02885.x</pub-id><pub-id pub-id-type="pmid">16611275</pub-id></element-citation></ref><ref id="B35-nutrients-15-01990"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortez-Pinto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jesus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Camilo</surname><given-names>M.E.</given-names></name></person-group><article-title>How Different Is the Dietary Pattern in Non-Alcoholic Steatohepatitis Patients?</article-title><source>Clin. Nutr.</source><year>2006</year><volume>25</volume><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2006.01.027</pub-id><pub-id pub-id-type="pmid">16677739</pub-id></element-citation></ref><ref id="B36-nutrients-15-01990"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tric&#242;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Biancalana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Solini</surname><given-names>A.</given-names></name></person-group><article-title>Protein and Amino Acids in Nonalcoholic Fatty Liver Disease</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><year>2021</year><volume>24</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1097/MCO.0000000000000706</pub-id><pub-id pub-id-type="pmid">33060460</pub-id></element-citation></ref><ref id="B37-nutrients-15-01990"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelber-Sagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivancovsky-Wajcman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fliss Isakov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shibolet</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kariv</surname><given-names>R.</given-names></name></person-group><article-title>High Red and Processed Meat Consumption Is Associated with Non-Alcoholic Fatty Liver Disease and Insulin Resistance</article-title><source>J. Hepatol.</source><year>2018</year><volume>68</volume><fpage>1239</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.01.015</pub-id><pub-id pub-id-type="pmid">29571924</pub-id></element-citation></ref><ref id="B38-nutrients-15-01990"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashemian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poustchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Radmard</surname><given-names>A.-R.</given-names></name><name name-style="western"><surname>Kamangar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hekmatdoost</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population with Low Meat Consumption: The Golestan Cohort Study</article-title><source>Am. J. Gastroenterol.</source><year>2021</year><volume>116</volume><fpage>1667</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000001229</pub-id><pub-id pub-id-type="pmid">33767101</pub-id><pub-id pub-id-type="pmcid">PMC8460710</pub-id></element-citation></ref><ref id="B39-nutrients-15-01990"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Unalp-Arida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Schwimmer</surname><given-names>J.B.</given-names></name></person-group><article-title>Modest Alcohol Consumption Is Associated with Decreased Prevalence of Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)</article-title><source>J. Hepatol.</source><year>2012</year><volume>57</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.03.024</pub-id><pub-id pub-id-type="pmid">22521357</pub-id><pub-id pub-id-type="pmcid">PMC3399018</pub-id></element-citation></ref><ref id="B40-nutrients-15-01990"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Greenson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Conjeevaram</surname><given-names>H.S.</given-names></name></person-group><article-title>Effect of Lifetime Alcohol Consumption on the Histological Severity of Non-Alcoholic Fatty Liver Disease</article-title><source>Liver Int.</source><year>2014</year><volume>34</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1111/liv.12230</pub-id><pub-id pub-id-type="pmid">23809459</pub-id></element-citation></ref><ref id="B41-nutrients-15-01990"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashiwagi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taniki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takaishi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>T.</given-names></name></person-group><article-title>Moderate Alcohol Consumption Is Not Associated with Subclinical Cardiovascular Damage but with Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease</article-title><source>Alcohol</source><year>2020</year><volume>89</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2020.07.010</pub-id><pub-id pub-id-type="pmid">32738385</pub-id></element-citation></ref><ref id="B42-nutrients-15-01990"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blomdahl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ekstedt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kechagias</surname><given-names>S.</given-names></name></person-group><article-title>Moderate Alcohol Consumption Is Associated with Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease and Shows a Synergistic Effect with Type 2 Diabetes Mellitus</article-title><source>Metabolism</source><year>2021</year><volume>115</volume><fpage>154439</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2020.154439</pub-id><pub-id pub-id-type="pmid">33246008</pub-id></element-citation></ref><ref id="B43-nutrients-15-01990"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascha</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hanouneh</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tamimi</surname><given-names>T.A.-R.</given-names></name><name name-style="western"><surname>Feldstein</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Zein</surname><given-names>N.N.</given-names></name></person-group><article-title>The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>1972</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1002/hep.23527</pub-id><pub-id pub-id-type="pmid">20209604</pub-id></element-citation></ref><ref id="B44-nutrients-15-01990"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarvis</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Keefe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanratty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>Q.M.</given-names></name></person-group><article-title>Does Moderate Alcohol Consumption Accelerate the Progression of Liver Disease in NAFLD? A Systematic Review and Narrative Synthesis</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e049767</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-049767</pub-id><pub-id pub-id-type="pmid">34983755</pub-id><pub-id pub-id-type="pmcid">PMC8728442</pub-id></element-citation></ref><ref id="B45-nutrients-15-01990"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinn</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Gwak</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Son</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>B.C.</given-names></name></person-group><article-title>Modest Alcohol Consumption and Carotid Plaques or Carotid Artery Stenosis in Men with Non-Alcoholic Fatty Liver Disease</article-title><source>Atherosclerosis</source><year>2014</year><volume>234</volume><fpage>270</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.03.001</pub-id><pub-id pub-id-type="pmid">24704629</pub-id></element-citation></ref><ref id="B46-nutrients-15-01990"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanWagner</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>H.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Ajmera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lloyd-Jones</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Terrault</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>J.</given-names></name></person-group><article-title>Alcohol Use and Cardiovascular Disease Risk in Patients with Nonalcoholic Fatty Liver Disease</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><fpage>1260</fpage><lpage>1272.e3</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.08.012</pub-id><pub-id pub-id-type="pmid">28802566</pub-id><pub-id pub-id-type="pmcid">PMC5669829</pub-id></element-citation></ref><ref id="B47-nutrients-15-01990"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butt</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>M.T.</given-names></name></person-group><article-title>Coffee and Its Consumption: Benefits and Risks</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2011</year><volume>51</volume><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1080/10408390903586412</pub-id><pub-id pub-id-type="pmid">21432699</pub-id></element-citation></ref><ref id="B48-nutrients-15-01990"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadhawan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>A.C.</given-names></name></person-group><article-title>Coffee and Liver Disease</article-title><source>J. Clin. Exp. Hepatol.</source><year>2016</year><volume>6</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2016.02.003</pub-id><pub-id pub-id-type="pmid">27194895</pub-id><pub-id pub-id-type="pmcid">PMC4862107</pub-id></element-citation></ref><ref id="B49-nutrients-15-01990"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sewter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heaney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>A.</given-names></name></person-group><article-title>Coffee Consumption and the Progression of NAFLD: A Systematic Review</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>2381</elocation-id><pub-id pub-id-type="doi">10.3390/nu13072381</pub-id><pub-id pub-id-type="pmid">34371891</pub-id><pub-id pub-id-type="pmcid">PMC8308484</pub-id></element-citation></ref><ref id="B50-nutrients-15-01990"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marjoux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iannelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patouraux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Bonnafous</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amzolini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ben-Amor</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saint-Paul</surname><given-names>M.-C.</given-names></name><etal/></person-group><article-title>Regular Coffee but Not Espresso Drinking Is Protective against Fibrosis in a Cohort Mainly Composed of Morbidly Obese European Women with NAFLD Undergoing Bariatric Surgery</article-title><source>J. Hepatol.</source><year>2012</year><volume>57</volume><fpage>1090</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.07.014</pub-id><pub-id pub-id-type="pmid">22820478</pub-id></element-citation></ref><ref id="B51-nutrients-15-01990"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saab</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mallam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cox II</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>M.J.</given-names></name></person-group><article-title>Impact of Coffee on Liver Diseases: A Systematic Review</article-title><source>Liver Int.</source><year>2014</year><volume>34</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1111/liv.12304</pub-id><pub-id pub-id-type="pmid">24102757</pub-id></element-citation></ref><ref id="B52-nutrients-15-01990"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dranoff</surname><given-names>J.A.</given-names></name></person-group><article-title>Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis</article-title><source>Gene Expr.</source><year>2018</year><volume>18</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.3727/105221617X15046391179559</pub-id><pub-id pub-id-type="pmid">28893365</pub-id><pub-id pub-id-type="pmcid">PMC5885142</pub-id></element-citation></ref><ref id="B53-nutrients-15-01990"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohajeri-Tehrani</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Samadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qorbani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adibi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poustchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hekmatdoost</surname><given-names>A.</given-names></name></person-group><article-title>Effects of Supplementation with Main Coffee Components Including Caffeine and/or Chlorogenic Acid on Hepatic, Metabolic, and Inflammatory Indices in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial</article-title><source>Nutr. J.</source><year>2021</year><volume>20</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s12937-021-00694-5</pub-id><pub-id pub-id-type="pmid">33838673</pub-id><pub-id pub-id-type="pmcid">PMC8037901</pub-id></element-citation></ref><ref id="B54-nutrients-15-01990"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dongiovanni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lanti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Riso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>L.</given-names></name></person-group><article-title>Nutritional Therapy for Nonalcoholic Fatty Liver Disease</article-title><source>J. Nutr. Biochem.</source><year>2016</year><volume>29</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.08.024</pub-id><pub-id pub-id-type="pmid">26895659</pub-id></element-citation></ref><ref id="B55-nutrients-15-01990"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perumpail</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>John</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sallam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cholankeril</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name></person-group><article-title>The Role of Vitamin E in the Treatment of NAFLD</article-title><source>Diseases</source><year>2018</year><volume>6</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.3390/diseases6040086</pub-id><pub-id pub-id-type="pmid">30249972</pub-id><pub-id pub-id-type="pmcid">PMC6313719</pub-id></element-citation></ref><ref id="B56-nutrients-15-01990"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kowdley</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bass</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Neuschwander-Tetri</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Tonascia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unalp</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>1675</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0907929</pub-id><pub-id pub-id-type="pmid">20427778</pub-id><pub-id pub-id-type="pmcid">PMC2928471</pub-id></element-citation></ref><ref id="B57-nutrients-15-01990"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavine</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Schwimmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Van Natta</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Molleston</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Scheimann</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.520</pub-id><pub-id pub-id-type="pmid">21521847</pub-id><pub-id pub-id-type="pmcid">PMC3110082</pub-id></element-citation></ref><ref id="B58-nutrients-15-01990"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vuppalanchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gawrieh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghabril</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>O.W.</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name></person-group><article-title>Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><fpage>495</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1002/hep.30368</pub-id><pub-id pub-id-type="pmid">30506586</pub-id></element-citation></ref><ref id="B59-nutrients-15-01990"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S.A.</given-names></name></person-group><article-title>Vitamin D and Nonalcoholic Fatty Liver Disease (NAFLD): Is It More than Just an Association?</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><fpage>1166</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1002/hep.26390</pub-id><pub-id pub-id-type="pmid">23504808</pub-id></element-citation></ref><ref id="B60-nutrients-15-01990"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandol</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name></person-group><article-title>Vitamin D Deficiency Promotes Nonalcoholic Steatohepatitis through Impaired Enterohepatic Circulation in Animal Model</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2014</year><volume>307</volume><fpage>G883</fpage><lpage>G893</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00427.2013</pub-id><pub-id pub-id-type="pmid">25214402</pub-id><pub-id pub-id-type="pmcid">PMC4216990</pub-id></element-citation></ref><ref id="B61-nutrients-15-01990"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leblanc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>601</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.028</pub-id><pub-id pub-id-type="pmid">23622244</pub-id><pub-id pub-id-type="pmcid">PMC3673534</pub-id></element-citation></ref><ref id="B62-nutrients-15-01990"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliades</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lazo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brancati</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Koteish</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Guallar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hernaez</surname><given-names>R.</given-names></name></person-group><article-title>Meta-Analysis: Vitamin D and Non-Alcoholic Fatty Liver Disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2013</year><volume>38</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1111/apt.12377</pub-id><pub-id pub-id-type="pmid">23786213</pub-id></element-citation></ref><ref id="B63-nutrients-15-01990"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.-H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-B.</given-names></name></person-group><article-title>Association of Serum Vitamin D Level and Nonalcoholic Fatty Liver Disease: A Meta-Analysis</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2020</year><volume>32</volume><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000001486</pub-id><pub-id pub-id-type="pmid">31895886</pub-id></element-citation></ref><ref id="B64-nutrients-15-01990"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pop</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>S&#238;rbe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ben&#355;a</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mititelu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grama</surname><given-names>A.</given-names></name></person-group><article-title>The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>10705</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231810705</pub-id><pub-id pub-id-type="pmid">36142636</pub-id><pub-id pub-id-type="pmcid">PMC9503777</pub-id></element-citation></ref><ref id="B65-nutrients-15-01990"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaruvongvanich</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sanguankeo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wijarnpreecha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Upala</surname><given-names>S.</given-names></name></person-group><article-title>Vitamin D and Histologic Severity of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis</article-title><source>Dig. Liver Dis.</source><year>2017</year><volume>49</volume><fpage>618</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2017.02.003</pub-id><pub-id pub-id-type="pmid">28274829</pub-id></element-citation></ref><ref id="B66-nutrients-15-01990"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Vitamin D and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials</article-title><source>Food Funct.</source><year>2020</year><volume>11</volume><fpage>7389</fpage><lpage>7399</lpage><pub-id pub-id-type="doi">10.1039/D0FO01095B</pub-id><pub-id pub-id-type="pmid">32966467</pub-id></element-citation></ref><ref id="B67-nutrients-15-01990"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliades</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>E.</given-names></name></person-group><article-title>Vitamin D: A New Player in Non-Alcoholic Fatty Liver Disease?</article-title><source>World J. Gastroenterol.</source><year>2015</year><volume>21</volume><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i6.1718</pub-id><pub-id pub-id-type="pmid">25684936</pub-id><pub-id pub-id-type="pmcid">PMC4323447</pub-id></element-citation></ref><ref id="B68-nutrients-15-01990"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abenavoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Larussa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Corea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Procopio</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Boccuto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dallio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luzza</surname><given-names>F.</given-names></name></person-group><article-title>Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>494</elocation-id><pub-id pub-id-type="doi">10.3390/nu13020494</pub-id><pub-id pub-id-type="pmid">33546130</pub-id><pub-id pub-id-type="pmcid">PMC7913263</pub-id></element-citation></ref><ref id="B69-nutrients-15-01990"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asgary</surname><given-names>S.</given-names></name><name name-style="western"><surname>Askari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keshvari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatamipour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of Non-Alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-Controlled Trial</article-title><source>Phytother. Res.</source><year>2016</year><volume>30</volume><fpage>1540</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1002/ptr.5659</pub-id><pub-id pub-id-type="pmid">27270872</pub-id></element-citation></ref><ref id="B70-nutrients-15-01990"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panahi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kianpour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohtashami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simental-Mend&#237;a</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial</article-title><source>Drug Res.</source><year>2017</year><volume>67</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1055/s-0043-100019</pub-id><pub-id pub-id-type="pmid">28158893</pub-id></element-citation></ref><ref id="B71-nutrients-15-01990"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name></person-group><article-title>The Therapeutic Effect of Silymarin in the Treatment of Nonalcoholic Fatty Disease</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>e9061</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000009061</pub-id><pub-id pub-id-type="pmid">29245314</pub-id><pub-id pub-id-type="pmcid">PMC5728929</pub-id></element-citation></ref><ref id="B72-nutrients-15-01990"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheraghpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ommi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alavian</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Karimi-Shahrbabak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hedayati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hekmatdoost</surname><given-names>A.</given-names></name></person-group><article-title>Hesperidin Improves Hepatic Steatosis, Hepatic Enzymes, and Metabolic and Inflammatory Parameters in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-controlled, Double-blind Clinical Trial</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>2118</fpage><lpage>2125</lpage><pub-id pub-id-type="doi">10.1002/ptr.6406</pub-id><pub-id pub-id-type="pmid">31264313</pub-id></element-citation></ref><ref id="B73-nutrients-15-01990"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakubczyk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Skonieczna-&#379;ydecka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ka&#322;du&#324;ska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stachowska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gutowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Janda</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease&#8212;A Meta-Analysis</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>2435</elocation-id><pub-id pub-id-type="doi">10.3390/nu12082435</pub-id><pub-id pub-id-type="pmid">32823621</pub-id><pub-id pub-id-type="pmcid">PMC7469003</pub-id></element-citation></ref><ref id="B74-nutrients-15-01990"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mboumba Bouassa</surname><given-names>R.-S.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Marzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jenabian</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Costiniuk</surname><given-names>C.T.</given-names></name></person-group><article-title>Cannabinoids and Chronic Liver Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>9423</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23169423</pub-id><pub-id pub-id-type="pmid">36012687</pub-id><pub-id pub-id-type="pmcid">PMC9408890</pub-id></element-citation></ref><ref id="B75-nutrients-15-01990"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adejumo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Alliu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ajayi</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Adejumo</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Adegbala</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Onyeakusi</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Akinjero</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Durojaiye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bukong</surname><given-names>T.N.</given-names></name></person-group><article-title>Cannabis Use Is Associated with Reduced Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0176416</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0176416</pub-id><pub-id pub-id-type="pmid">28441459</pub-id><pub-id pub-id-type="pmcid">PMC5404771</pub-id></element-citation></ref><ref id="B76-nutrients-15-01990"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Yim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name></person-group><article-title>Inverse Association of Marijuana Use with Nonalcoholic Fatty Liver Disease among Adults in the United States</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0186702</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0186702</pub-id><pub-id pub-id-type="pmid">29049354</pub-id><pub-id pub-id-type="pmcid">PMC5648282</pub-id></element-citation></ref><ref id="B77-nutrients-15-01990"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Strat</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Le Foll</surname><given-names>B.</given-names></name></person-group><article-title>Obesity and Cannabis Use: Results from 2 Representative National Surveys</article-title><source>Am. J. Epidemiol.</source><year>2011</year><volume>174</volume><fpage>929</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1093/aje/kwr200</pub-id><pub-id pub-id-type="pmid">21868374</pub-id></element-citation></ref><ref id="B78-nutrients-15-01990"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajavashisth</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>T.C.</given-names></name></person-group><article-title>Decreased Prevalence of Diabetes in Marijuana Users: Cross-Sectional Data from the National Health and Nutrition Examination Survey (NHANES) III</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><fpage>e000494</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2011-000494</pub-id><pub-id pub-id-type="pmcid">PMC3289985</pub-id><pub-id pub-id-type="pmid">22368296</pub-id></element-citation></ref><ref id="B79-nutrients-15-01990"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidot</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Prado</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hlaing</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Florez</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Arheart</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Messiah</surname><given-names>S.E.</given-names></name></person-group><article-title>Metabolic Syndrome Among Marijuana Users in the United States: An Analysis of National Health and Nutrition Examination Survey Data</article-title><source>Am. J. Med.</source><year>2016</year><volume>129</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2015.10.019</pub-id><pub-id pub-id-type="pmid">26548604</pub-id><pub-id pub-id-type="pmcid">PMC4718895</pub-id></element-citation></ref><ref id="B80-nutrients-15-01990"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millar</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Bellman</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>England</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>S.E.</given-names></name></person-group><article-title>A Systematic Review of Cannabidiol Dosing in Clinical Populations</article-title><source>Br. J. Clin. Pharmacol.</source><year>2019</year><volume>85</volume><fpage>1888</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1111/bcp.14038</pub-id><pub-id pub-id-type="pmid">31222854</pub-id><pub-id pub-id-type="pmcid">PMC6710502</pub-id></element-citation></ref><ref id="B81-nutrients-15-01990"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arendt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.W.L.</given-names></name><name name-style="western"><surname>Aghdassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salit</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.K.H.</given-names></name><name name-style="western"><surname>Guindi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heathcote</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>J.P.</given-names></name></person-group><article-title>Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition</article-title><source>Curr. HIV Res.</source><year>2011</year><volume>9</volume><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.2174/157016211795569140</pub-id><pub-id pub-id-type="pmid">21434863</pub-id></element-citation></ref><ref id="B82-nutrients-15-01990"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Sanz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Serrano-Villar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montes</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Mart&#237;n-Mateos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Burgos-Santamar&#237;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>D&#237;az-&#193;lvarez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Talavera-Rodr&#237;guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effects of HIV Infection in Plasma Free Fatty Acid Profiles among People with Non-Alcoholic Fatty Liver Disease</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>3842</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11133842</pub-id><pub-id pub-id-type="pmid">35807127</pub-id><pub-id pub-id-type="pmcid">PMC9267237</pub-id></element-citation></ref><ref id="B83-nutrients-15-01990"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Almeida</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>C.S.D.A.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>de Andrade</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Peres</surname><given-names>W.A.F.</given-names></name><name name-style="western"><surname>do Brasil</surname><given-names>P.E.A.A.</given-names></name><etal/></person-group><article-title>Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>3462</elocation-id><pub-id pub-id-type="doi">10.3390/nu13103462</pub-id><pub-id pub-id-type="pmid">34684463</pub-id><pub-id pub-id-type="pmcid">PMC8539489</pub-id></element-citation></ref><ref id="B84-nutrients-15-01990"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Bacchetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>French</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Glesby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Golub</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Augenbraun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plankey</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Moderate Alcohol Use Is Not Associated with Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus&#8211;Coinfected Women: A Prospective Cohort Study</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>65</volume><fpage>2050</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1093/cid/cix716</pub-id><pub-id pub-id-type="pmid">29020382</pub-id><pub-id pub-id-type="pmcid">PMC5850438</pub-id></element-citation></ref><ref id="B85-nutrients-15-01990"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkegaard-Klitbo</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sigvardsen</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>K&#252;hl</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kofoed</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>K&#248;ber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nordestgaard</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Bendtsen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mocroft</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-Morbidity Liver Study</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>1353</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa246</pub-id><pub-id pub-id-type="pmid">32417886</pub-id></element-citation></ref><ref id="B86-nutrients-15-01990"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrieri</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Lions</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sogni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winnock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonnard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dabis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Spire</surname><given-names>B.</given-names></name></person-group><article-title>Association between Elevated Coffee Consumption and Daily Chocolate Intake with Normal Liver Enzymes in HIV-HCV Infected Individuals: Results from the ANRS CO13 HEPAVIH Cohort Study</article-title><source>J. Hepatol.</source><year>2014</year><volume>60</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2013.08.014</pub-id><pub-id pub-id-type="pmid">23978720</pub-id></element-citation></ref><ref id="B87-nutrients-15-01990"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrieri</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Protopopescu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rosellini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wittkop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Esterle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zucman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raffi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Poizot-Martin</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Protective Effect of Coffee Consumption on All-Cause Mortality of French HIV-HCV Co-Infected Patients</article-title><source>J. Hepatol.</source><year>2017</year><volume>67</volume><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.08.005</pub-id><pub-id pub-id-type="pmid">28942916</pub-id></element-citation></ref><ref id="B88-nutrients-15-01990"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrieri</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Protopopescu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wittkop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lacombe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Esterle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sogni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Salmon-Ceron</surname><given-names>D.</given-names></name></person-group><article-title>The Impact of Coffee Consumption on Fibrosis and Steatosis in HIV-HCV Co-Infected Patients</article-title><source>J. Hepatol.</source><year>2018</year><volume>68</volume><fpage>845</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.10.025</pub-id><pub-id pub-id-type="pmid">29104123</pub-id></element-citation></ref><ref id="B89-nutrients-15-01990"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaya</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morlat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Protopopescu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pialoux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wittkop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Esterle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort)</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>705</elocation-id><pub-id pub-id-type="doi">10.3390/nu10060705</pub-id><pub-id pub-id-type="pmid">29857547</pub-id><pub-id pub-id-type="pmcid">PMC6024311</pub-id></element-citation></ref><ref id="B90-nutrients-15-01990"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sprinz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lazzaretti</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kuhmmer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>J.P.</given-names></name></person-group><article-title>Dyslipidemia in HIV-Infected Individuals</article-title><source>Braz. J. Infect. Dis.</source><year>2010</year><volume>14</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/S1413-8670(10)70115-X</pub-id><pub-id pub-id-type="pmid">21340298</pub-id></element-citation></ref><ref id="B91-nutrients-15-01990"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunfeld</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doerrler</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shigenaga</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feingold</surname><given-names>K.R.</given-names></name></person-group><article-title>Lipids, Lipoproteins, Triglyceride Clearance, and Cytokines in Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome</article-title><source>J. Clin. Endocrinol. Metab</source><year>1992</year><volume>74</volume><fpage>1045</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1210/jcem.74.5.1373735</pub-id><pub-id pub-id-type="pmid">1373735</pub-id></element-citation></ref><ref id="B92-nutrients-15-01990"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funderburg</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>N.N.</given-names></name></person-group><article-title>Lipid Abnormalities and Inflammation in HIV Inflection</article-title><source>Curr. HIV/AIDS Rep.</source><year>2016</year><volume>13</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1007/s11904-016-0321-0</pub-id><pub-id pub-id-type="pmid">27245605</pub-id><pub-id pub-id-type="pmcid">PMC4977198</pub-id></element-citation></ref><ref id="B93-nutrients-15-01990"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oosthuizen</surname><given-names>W.</given-names></name><name name-style="western"><surname>van Graan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vorster</surname><given-names>H.H.</given-names></name></person-group><article-title>Polyunsaturated Fatty Acid Intake Is Adversely Related to Liver Function in HIV-Infected Subjects: The THUSA Study</article-title><source>Am. J. Clin. Nutr.</source><year>2006</year><volume>83</volume><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1093/ajcn/83.5.1193</pub-id><pub-id pub-id-type="pmid">16685065</pub-id></element-citation></ref><ref id="B94-nutrients-15-01990"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stonehouse</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smuts</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Loots</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Wentzel-Viljoen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vorster</surname><given-names>H.H.</given-names></name></person-group><article-title>Plasma Polyunsaturated Fatty Acids and Liver Enzymes in HIV-Infected Subjects: The Prospective Urban and Rural Epidemiology (PURE) Study</article-title><source>Am. J. Clin. Nutr.</source><year>2010</year><volume>91</volume><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28874</pub-id><pub-id pub-id-type="pmid">20071647</pub-id></element-citation></ref><ref id="B95-nutrients-15-01990"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogacci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Strocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Veronesi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cicero</surname><given-names>A.F.G.</given-names></name></person-group><article-title>Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials</article-title><source>Mar. Drugs</source><year>2020</year><volume>18</volume><elocation-id>292</elocation-id><pub-id pub-id-type="doi">10.3390/md18060292</pub-id><pub-id pub-id-type="pmid">32492789</pub-id><pub-id pub-id-type="pmcid">PMC7345035</pub-id></element-citation></ref><ref id="B96-nutrients-15-01990"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morvaridzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sepidarkish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yavari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tahvilian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heydarian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khazdouz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farsi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Persad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heshmati</surname><given-names>J.</given-names></name></person-group><article-title>The Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Factors in HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials</article-title><source>Cytokine</source><year>2020</year><volume>136</volume><fpage>155298</fpage><pub-id pub-id-type="doi">10.1016/j.cyto.2020.155298</pub-id><pub-id pub-id-type="pmid">32977239</pub-id></element-citation></ref><ref id="B97-nutrients-15-01990"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>K.E.</given-names></name></person-group><article-title>Fatty Liver Disease in Persons with HIV Infection</article-title><source>Top. Antivir. Med.</source><year>2019</year><volume>27</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">31136997</pub-id><pub-id pub-id-type="pmcid">PMC6550355</pub-id></element-citation></ref><ref id="B98-nutrients-15-01990"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sulkowski</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Chander</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.D.</given-names></name></person-group><article-title>Hazardous Drinking Is Associated with an Elevated Aspartate Aminotransferase to Platelet Ratio Index in an Urban HIV-Infected Clinical Cohort</article-title><source>HIV Med.</source><year>2009</year><volume>10</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2008.00662.x</pub-id><pub-id pub-id-type="pmid">19207596</pub-id><pub-id pub-id-type="pmcid">PMC2654191</pub-id></element-citation></ref><ref id="B99-nutrients-15-01990"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baum</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Rafie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>S.</given-names></name><name name-style="western"><surname>Page</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Campa</surname><given-names>A.</given-names></name></person-group><article-title>Alcohol Use Accelerates HIV Disease Progression</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2010</year><volume>26</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1089/aid.2009.0211</pub-id><pub-id pub-id-type="pmid">20455765</pub-id><pub-id pub-id-type="pmcid">PMC2875959</pub-id></element-citation></ref><ref id="B100-nutrients-15-01990"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hahn</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Samet</surname><given-names>J.H.</given-names></name></person-group><article-title>Alcohol and HIV Disease Progression: Weighing the Evidence</article-title><source>Curr. HIV/AIDS Rep.</source><year>2010</year><volume>7</volume><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1007/s11904-010-0060-6</pub-id><pub-id pub-id-type="pmid">20814765</pub-id><pub-id pub-id-type="pmcid">PMC2938419</pub-id></element-citation></ref><ref id="B101-nutrients-15-01990"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balagopal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Philp</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Astemborski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Block</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Long</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.022</pub-id><pub-id pub-id-type="pmid">18457674</pub-id><pub-id pub-id-type="pmcid">PMC2644903</pub-id></element-citation></ref><ref id="B102-nutrients-15-01990"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>G.</given-names></name></person-group><article-title>Mechanisms of Alcohol-Mediated Hepatotoxicity in Human-Immunodeficiency-Virus-Infected Patients</article-title><source>WJG</source><year>2011</year><volume>17</volume><fpage>2500</fpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i20.2500</pub-id><pub-id pub-id-type="pmid">21633654</pub-id><pub-id pub-id-type="pmcid">PMC3103807</pub-id></element-citation></ref><ref id="B103-nutrients-15-01990"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>M.</given-names></name><name name-style="western"><surname>New-Aaron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kharbanda</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Kidambi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poluektova</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Osna</surname><given-names>N.A.</given-names></name></person-group><article-title>Alcohol Metabolism Potentiates HIV-Induced Hepatotoxicity: Contribution to End-Stage Liver Disease</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>851</elocation-id><pub-id pub-id-type="doi">10.3390/biom9120851</pub-id><pub-id pub-id-type="pmid">31835520</pub-id><pub-id pub-id-type="pmcid">PMC6995634</pub-id></element-citation></ref><ref id="B104-nutrients-15-01990"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>New-Aaron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomes</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dagur</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Kusum</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Poluektova</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Osna</surname><given-names>N.A.</given-names></name></person-group><article-title>Alcohol-Induced Lysosomal Damage and Suppression of Lysosome Biogenesis Contribute to Hepatotoxicity in HIV-Exposed Liver Cells</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1497</elocation-id><pub-id pub-id-type="doi">10.3390/biom11101497</pub-id><pub-id pub-id-type="pmid">34680130</pub-id><pub-id pub-id-type="pmcid">PMC8533635</pub-id></element-citation></ref><ref id="B105-nutrients-15-01990"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebastiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lebouche</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Pokomandy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haraoui</surname><given-names>L.-P.</given-names></name><name name-style="western"><surname>Routy</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deschenes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghali</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Vitamin E Is an Effective Treatment for Nonalcoholic Steatohepatitis in HIV Mono-Infected Patients</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002412</pub-id><pub-id pub-id-type="pmid">31651429</pub-id></element-citation></ref><ref id="B106-nutrients-15-01990"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzm&#225;n-Fulgencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-&#193;lvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berenguer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Sousa</surname><given-names>M.&#193;.</given-names></name><name name-style="western"><surname>Cos&#237;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pineda-Tenor</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ald&#225;miz</surname><given-names>T.</given-names></name><name name-style="western"><surname>&#193;lvarez</surname><given-names>E.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Vitamin D Deficiency Is Associated with Severity of Liver Disease in HIV/HCV Coinfected Patients</article-title><source>J. Infect.</source><year>2014</year><volume>68</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2013.10.011</pub-id><pub-id pub-id-type="pmid">24184809</pub-id></element-citation></ref><ref id="B107-nutrients-15-01990"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terrier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carrat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piroth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Halfon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poynard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Souberbielle</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Cacoub</surname><given-names>P.</given-names></name></person-group><article-title>Low 25-OH Vitamin D Serum Levels Correlate with Severe Fibrosis in HIV-HCV Co-Infected Patients with Chronic Hepatitis</article-title><source>J. Hepatol.</source><year>2011</year><volume>55</volume><fpage>756</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.01.041</pub-id><pub-id pub-id-type="pmid">21334402</pub-id></element-citation></ref><ref id="B108-nutrients-15-01990"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Maouche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Torbenson</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Sulkowski</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T.T.</given-names></name></person-group><article-title>Vitamin D Deficiency and Its Relation to Bone Mineral Density and Liver Fibrosis in HIV&#8211;HCV Coinfection</article-title><source>Antivir. Ther.</source><year>2013</year><volume>18</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.3851/IMP2264</pub-id><pub-id pub-id-type="pmid">22910231</pub-id><pub-id pub-id-type="pmcid">PMC3790468</pub-id></element-citation></ref><ref id="B109-nutrients-15-01990"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menozzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schepis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Malagoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Besutti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Franconi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mussini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Liver Steatosis and Nonalcoholic Fatty Liver Disease with Fibrosis Are Predictors of Frailty in People Living with HIV</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>1915</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002650</pub-id><pub-id pub-id-type="pmid">33009010</pub-id></element-citation></ref><ref id="B110-nutrients-15-01990"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vilotitch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Esterle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spire</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salmon-Ceron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dabis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Daily Cannabis and Reduced Risk of Steatosis in Human Immunodeficiency Virus and Hepatitis C Virus-Co-Infected Patients (ANRS CO13-HEPAVIH)</article-title><source>J. Viral Hepat.</source><year>2018</year><volume>25</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/jvh.12797</pub-id><pub-id pub-id-type="pmid">28984055</pub-id></element-citation></ref><ref id="B111-nutrients-15-01990"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barr&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rojas Rojas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lacombe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Protopopescu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Poizot-Martin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nishimwe</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Zucman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Esterle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Billaud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aumaitre</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Cannabis Use and Reduced Risk of Elevated Fatty Liver Index in HIV-HCV Co-Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2021</year><volume>19</volume><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1080/14787210.2021.1884545</pub-id><pub-id pub-id-type="pmid">33538612</pub-id></element-citation></ref><ref id="B112-nutrients-15-01990"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuster</surname><given-names>D.</given-names></name><name name-style="western"><surname>So-Armah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gnatienko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lioznov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krupitsky</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Freiberg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Samet</surname><given-names>J.H.</given-names></name></person-group><article-title>Lack of Association between Recent Cannabis Use and Advanced Liver Fibrosis among HIV-Positive Heavy Drinkers</article-title><source>Curr. HIV Res.</source><year>2021</year><volume>19</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.2174/1570162X19666210519151320</pub-id><pub-id pub-id-type="pmid">34061004</pub-id><pub-id pub-id-type="pmcid">PMC8597417</pub-id></element-citation></ref><ref id="B113-nutrients-15-01990"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>French</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Glesby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Golub</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Augenbraun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plankey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>M.G.</given-names></name></person-group><article-title>Marijuana Use Is Not Associated with Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus&#8211;Coinfected Women</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw350</pub-id><pub-id pub-id-type="pmid">27225241</pub-id><pub-id pub-id-type="pmcid">PMC4967608</pub-id></element-citation></ref><ref id="B114-nutrients-15-01990"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>E.E.M.</given-names></name><name name-style="western"><surname>Rollet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Walmsley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.B.</given-names></name></person-group><article-title>Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV&#8211;Hepatitis C Coinfection: A Longitudinal Cohort Analysis</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>57</volume><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1093/cid/cit378</pub-id><pub-id pub-id-type="pmid">23811492</pub-id><pub-id pub-id-type="pmcid">PMC3739469</pub-id></element-citation></ref><ref id="B115-nutrients-15-01990"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kpewou</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Mensah</surname><given-names>F.O.</given-names></name><name name-style="western"><surname>Appiah</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Alidu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Badii</surname><given-names>V.S.</given-names></name></person-group><article-title>Serum Vitamin E Deficiency among People Living with HIV and Undergoing Antiretroviral Therapy at Ho Teaching Hospital, Ghana</article-title><source>Heliyon</source><year>2021</year><volume>7</volume><fpage>e07339</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e07339</pub-id><pub-id pub-id-type="pmid">34222691</pub-id><pub-id pub-id-type="pmcid">PMC8243377</pub-id></element-citation></ref><ref id="B116-nutrients-15-01990"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Semba</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Saah</surname><given-names>A.J.</given-names></name></person-group><article-title>Association between Serum Vitamin A and E Levels and HIV-1 Disease Progression</article-title><source>AIDS</source><year>1997</year><volume>11</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1097/00002030-199705000-00009</pub-id><pub-id pub-id-type="pmid">9108943</pub-id></element-citation></ref><ref id="B117-nutrients-15-01990"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Baeten</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Bankson</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Lavreys</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ndinya-Achola</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Mandaliya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Overbaugh</surname><given-names>J.</given-names></name><name name-style="western"><surname>McClelland</surname><given-names>R.S.</given-names></name></person-group><article-title>Higher Pre-Infection Vitamin E Levels Are Associated with Higher Mortality in HIV-1-Infected Kenyan Women: A Prospective Study</article-title><source>BMC Infect. Dis.</source><year>2007</year><volume>7</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-7-63</pub-id><pub-id pub-id-type="pmid">17594484</pub-id><pub-id pub-id-type="pmcid">PMC1914075</pub-id></element-citation></ref><ref id="B118-nutrients-15-01990"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Milic</surname><given-names>J.</given-names></name></person-group><article-title>Vitamin E as a &#8216;Bridge&#8217; Therapy for Nonalcoholic Steatohepatits in HIV: What Is Waiting on the Other Side of the Bridge?</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002413</pub-id><pub-id pub-id-type="pmid">31876593</pub-id></element-citation></ref><ref id="B119-nutrients-15-01990"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dao</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Overton</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Rhame</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pals</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>J.T.</given-names></name></person-group><article-title>The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Investigators Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq158</pub-id><pub-id pub-id-type="pmid">21217186</pub-id></element-citation></ref><ref id="B120-nutrients-15-01990"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chokuda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name></person-group><article-title>Association of Low Vitamin D with Complications of HIV and AIDS: A Literature Review</article-title><source>Infect. Disord. Drug Targets</source><year>2020</year><volume>20</volume><fpage>122</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.2174/1871526519666181221122731</pub-id><pub-id pub-id-type="pmid">30574856</pub-id></element-citation></ref><ref id="B121-nutrients-15-01990"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>S.S.L.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>P.S.M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.T.B.</given-names></name><name name-style="western"><surname>Ponnampalavanar</surname><given-names>S.</given-names></name></person-group><article-title>Reduced Bone Mineral Density in Human Immunodeficiency Virus-Infected Individuals: A Meta-Analysis of Its Prevalence and Risk Factors: Supplementary Presentation</article-title><source>Osteoporos. Int.</source><year>2018</year><volume>29</volume><fpage>1683</fpage><pub-id pub-id-type="doi">10.1007/s00198-018-4379-y</pub-id><pub-id pub-id-type="pmid">29737369</pub-id></element-citation></ref><ref id="B122-nutrients-15-01990"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milazzo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mazzali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bestetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Foschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Viola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vago</surname><given-names>T.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parravicini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Antinori</surname><given-names>S.</given-names></name></person-group><article-title>Liver-Related Factors Associated with Low Vitamin D Levels in HIV and HIV/HCV Coinfected Patients and Comparison to General Population</article-title><source>Curr. HIV Res.</source><year>2011</year><volume>9</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.2174/157016211795945269</pub-id><pub-id pub-id-type="pmid">21585333</pub-id></element-citation></ref><ref id="B123-nutrients-15-01990"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandorfer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Payer</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Schwabl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferlitsch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aichelburg</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>St&#228;ttermayer</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Ferenci</surname><given-names>P.</given-names></name><name name-style="western"><surname>Obermayer-Pietsch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grabmeier-Pfistershammer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Revisiting Liver Disease Progression in HIV/HCV-Coinfected Patients: The Influence of Vitamin D, Insulin Resistance, Immune Status, IL28B and PNPLA3</article-title><source>Liver Int.</source><year>2015</year><volume>35</volume><fpage>876</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1111/liv.12615</pub-id><pub-id pub-id-type="pmid">24905495</pub-id></element-citation></ref><ref id="B124-nutrients-15-01990"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branch</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Barin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stock</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schiano</surname><given-names>T.D.</given-names></name></person-group><article-title>Vitamin D Status of HIV-Positive Patients with Advanced Liver Disease Enrolled in the Solid Organ Transplantation in HIV Multi-Site Study</article-title><source>Liver Transplant.</source><year>2014</year><volume>20</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1002/lt.23784</pub-id><pub-id pub-id-type="pmcid">PMC3946843</pub-id><pub-id pub-id-type="pmid">24338934</pub-id></element-citation></ref><ref id="B125-nutrients-15-01990"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-P&#233;rez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Portilla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esco&#237;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alfayate</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boix</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bernabeu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mauri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of Vitamin D Insufficiency on Insulin Homeostasis and Beta Cell Function in Nondiabetic Male HIV-Infected Patients: Vitamin D, Insulin Homeostasis and HIV</article-title><source>HIV Med.</source><year>2013</year><volume>14</volume><fpage>540</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1111/hiv.12042</pub-id><pub-id pub-id-type="pmid">23651392</pub-id></element-citation></ref><ref id="B126-nutrients-15-01990"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bugianesi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moscatiello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciaravella</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Marchesini</surname><given-names>G.</given-names></name></person-group><article-title>Insulin Resistance in Nonalcoholic Fatty Liver Disease</article-title><source>Curr. Pharm. Des.</source><year>2010</year><volume>16</volume><fpage>1941</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.2174/138161210791208875</pub-id><pub-id pub-id-type="pmid">20370677</pub-id></element-citation></ref><ref id="B127-nutrients-15-01990"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costiniuk</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Jenabian</surname><given-names>M.-A.</given-names></name></person-group><article-title>Cannabinoids and Inflammation: Implications for People Living with HIV</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>2273</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002345</pub-id><pub-id pub-id-type="pmid">31764093</pub-id></element-citation></ref><ref id="B128-nutrients-15-01990"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barr&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sogni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zaegel-Faucher</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wittkop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carrieri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salmon-C&#233;ron</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cannabis Use as a Protective Factor Against Overweight in HIV-Hepatitis C Virus Co-Infected People (ANRS CO13 HEPAVIH Cohort)</article-title><source>AIDS Educ. Prev.</source><year>2022</year><volume>34</volume><fpage>272</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1521/aeap.2022.34.4.272</pub-id><pub-id pub-id-type="pmid">35994579</pub-id></element-citation></ref><ref id="B129-nutrients-15-01990"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrieri</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Serfaty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vilotitch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Winnock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poizot-Martin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Loko</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Lions</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lascoux-Combe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Salmon-Ceron</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>61</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1093/cid/civ217</pub-id><pub-id pub-id-type="pmid">25778750</pub-id></element-citation></ref><ref id="B130-nutrients-15-01990"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weizman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>A.</given-names></name></person-group><article-title>Positive and Negative Effects of Cannabis and Cannabinoids on Health</article-title><source>Clin. Pharmacol. Ther.</source><year>2019</year><volume>105</volume><fpage>1139</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1002/cpt.1381</pub-id><pub-id pub-id-type="pmid">30703255</pub-id></element-citation></ref><ref id="B131-nutrients-15-01990"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mboumba Bouassa</surname><given-names>R.-S.</given-names></name><name name-style="western"><surname>Needham</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nohynek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bobeuf</surname><given-names>F.</given-names></name><name name-style="western"><surname>Samarani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Del Balso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paisible</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vertzagias</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>3168</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10123168</pub-id><pub-id pub-id-type="pmid">36551926</pub-id><pub-id pub-id-type="pmcid">PMC9775551</pub-id></element-citation></ref><ref id="B132-nutrients-15-01990"><label>132.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Canada</surname><given-names>H.</given-names></name></person-group><article-title>Household Food Insecurity in Canada: Overview</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/household-food-insecurity-canada-overview.html" ext-link-type="uri">https://www.canada.ca/en/health-canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-community-health-survey-cchs/household-food-insecurity-canada-overview.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-09">(accessed on 9 February 2023)</date-in-citation></element-citation></ref><ref id="B133-nutrients-15-01990"><label>133.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>C.A.</given-names></name></person-group><article-title>Food Insecurity, Chronic Disease, and Health Among Working-Age Adults</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ageconsearch.umn.edu/record/261813/" ext-link-type="uri">https://ageconsearch.umn.edu/record/261813/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-20">(accessed on 20 February 2023)</date-in-citation></element-citation></ref><ref id="B134-nutrients-15-01990"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Eicher-Miller</surname><given-names>H.A.</given-names></name></person-group><article-title>Food Insecurity and Cardiovascular Disease Risk</article-title><source>Curr. Atheroscler. Rep.</source><year>2021</year><volume>23</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1007/s11883-021-00923-6</pub-id><pub-id pub-id-type="pmid">33772668</pub-id><pub-id pub-id-type="pmcid">PMC8000689</pub-id></element-citation></ref><ref id="B135-nutrients-15-01990"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seligman</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Schillinger</surname><given-names>D.</given-names></name></person-group><article-title>Hunger and Socioeconomic Disparities in Chronic Disease</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>6</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1000072</pub-id><pub-id pub-id-type="pmid">20592297</pub-id></element-citation></ref><ref id="B136-nutrients-15-01990"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nkambule</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moodley</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kuupiel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mashamba-Thompson</surname><given-names>T.P.</given-names></name></person-group><article-title>Association between Food Insecurity and Key Metabolic Risk Factors for Diet-Sensitive Non-Communicable Diseases in Sub-Saharan Africa: A Systematic Review and Meta-Analysis</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>5178</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-84344-0</pub-id><pub-id pub-id-type="pmid">33664339</pub-id><pub-id pub-id-type="pmcid">PMC7933340</pub-id></element-citation></ref><ref id="B137-nutrients-15-01990"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardashian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serper</surname><given-names>M.</given-names></name><name name-style="western"><surname>Terrault</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nephew</surname><given-names>L.D.</given-names></name></person-group><article-title>Health Disparities in Chronic Liver Disease</article-title><source>Hepatology</source><year>2022</year><comment><italic toggle="yes">early view</italic></comment><pub-id pub-id-type="doi">10.1002/hep.32743</pub-id><pub-id pub-id-type="pmid">35993341</pub-id><pub-id pub-id-type="pmcid">PMC10026975</pub-id></element-citation></ref><ref id="B138-nutrients-15-01990"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golovaty</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Price</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Sheira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seligman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>S.D.</given-names></name></person-group><article-title>Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States</article-title><source>J. Nutr.</source><year>2020</year><volume>150</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1093/jn/nxz212</pub-id><pub-id pub-id-type="pmid">31504710</pub-id><pub-id pub-id-type="pmcid">PMC6946902</pub-id></element-citation></ref><ref id="B139-nutrients-15-01990"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardashian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Terrault</surname><given-names>N.A.</given-names></name></person-group><article-title>Food Insecurity Is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2022</year><volume>20</volume><fpage>2790</fpage><lpage>2799.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.11.029</pub-id><pub-id pub-id-type="pmid">34958747</pub-id></element-citation></ref><ref id="B140-nutrients-15-01990"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pellowski</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kalichman</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>N.</given-names></name></person-group><article-title>A Pandemic of the Poor: Social Disadvantage and the U.S. HIV Epidemic</article-title><source>Am. Psychol.</source><year>2013</year><volume>68</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1037/a0032694</pub-id><pub-id pub-id-type="pmid">23688088</pub-id><pub-id pub-id-type="pmcid">PMC3700367</pub-id></element-citation></ref><ref id="B141-nutrients-15-01990"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Clay</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Saag</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Overton</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Willig</surname><given-names>A.L.</given-names></name></person-group><article-title>Associations of Food Insecurity and Psychosocial Measures with Diet Quality in Adults Aging with HIV</article-title><source>AIDS Care</source><year>2019</year><volume>31</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1080/09540121.2018.1554239</pub-id><pub-id pub-id-type="pmid">30558446</pub-id><pub-id pub-id-type="pmcid">PMC8513133</pub-id></element-citation></ref><ref id="B142-nutrients-15-01990"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamargo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Campa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Teeman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mandler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ehman</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Food Insecurity Is Associated with Magnetic Resonance&#8211;Determined Nonalcoholic Fatty Liver and Liver Fibrosis in Low-Income, Middle-Aged Adults with and without HIV</article-title><source>Am. J. Clin. Nutr.</source><year>2021</year><volume>113</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqaa362</pub-id><pub-id pub-id-type="pmid">33515016</pub-id><pub-id pub-id-type="pmcid">PMC7948863</pub-id></element-citation></ref><ref id="B143-nutrients-15-01990"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Members</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Donato</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Apovian</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ard</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Comuzzie</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Jakicic</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Executive Summary: Guidelines (2013) for the Management of Overweight and Obesity in Adults</article-title><source>Obesity</source><year>2014</year><volume>22</volume><fpage>S5</fpage><lpage>S39</lpage><pub-id pub-id-type="doi">10.1002/oby.20821</pub-id><pub-id pub-id-type="pmid">24961825</pub-id></element-citation></ref><ref id="B144-nutrients-15-01990"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martinez-Perez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Calzadilla-Bertot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Torres-Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gra-Oramas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonzalez-Fabian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Diago</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romero-Gomez</surname><given-names>M.</given-names></name></person-group><article-title>Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>367</fpage><lpage>378.e5</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.04.005</pub-id><pub-id pub-id-type="pmid">25865049</pub-id></element-citation></ref><ref id="B145-nutrients-15-01990"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vi&#241;uela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>F.</given-names></name></person-group><article-title>Lifestyle Changes in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0263931</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0263931</pub-id><pub-id pub-id-type="pmid">35176096</pub-id><pub-id pub-id-type="pmcid">PMC8853532</pub-id></element-citation></ref><ref id="B146-nutrients-15-01990"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugliese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Plaz Torres</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Petta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Aghemo</surname><given-names>A.</given-names></name></person-group><article-title>Is There an &#8216;Ideal&#8217; Diet for Patients with NAFLD?</article-title><source>Eur. J. Clin. Investig.</source><year>2022</year><volume>52</volume><fpage>e13659</fpage><pub-id pub-id-type="doi">10.1111/eci.13659</pub-id><pub-id pub-id-type="pmid">34309833</pub-id></element-citation></ref><ref id="B147-nutrients-15-01990"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zafer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torimura</surname><given-names>T.</given-names></name></person-group><article-title>Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials</article-title><source>Semin. Liver Dis.</source><year>2021</year><volume>41</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1055/s-0041-1723751</pub-id><pub-id pub-id-type="pmid">34147036</pub-id></element-citation></ref><ref id="B148-nutrients-15-01990"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haigh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>C.</given-names></name><name name-style="western"><surname>El Gendy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Errington</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mathers</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>Q.M.</given-names></name></person-group><article-title>The Effectiveness and Acceptability of Mediterranean Diet and Calorie Restriction in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis</article-title><source>Clin. Nutr.</source><year>2022</year><volume>41</volume><fpage>1913</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2022.06.037</pub-id><pub-id pub-id-type="pmid">35947894</pub-id></element-citation></ref><ref id="B149-nutrients-15-01990"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouvari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boutari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chrysohoou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fragkopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antonopoulou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tousoulis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pitsavos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Panagiotakos</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Mantzoros</surname><given-names>C.S.</given-names></name></person-group><article-title>ATTICA study Investigators Mediterranean Diet Is Inversely Associated with Steatosis and Fibrosis and Decreases Ten-Year Diabetes and Cardiovascular Risk in NAFLD Subjects: Results from the ATTICA Prospective Cohort Study</article-title><source>Clin. Nutr.</source><year>2021</year><volume>40</volume><fpage>3314</fpage><lpage>3324</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2020.10.058</pub-id><pub-id pub-id-type="pmid">33234342</pub-id></element-citation></ref><ref id="B150-nutrients-15-01990"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurtda&#351;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akbulut</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Y&#305;lmaz</surname><given-names>C.</given-names></name></person-group><article-title>The Effects of Mediterranean Diet on Hepatic Steatosis, Oxidative Stress, and Inflammation in Adolescents with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial</article-title><source>Pediatr. Obes.</source><year>2022</year><volume>17</volume><fpage>e12872</fpage><pub-id pub-id-type="doi">10.1111/ijpo.12872</pub-id><pub-id pub-id-type="pmid">34881510</pub-id></element-citation></ref><ref id="B151-nutrients-15-01990"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Itsiopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>A.C.</given-names></name></person-group><article-title>Impact of a Mediterranean Diet on Hepatic and Metabolic Outcomes in Non-Alcoholic Fatty Liver Disease: The MEDINA Randomised Controlled Trial</article-title><source>Liver Int.</source><year>2022</year><volume>42</volume><fpage>1308</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1111/liv.15264</pub-id><pub-id pub-id-type="pmid">35357066</pub-id><pub-id pub-id-type="pmcid">PMC9544144</pub-id></element-citation></ref><ref id="B152-nutrients-15-01990"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodami</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hatami</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Alavian</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Varkaneh</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Hekmatdoost</surname><given-names>A.</given-names></name></person-group><article-title>Effects of a Low Free Sugar Diet on the Management of Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial</article-title><source>Eur. J. Clin. Nutr.</source><year>2022</year><volume>76</volume><fpage>987</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/s41430-022-01081-x</pub-id><pub-id pub-id-type="pmid">35058605</pub-id></element-citation></ref><ref id="B153-nutrients-15-01990"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visseren</surname><given-names>F.L.J.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Smulders</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Carballo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>B&#228;ck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benetos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biffi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boavida</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Capodanno</surname><given-names>D.</given-names></name><etal/></person-group><article-title>2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice</article-title><source>Eur. Heart J.</source><year>2021</year><volume>42</volume><fpage>3227</fpage><lpage>3337</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab484</pub-id><pub-id pub-id-type="pmid">34458905</pub-id></element-citation></ref><ref id="B154-nutrients-15-01990"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kistler</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sallis</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Schwimmer</surname><given-names>J.B.</given-names></name></person-group><article-title>Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease</article-title><source>Am. J. Gastroenterol.</source><year>2011</year><volume>106</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/ajg.2010.488</pub-id><pub-id pub-id-type="pmid">21206486</pub-id><pub-id pub-id-type="pmcid">PMC3070294</pub-id></element-citation></ref><ref id="B155-nutrients-15-01990"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.K.</given-names></name><etal/></person-group><article-title>Relationship of Sitting Time and Physical Activity with Non-Alcoholic Fatty Liver Disease</article-title><source>J. Hepatol.</source><year>2015</year><volume>63</volume><fpage>1229</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.07.010</pub-id><pub-id pub-id-type="pmid">26385766</pub-id></element-citation></ref><ref id="B156-nutrients-15-01990"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keating</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N.A.</given-names></name></person-group><article-title>Exercise and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis</article-title><source>J. Hepatol.</source><year>2012</year><volume>57</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.02.023</pub-id><pub-id pub-id-type="pmid">22414768</pub-id></element-citation></ref><ref id="B157-nutrients-15-01990"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Negri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Faccioli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lanza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoppini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zanolin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moghetti</surname><given-names>P.</given-names></name></person-group><article-title>Both Resistance Training and Aerobic Training Reduce Hepatic Fat Content in Type 2 Diabetic Subjects with Nonalcoholic Fatty Liver Disease (the RAED2 Randomized Trial)</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><fpage>1287</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1002/hep.26393</pub-id><pub-id pub-id-type="pmid">23504926</pub-id></element-citation></ref><ref id="B158-nutrients-15-01990"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashida</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bekki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Omoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nago</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>H.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Aerobic vs. Resistance Exercise in Non-Alcoholic Fatty Liver Disease: A Systematic Review</article-title><source>J. Hepatol.</source><year>2017</year><volume>66</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.08.023</pub-id><pub-id pub-id-type="pmid">27639843</pub-id></element-citation></ref><ref id="B159-nutrients-15-01990"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero-G&#243;mez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zelber-Sagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trenell</surname><given-names>M.</given-names></name></person-group><article-title>Treatment of NAFLD with Diet, Physical Activity and Exercise</article-title><source>J. Hepatol.</source><year>2017</year><volume>67</volume><fpage>829</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.05.016</pub-id><pub-id pub-id-type="pmid">28545937</pub-id></element-citation></ref><ref id="B160-nutrients-15-01990"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thuluvath</surname><given-names>P.J.</given-names></name></person-group><article-title>Bariatric Surgery in NAFLD</article-title><source>Dig. Dis. Sci.</source><year>2022</year><volume>67</volume><fpage>408</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/s10620-021-07317-3</pub-id><pub-id pub-id-type="pmid">34981313</pub-id></element-citation></ref><ref id="B161-nutrients-15-01990"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallsworth</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fattakhova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hollingsworth</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Thoma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Day</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Trenell</surname><given-names>M.I.</given-names></name></person-group><article-title>Resistance Exercise Reduces Liver Fat and Its Mediators in Non-Alcoholic Fatty Liver Disease Independent of Weight Loss</article-title><source>Gut</source><year>2011</year><volume>60</volume><fpage>1278</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1136/gut.2011.242073</pub-id><pub-id pub-id-type="pmid">21708823</pub-id><pub-id pub-id-type="pmcid">PMC3152868</pub-id></element-citation></ref><ref id="B162-nutrients-15-01990"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.-H.</given-names></name></person-group><article-title>Role of Physical Activity in Nonalcoholic Fatty Liver Disease in Terms of Visceral Obesity and Insulin Resistance</article-title><source>Liver Int.</source><year>2015</year><volume>35</volume><fpage>944</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1111/liv.12552</pub-id><pub-id pub-id-type="pmid">24684289</pub-id></element-citation></ref><ref id="B163-nutrients-15-01990"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Hur</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Regular Exercise Is Associated with a Reduction in the Risk of NAFLD and Decreased Liver Enzymes in Individuals with NAFLD Independent of Obesity in Korean Adults</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e46819</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046819</pub-id><pub-id pub-id-type="pmid">23110056</pub-id><pub-id pub-id-type="pmcid">PMC3478288</pub-id></element-citation></ref><ref id="B164-nutrients-15-01990"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worm</surname><given-names>N.</given-names></name></person-group><article-title>Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>1316</elocation-id><pub-id pub-id-type="doi">10.3390/nu12051316</pub-id><pub-id pub-id-type="pmid">32384593</pub-id><pub-id pub-id-type="pmcid">PMC7284418</pub-id></element-citation></ref><ref id="B165-nutrients-15-01990"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernal</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Ekong</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dasarathy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>E.J.</given-names></name></person-group><article-title>Malnutrition, Frailty, and Sarcopenia in Patients with Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>1611</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1002/hep.32049</pub-id><pub-id pub-id-type="pmid">34233031</pub-id><pub-id pub-id-type="pmcid">PMC9134787</pub-id></element-citation></ref><ref id="B166-nutrients-15-01990"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eslamparast</surname><given-names>T.</given-names></name><name name-style="western"><surname>Montano-Loza</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>P.</given-names></name></person-group><article-title>Sarcopenic Obesity in Cirrhosis-The Confluence of 2 Prognostic Titans</article-title><source>Liver Int.</source><year>2018</year><volume>38</volume><fpage>1706</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1111/liv.13876</pub-id><pub-id pub-id-type="pmid">29738109</pub-id></element-citation></ref><ref id="B167-nutrients-15-01990"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anema</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogenthaler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frongillo</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kadiyala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>S.D.</given-names></name></person-group><article-title>Food Insecurity and HIV/AIDS: Current Knowledge, Gaps, and Research Priorities</article-title><source>Curr. HIV/AIDS Rep.</source><year>2009</year><volume>6</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1007/s11904-009-0030-z</pub-id><pub-id pub-id-type="pmid">19849966</pub-id><pub-id pub-id-type="pmcid">PMC5917641</pub-id></element-citation></ref><ref id="B168-nutrients-15-01990"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duran</surname><given-names>A.C.F.L.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Segurado</surname><given-names>A.a.C.</given-names></name><name name-style="western"><surname>Jaime</surname><given-names>P.C.</given-names></name></person-group><article-title>Diet Quality of Persons Living with HIV/AIDS on Highly Active Antiretroviral Therapy</article-title><source>J. Hum. Nutr. Diet</source><year>2008</year><volume>21</volume><fpage>346</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1111/j.1365-277X.2008.00886.x</pub-id><pub-id pub-id-type="pmid">18721401</pub-id></element-citation></ref><ref id="B169-nutrients-15-01990"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vancampfort</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mugisha</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Hert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Probst</surname><given-names>M.</given-names></name><name name-style="western"><surname>Firth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorczynski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stubbs</surname><given-names>B.</given-names></name></person-group><article-title>Global Physical Activity Levels among People Living with HIV: A Systematic Review and Meta-Analysis</article-title><source>Disabil. Rehabil.</source><year>2018</year><volume>40</volume><fpage>388</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1080/09638288.2016.1260645</pub-id><pub-id pub-id-type="pmid">27929355</pub-id></element-citation></ref><ref id="B170-nutrients-15-01990"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erlandson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>MaWhinney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>L.</given-names></name><name name-style="western"><surname>McCandless</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Kohrt</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>C.M.</given-names></name></person-group><article-title>Physical Function Improvements with Moderate or High-Intensity Exercise Among Older Adults with or without HIV Infection</article-title><source>AIDS</source><year>2018</year><volume>32</volume><fpage>2317</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001984</pub-id><pub-id pub-id-type="pmid">30134299</pub-id><pub-id pub-id-type="pmcid">PMC6170687</pub-id></element-citation></ref><ref id="B171-nutrients-15-01990"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erlandson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lake</surname><given-names>J.E.</given-names></name></person-group><article-title>Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection</article-title><source>Curr. HIV/AIDS Rep.</source><year>2016</year><volume>13</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s11904-016-0298-8</pub-id><pub-id pub-id-type="pmid">26830284</pub-id><pub-id pub-id-type="pmcid">PMC4779424</pub-id></element-citation></ref><ref id="B172-nutrients-15-01990"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelson</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Agin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kenya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Werber-Zion</surname><given-names>G.</given-names></name><name name-style="western"><surname>Luty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Albu</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kotler</surname><given-names>D.P.</given-names></name></person-group><article-title>Body Composition and Metabolic Effects of a Diet and Exercise Weight Loss Regimen on Obese, HIV-Infected Women</article-title><source>Metabolism</source><year>2006</year><volume>55</volume><fpage>1327</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2006.05.018</pub-id><pub-id pub-id-type="pmid">16979403</pub-id></element-citation></ref><ref id="B173-nutrients-15-01990"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sprinz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>J.P.</given-names></name></person-group><article-title>Exercise Training in HIV-1-Infected Individuals with Dyslipidemia and Lipodystrophy</article-title><source>Med. Sci. Sport. Exerc.</source><year>2006</year><volume>38</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1249/01.mss.0000191347.73848.80</pub-id><pub-id pub-id-type="pmid">16540826</pub-id></element-citation></ref><ref id="B174-nutrients-15-01990"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutimura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crowther</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Cade</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Yarasheski</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>A.</given-names></name></person-group><article-title>Exercise Training Reduces Central Adiposity and Improves Metabolic Indices in HAART-Treated HIV-Positive Subjects in Rwanda: A Randomized Controlled Trial</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2008</year><volume>24</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1089/aid.2007.0023</pub-id><pub-id pub-id-type="pmid">18275343</pub-id><pub-id pub-id-type="pmcid">PMC3936606</pub-id></element-citation></ref><ref id="B175-nutrients-15-01990"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becofsky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>McCaffery</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>R.R.</given-names></name></person-group><article-title>A Randomized Controlled Trial of a Behavioral Weight Loss Program for Human Immunodeficiency Virus-Infected Patients</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>65</volume><fpage>154</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1093/cid/cix238</pub-id><pub-id pub-id-type="pmid">28369269</pub-id><pub-id pub-id-type="pmcid">PMC6433423</pub-id></element-citation></ref><ref id="B176-nutrients-15-01990"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeds</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Pietka</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Yarasheski</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cade</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Okunade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abumrad</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S.</given-names></name></person-group><article-title>HIV Infection Does Not Prevent the Metabolic Benefits of Diet-Induced Weight Loss in Women with Obesity: Effects of Weight Loss in HIV+ Women</article-title><source>Obesity</source><year>2017</year><volume>25</volume><fpage>682</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1002/oby.21793</pub-id><pub-id pub-id-type="pmid">28245099</pub-id><pub-id pub-id-type="pmcid">PMC5373981</pub-id></element-citation></ref><ref id="B177-nutrients-15-01990"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lake</surname><given-names>J.E.</given-names></name></person-group><article-title>The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection</article-title><source>Curr. HIV/AIDS Rep.</source><year>2017</year><volume>14</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1007/s11904-017-0368-6</pub-id><pub-id pub-id-type="pmid">29043609</pub-id><pub-id pub-id-type="pmcid">PMC5694708</pub-id></element-citation></ref><ref id="B178-nutrients-15-01990"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Fourman</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Feldpausch</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Purdy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Aepfelbacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buckless</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kellogg</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial</article-title><source>Lancet HIV</source><year>2019</year><volume>6</volume><fpage>e821</fpage><lpage>e830</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30338-8</pub-id><pub-id pub-id-type="pmid">31611038</pub-id><pub-id pub-id-type="pmcid">PMC6981288</pub-id></element-citation></ref><ref id="B179-nutrients-15-01990"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dinatale</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>S.</given-names></name><name name-style="western"><surname>St. Jacques</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oursler</surname><given-names>K.A.</given-names></name></person-group><article-title>Barriers and Health Beliefs Related to Weight Management Among Veterans with Human Immunodeficiency Virus</article-title><source>Mil. Med.</source><year>2017</year><volume>182</volume><fpage>e1596</fpage><lpage>e1602</lpage><pub-id pub-id-type="doi">10.7205/MILMED-D-16-00086</pub-id><pub-id pub-id-type="pmid">28051979</pub-id></element-citation></ref><ref id="B180-nutrients-15-01990"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Policarpo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Cortez-Pinto</surname><given-names>H.</given-names></name></person-group><article-title>Telemedicine as a Tool for Dietary Intervention in NAFLD-HIV Patients during the COVID-19 Lockdown: A Randomized Controlled Trial</article-title><source>Clin. Nutr. ESPEN</source><year>2021</year><volume>43</volume><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.clnesp.2021.03.031</pub-id><pub-id pub-id-type="pmid">34024536</pub-id><pub-id pub-id-type="pmcid">PMC8056479</pub-id></element-citation></ref><ref id="B181-nutrients-15-01990"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cinque</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cespiati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maffi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alletto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Colavolpe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Francione</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oberti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fatta</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>556</elocation-id><pub-id pub-id-type="doi">10.3390/nu14030556</pub-id><pub-id pub-id-type="pmid">35276911</pub-id><pub-id pub-id-type="pmcid">PMC8838646</pub-id></element-citation></ref><ref id="B182-nutrients-15-01990"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montemayor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mascar&#243;</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ugarriza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Tur</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bouzas</surname><given-names>C.</given-names></name></person-group><article-title>Intrahepatic Fat Content and COVID-19 Lockdown in Adults with NAFLD and Metabolic Syndrome</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>3462</elocation-id><pub-id pub-id-type="doi">10.3390/nu14173462</pub-id><pub-id pub-id-type="pmid">36079720</pub-id><pub-id pub-id-type="pmcid">PMC9457922</pub-id></element-citation></ref><ref id="B183-nutrients-15-01990"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Gonz&#225;lez</surname><given-names>&#193;.A.</given-names></name><name name-style="western"><surname>Altisench Jan&#233;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Masmiquel Comas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arroyo Bote</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gonz&#225;lez San Miguel</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ram&#237;rez Manent</surname><given-names>J.I.</given-names></name></person-group><article-title>Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>2795</elocation-id><pub-id pub-id-type="doi">10.3390/nu14142795</pub-id><pub-id pub-id-type="pmid">35889752</pub-id><pub-id pub-id-type="pmcid">PMC9319232</pub-id></element-citation></ref><ref id="B184-nutrients-15-01990"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>O.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y.</given-names></name></person-group><article-title>The Effectiveness of EHealth Interventions on Lifestyle Modification in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis</article-title><source>J. Med. Internet Res.</source><year>2023</year><volume>25</volume><fpage>e37487</fpage><pub-id pub-id-type="doi">10.2196/37487</pub-id><pub-id pub-id-type="pmid">36689264</pub-id><pub-id pub-id-type="pmcid">PMC9903182</pub-id></element-citation></ref><ref id="B185-nutrients-15-01990"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarasheski</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cade</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Overton</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Mondy</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laciny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lassa-Claxton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reeds</surname><given-names>D.N.</given-names></name></person-group><article-title>Exercise Training Augments the Peripheral Insulin-Sensitizing Effects of Pioglitazone in HIV-Infected Adults with Insulin Resistance and Central Adiposity</article-title><source>Am. J. Physiol.-Endocrinol. Metab.</source><year>2011</year><volume>300</volume><fpage>E243</fpage><lpage>E251</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00468.2010</pub-id><pub-id pub-id-type="pmid">20959530</pub-id><pub-id pub-id-type="pmcid">PMC3023206</pub-id></element-citation></ref><ref id="B186-nutrients-15-01990"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Chairez</surname><given-names>C.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nettles</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zemanick</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Benator</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hadigan</surname><given-names>C.</given-names></name></person-group><article-title>Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2015</year><volume>31</volume><fpage>961</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0093</pub-id><pub-id pub-id-type="pmid">26214341</pub-id><pub-id pub-id-type="pmcid">PMC4576938</pub-id></element-citation></ref><ref id="B187-nutrients-15-01990"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamolvisit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chirnaksorn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nimitphong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sungkanuparph</surname><given-names>S.</given-names></name></person-group><article-title>Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living with HIV and Prediabetes</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e19046</fpage><pub-id pub-id-type="doi">10.7759/cureus.19046</pub-id><pub-id pub-id-type="pmid">34858740</pub-id><pub-id pub-id-type="pmcid">PMC8613454</pub-id></element-citation></ref><ref id="B188-nutrients-15-01990"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajmera</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Cachay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vodkin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bassirian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mangla</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aldous</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Novel MRI Assessment of Treatment Response in HIV-Associated NAFLD: A Randomized Trial of an SCD1 Inhibitor (ARRIVE Trial)</article-title><source>Hepatology</source><year>2019</year><volume>70</volume><fpage>1531</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1002/hep.30674</pub-id><pub-id pub-id-type="pmid">31013363</pub-id><pub-id pub-id-type="pmcid">PMC7164416</pub-id></element-citation></ref><ref id="B189-nutrients-15-01990"><label>189.</label><element-citation publication-type="webpage"><article-title>ISRCTN-ISRCTN15410818: Investigating the Impact of Maraviroc on Liver Inflammation in Patients with HIV and Fatty Liver Disease</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.isrctn.com/ISRCTN15410818" ext-link-type="uri">https://www.isrctn.com/ISRCTN15410818</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-10">(accessed on 10 February 2023)</date-in-citation></element-citation></ref><ref id="B190-nutrients-15-01990"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monteith</surname><given-names>K.</given-names></name><name name-style="western"><surname>Milic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsochatzis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bhagani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Price</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ingiliz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>New Drugs for NASH and HIV Infection: Great Expectations for a Great Need</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><fpage>1831</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1002/hep.31177</pub-id><pub-id pub-id-type="pmid">32052857</pub-id></element-citation></ref><ref id="B191-nutrients-15-01990"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lemoine</surname><given-names>M.</given-names></name></person-group><article-title>Are Separate Clinical Trials Still Required in Nonalcoholic Steatohepatitis for Patients with and Without Human Immunodeficiency Virus (HIV)?</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>72</volume><fpage>908</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa795</pub-id><pub-id pub-id-type="pmid">32562488</pub-id></element-citation></ref><ref id="B192-nutrients-15-01990"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryom</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Miguel</surname><given-names>R.</given-names></name><name name-style="western"><surname>B&#233;guelin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Podlekareva</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arribas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mallon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>O.</given-names></name><etal/></person-group><article-title>2019 Update of the European AIDS Clinical Society Guidelines for Treatment of People Living with HIV Version 10.0</article-title><source>HIV Med.</source><year>2020</year><volume>21</volume><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1111/hiv.12878</pub-id><pub-id pub-id-type="pmid">32885559</pub-id><pub-id pub-id-type="pmcid">PMC7754379</pub-id></element-citation></ref><ref id="B193-nutrients-15-01990"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mazzola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schepis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krahn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lebouche</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deschenes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cascio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guaraldi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living with Human Immunodeficiency Virus</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><fpage>e694</fpage><lpage>e701</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa430</pub-id><pub-id pub-id-type="pmid">32280969</pub-id></element-citation></ref><ref id="B194-nutrients-15-01990"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duseja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badhala</surname><given-names>P.</given-names></name><name name-style="western"><surname>Taneja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name></person-group><article-title>Indian Patients with Human Immunodeficiency Virus Infection Have High Prevalence but Mild Severity of Non-Alcoholic Fatty Liver Disease</article-title><source>Diabetes Metab. Syndr. Clin. Res. Rev.</source><year>2022</year><volume>16</volume><fpage>102679</fpage><pub-id pub-id-type="doi">10.1016/j.dsx.2022.102679</pub-id><pub-id pub-id-type="pmid">36450180</pub-id></element-citation></ref><ref id="B195-nutrients-15-01990"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Noureddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.K.</given-names></name></person-group><article-title>AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review</article-title><source>Gastroenterology</source><year>2022</year><volume>163</volume><fpage>764</fpage><lpage>774.e1</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.06.023</pub-id><pub-id pub-id-type="pmid">35842345</pub-id><pub-id pub-id-type="pmcid">PMC9398982</pub-id></element-citation></ref><ref id="B196-nutrients-15-01990"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammed</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Aghdassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salit</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Avand</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guindi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heathcote</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>J.P.</given-names></name></person-group><article-title>HIV-Positive Patients With Nonalcoholic Fatty Liver Disease Have a Lower Body Mass Index and Are More Physically Active Than HIV-Negative Patients</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>2007</year><volume>45</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e318074efe3</pub-id><pub-id pub-id-type="pmid">17558337</pub-id></element-citation></ref><ref id="B197-nutrients-15-01990"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>V.W.-S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.L.-H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>R.S.-M.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>S.S.-T.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>B.H.-K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Chim</surname><given-names>A.M.-L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.K.-M.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.K.-Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>W.C.-W.</given-names></name><etal/></person-group><article-title>Beneficial Effects of Lifestyle Intervention in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease</article-title><source>J. Hepatol.</source><year>2018</year><volume>69</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.08.011</pub-id><pub-id pub-id-type="pmid">30142427</pub-id></element-citation></ref><ref id="B198-nutrients-15-01990"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duranti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bottacini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Turroni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mahony</surname><given-names>J.</given-names></name><name name-style="western"><surname>Belzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Delgado Palacio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arboleya Montes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mancabelli</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2017</year><volume>81</volume><fpage>e00036-17</fpage><pub-id pub-id-type="doi">10.1128/MMBR.00036-17</pub-id><pub-id pub-id-type="pmid">29118049</pub-id><pub-id pub-id-type="pmcid">PMC5706746</pub-id></element-citation></ref><ref id="B199-nutrients-15-01990"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Littman</surname><given-names>D.R.</given-names></name></person-group><article-title>The Microbiome in Infectious Disease and Inflammation</article-title><source>Annu. Rev. Immunol.</source><year>2012</year><volume>30</volume><fpage>759</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-074937</pub-id><pub-id pub-id-type="pmid">22224764</pub-id><pub-id pub-id-type="pmcid">PMC4426968</pub-id></element-citation></ref><ref id="B200-nutrients-15-01990"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Mahowald</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Magrini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mardis</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>1027</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1038/nature05414</pub-id><pub-id pub-id-type="pmid">17183312</pub-id></element-citation></ref><ref id="B201-nutrients-15-01990"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>DiBaise</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Zuccolo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kudrna</surname><given-names>D.</given-names></name><name name-style="western"><surname>Braidotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Parameswaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rittmann</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>Human Gut Microbiota in Obesity and after Gastric Bypass</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>2365</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812600106</pub-id><pub-id pub-id-type="pmid">19164560</pub-id><pub-id pub-id-type="pmcid">PMC2629490</pub-id></element-citation></ref><ref id="B202-nutrients-15-01990"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.-X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.-R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.-J.</given-names></name></person-group><article-title>Gut Microbiota and Metabolic Syndrome</article-title><source>Chin. Med. J.</source><year>2020</year><volume>133</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000000696</pub-id><pub-id pub-id-type="pmid">32106124</pub-id><pub-id pub-id-type="pmcid">PMC7147654</pub-id></element-citation></ref><ref id="B203-nutrients-15-01990"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A Metagenome-Wide Association Study of Gut Microbiota in Type 2 Diabetes</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nature11450</pub-id><pub-id pub-id-type="pmid">23023125</pub-id></element-citation></ref><ref id="B204-nutrients-15-01990"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Klipfell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Koeth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levison</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>DuGar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feldstein</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Britt</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.-M.</given-names></name><etal/></person-group><article-title>Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature09922</pub-id><pub-id pub-id-type="pmid">21475195</pub-id><pub-id pub-id-type="pmcid">PMC3086762</pub-id></element-citation></ref><ref id="B205-nutrients-15-01990"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boursier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>A.M.</given-names></name></person-group><article-title>Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004559</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004559</pub-id><pub-id pub-id-type="pmid">25625278</pub-id><pub-id pub-id-type="pmcid">PMC4308105</pub-id></element-citation></ref><ref id="B206-nutrients-15-01990"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnabl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>D.A.</given-names></name></person-group><article-title>Interactions between the Intestinal Microbiome and Liver Diseases</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>1513</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.01.020</pub-id><pub-id pub-id-type="pmid">24440671</pub-id><pub-id pub-id-type="pmcid">PMC3996054</pub-id></element-citation></ref><ref id="B207-nutrients-15-01990"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boursier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>O.</given-names></name><name name-style="western"><surname>Barret</surname><given-names>M.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fizanne</surname><given-names>L.</given-names></name><name name-style="western"><surname>Araujo-Perez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Seed</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Rawls</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>David</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>The Severity of NAFLD Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>764</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1002/hep.28356</pub-id><pub-id pub-id-type="pmid">26600078</pub-id><pub-id pub-id-type="pmcid">PMC4975935</pub-id></element-citation></ref><ref id="B208-nutrients-15-01990"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krajmalnik-Brown</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ilhan</surname><given-names>Z.-E.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>DiBaise</surname><given-names>J.K.</given-names></name></person-group><article-title>Effects of Gut Microbes on Nutrient Absorption and Energy Regulation</article-title><source>Nutr. Clin. Pract.</source><year>2012</year><volume>27</volume><fpage>201</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1177/0884533611436116</pub-id><pub-id pub-id-type="pmid">22367888</pub-id><pub-id pub-id-type="pmcid">PMC3601187</pub-id></element-citation></ref><ref id="B209-nutrients-15-01990"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Chatelier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prifti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Falony</surname><given-names>G.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Batto</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Richness of Human Gut Microbiome Correlates with Metabolic Markers</article-title><source>Nature</source><year>2013</year><volume>500</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nature12506</pub-id><pub-id pub-id-type="pmid">23985870</pub-id></element-citation></ref><ref id="B210-nutrients-15-01990"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Chierico</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vernocchi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Stefanis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gnani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Furlanello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zandon&#224;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paci</surname><given-names>P.</given-names></name><name name-style="western"><surname>Capuani</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Gut Microbiota Profiling of Pediatric Nonalcoholic Fatty Liver Disease and Obese Patients Unveiled by an Integrated Meta-Omics-Based Approach</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/hep.28572</pub-id><pub-id pub-id-type="pmid">27028797</pub-id></element-citation></ref><ref id="B211-nutrients-15-01990"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group><article-title>Microbial Ecology: Human Gut Microbes Associated with Obesity</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>1022</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1038/4441022a</pub-id><pub-id pub-id-type="pmid">17183309</pub-id></element-citation></ref><ref id="B212-nutrients-15-01990"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seguritan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Long</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klitgord</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dulai</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Caussy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Highlander</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Gut Microbiome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease</article-title><source>Cell Metab.</source><year>2017</year><volume>25</volume><fpage>1054</fpage><lpage>1062.e5</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.04.001</pub-id><pub-id pub-id-type="pmid">28467925</pub-id><pub-id pub-id-type="pmcid">PMC5502730</pub-id></element-citation></ref><ref id="B213-nutrients-15-01990"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aron-Wisnewsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vigliotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Witjes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le</surname><given-names>P.</given-names></name><name name-style="western"><surname>Holleboom</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Verheij</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nieuwdorp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cl&#233;ment</surname><given-names>K.</given-names></name></person-group><article-title>Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year><volume>17</volume><fpage>279</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-0269-9</pub-id><pub-id pub-id-type="pmid">32152478</pub-id></element-citation></ref><ref id="B214-nutrients-15-01990"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svegliati-Baroni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Patr&#237;cio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lioci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Gastaldelli</surname><given-names>A.</given-names></name></person-group><article-title>Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>5820</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21165820</pub-id><pub-id pub-id-type="pmid">32823659</pub-id><pub-id pub-id-type="pmcid">PMC7461212</pub-id></element-citation></ref><ref id="B215-nutrients-15-01990"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Montes de Oca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Juli&#225;n</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puig-Domingo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>N.</given-names></name></person-group><article-title>Microbiota, Fiber, and NAFLD: Is There Any Connection?</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>3100</elocation-id><pub-id pub-id-type="doi">10.3390/nu12103100</pub-id><pub-id pub-id-type="pmid">33053631</pub-id><pub-id pub-id-type="pmcid">PMC7600472</pub-id></element-citation></ref><ref id="B216-nutrients-15-01990"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dillon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.C.</given-names></name></person-group><article-title>The Gut Microbiome and HIV-1 Pathogenesis: A Two-Way Street</article-title><source>AIDS</source><year>2016</year><volume>30</volume><fpage>2737</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001289</pub-id><pub-id pub-id-type="pmid">27755100</pub-id><pub-id pub-id-type="pmcid">PMC5101180</pub-id></element-citation></ref><ref id="B217-nutrients-15-01990"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesterbacka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noyan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neogi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Calle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>R.</given-names></name><name name-style="western"><surname>S&#246;nnerborg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Noguera-Julian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>P.</given-names></name></person-group><article-title>Richer Gut Microbiota with Distinct Metabolic Profile in HIV Infected Elite Controllers</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>6269</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-06675-1</pub-id><pub-id pub-id-type="pmid">28740260</pub-id><pub-id pub-id-type="pmcid">PMC5524949</pub-id></element-citation></ref><ref id="B218-nutrients-15-01990"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourgi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wanjalla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koethe</surname><given-names>J.R.</given-names></name></person-group><article-title>Inflammation and Metabolic Complications in HIV</article-title><source>Curr. HIV/AIDS Rep.</source><year>2018</year><volume>15</volume><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1007/s11904-018-0411-2</pub-id><pub-id pub-id-type="pmid">30058057</pub-id></element-citation></ref><ref id="B219-nutrients-15-01990"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Troseid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avershina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barqasho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Neogi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hov</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Noyan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vesterbacka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sv&#228;rd</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Gut Microbiota Diversity Predicts Immune Status in HIV-1 Infection</article-title><source>AIDS</source><year>2015</year><volume>29</volume><fpage>2409</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000869</pub-id><pub-id pub-id-type="pmid">26355675</pub-id></element-citation></ref><ref id="B220-nutrients-15-01990"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubourg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Surenaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#233;vy</surname><given-names>Y.</given-names></name><name name-style="western"><surname>H&#252;e</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Microbiome of HIV-Infected People</article-title><source>Microb. Pathog.</source><year>2017</year><volume>106</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2016.05.015</pub-id><pub-id pub-id-type="pmid">27216237</pub-id></element-citation></ref><ref id="B221-nutrients-15-01990"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lozupone</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Neff</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Fontenot</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>B.E.</given-names></name></person-group><article-title>HIV-Induced Alteration in Gut Microbiota: Driving Factors, Consequences, and Effects of Antiretroviral Therapy</article-title><source>Gut Microbes</source><year>2014</year><volume>5</volume><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.4161/gmic.32132</pub-id><pub-id pub-id-type="pmid">25078714</pub-id></element-citation></ref><ref id="B222-nutrients-15-01990"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az-Delf&#237;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villarroya</surname><given-names>F.</given-names></name></person-group><article-title>Maraviroc Reduces Cytokine Expression and Secretion in Human Adipose Cells without Altering Adipogenic Differentiation</article-title><source>Cytokine</source><year>2013</year><volume>61</volume><fpage>808</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2012.12.013</pub-id><pub-id pub-id-type="pmid">23357304</pub-id></element-citation></ref><ref id="B223-nutrients-15-01990"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Matute</surname><given-names>P.</given-names></name><name name-style="western"><surname>P&#233;rez-Mart&#237;nez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguilera-Lizarraga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Oteo</surname><given-names>J.A.</given-names></name></person-group><article-title>Maraviroc Modifies Gut Microbiota Composition in a Mouse Model of Obesity: A Plausible Therapeutic Option to Prevent Metabolic Disorders in HIV-Infected Patients</article-title><source>Rev. Espa&#241;ola Quimioter.</source><year>2015</year><volume>28</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">26200028</pub-id></element-citation></ref><ref id="B224-nutrients-15-01990"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanavich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perazzo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zabih</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>C.</given-names></name><name name-style="western"><surname>Veloso</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A Pilot Study of Microbial Signatures of Liver Disease in Those with HIV Mono-Infection in Rio de Janeiro, Brazil</article-title><source>AIDS</source><year>2022</year><volume>36</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003084</pub-id><pub-id pub-id-type="pmid">34873092</pub-id><pub-id pub-id-type="pmcid">PMC8667204</pub-id></element-citation></ref><ref id="B225-nutrients-15-01990"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Scurlock</surname><given-names>B.</given-names></name><name name-style="western"><surname>Acosta-Martinez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lyte</surname><given-names>M.</given-names></name></person-group><article-title>Memory and Learning Behavior in Mice Is Temporally Associated with Diet-Induced Alterations in Gut Bacteria</article-title><source>Physiol. Behav.</source><year>2009</year><volume>96</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2008.12.004</pub-id><pub-id pub-id-type="pmid">19135464</pub-id></element-citation></ref><ref id="B226-nutrients-15-01990"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Filippo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cavalieri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Paola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramazzotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poullet</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Massart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Collini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pieraccini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lionetti</surname><given-names>P.</given-names></name></person-group><article-title>Impact of Diet in Shaping Gut Microbiota Revealed by a Comparative Study in Children from Europe and Rural Africa</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>14691</fpage><lpage>14696</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005963107</pub-id><pub-id pub-id-type="pmid">20679230</pub-id><pub-id pub-id-type="pmcid">PMC2930426</pub-id></element-citation></ref><ref id="B227-nutrients-15-01990"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bittinger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Keilbaugh</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bewtra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knights</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1126/science.1208344</pub-id><pub-id pub-id-type="pmid">21885731</pub-id><pub-id pub-id-type="pmcid">PMC3368382</pub-id></element-citation></ref><ref id="B228-nutrients-15-01990"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinninella</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cintoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raoul</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lopetuso</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Scaldaferri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pulcini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miggiano</surname><given-names>G.A.D.</given-names></name><name name-style="western"><surname>Gasbarrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mele</surname><given-names>M.C.</given-names></name></person-group><article-title>Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>2393</elocation-id><pub-id pub-id-type="doi">10.3390/nu11102393</pub-id><pub-id pub-id-type="pmid">31591348</pub-id><pub-id pub-id-type="pmcid">PMC6835969</pub-id></element-citation></ref><ref id="B229-nutrients-15-01990"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Garvey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsochatzis</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Wiltshire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guppy</surname><given-names>N.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Monocyte-Macrophage Activation Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in HIV Monoinfection Independently of the Gut Microbiome and Bacterial Translocation</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>805</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002133</pub-id><pub-id pub-id-type="pmid">30882489</pub-id></element-citation></ref><ref id="B230-nutrients-15-01990"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angeli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Francoz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mookerjee</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Trebicka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krag</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laleman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gines</surname><given-names>P.</given-names></name></person-group><article-title>EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis</article-title><source>J. Hepatol.</source><year>2018</year><volume>69</volume><fpage>406</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.024</pub-id><pub-id pub-id-type="pmid">29653741</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nutrients-15-01990-f001" orientation="portrait"><label>Figure 1</label><caption><p>The role of nutrients in NAFLD in people with HIV. Among people with HIV, nutrition has a key impact in both NAFLD onset and regression. An unhealthy diet, rich in refined carbohydrates, fructose and sugar-added beverages, saturated FAs, and red and processed meat, along with alcohol abuse, are associated with fatty liver. Conversely, a healthy diet, with high intake of fruits, vegetables, whole grains, which are good sources of fibers, unsaturated FAs, white meat, dark chocolate, and coffee shows a beneficial effect on NAFLD. <italic toggle="yes">Abbreviations</italic>: NAFLD; non-alcoholic fatty liver disease; and FAs, fatty acids.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01990-g001.jpg"/></fig><fig position="float" id="nutrients-15-01990-f002" orientation="portrait"><label>Figure 2</label><caption><p><bold>Lifestyle treatment of NAFLD in people with HIV.</bold> The goal of lifestyle treatment for NAFLD in PWH is weight loss, with a target of 7&#8211;10% in overweight/obese patients and 3&#8211;5% in lean individuals. Weight loss can be achieved through a patient-tailored approach, consisting of diet, physical activity, or, preferably, a combination of them. Calorie restriction diets such as Mediterranean diet, low-carbohydrate diets, low-fat diets, and intermittent fasting are recommended. Regarding physical activity, patients are advised to engage in at least 150 min of exercise (aerobic or resistance) per week, with possibly a minimum of 3&#8211;5 training sessions. <italic toggle="yes">Abbreviations</italic>: NAFLD, non-alcoholic fatty liver disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01990-g002.jpg"/></fig><table-wrap position="float" id="nutrients-15-01990-t001" orientation="portrait"><object-id pub-id-type="pii">nutrients-15-01990-t001_Table 1</object-id><label>Table 1</label><caption><p>Studies evaluating the role of macronutrients in hepatic steatosis and/or liver fibrosis in people with HIV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year, Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nutrients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Cohort</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients&#8217; Characteristics (Sex, Age, BMI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HIV Features (Duration of HIV Infection, cART, Viral Suppression)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic Method for NAFLD/<break/>NASH/Liver Fibrosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arendt et al., 2011, Canada [<xref rid="B81-nutrients-15-01990" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acids</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 participants:<list list-type="simple"><list-item><label>-</label><p>20 HIV-positive patients with NAFLD (<italic toggle="yes">HIV/NAFLD</italic>)</p></list-item><list-item><label>-</label><p>21 HIV-negative patients with NAFLD (<italic toggle="yes">NAFLD</italic>)</p></list-item><list-item><label>-</label><p>7 healthy controls</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic>: M 100%, age 44.5 (31&#8211;70) years, BMI 25.7 (20.8&#8211;31.6) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">NAFLD</italic>: M 100%, age 41 (18&#8211;69) years, BMI 29.1 (21.3&#8211;41)</p></list-item><list-item><label>-</label><p><italic toggle="yes">Controls</italic>: M 100%, age 47 (40&#8211;64) years, BMI 28.2 (25&#8211;30.5) kg/m<sup>2</sup></p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">HIV/NAFLD</italic>: 95% on cART,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: liver biopsy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic> had altered hepatic FAs composition, with higher <italic toggle="yes">n</italic>-6 polyunsaturated FAs and <italic toggle="yes">n</italic>-6/<italic toggle="yes">n</italic>-3 ratio vs. <italic toggle="yes">NAFLD</italic> and controls</p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic> had lower dietary intake of <italic toggle="yes">n</italic>-3 polyunsaturated FAs vs. controls</p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic> had lower indirect markers of enzymatic FAs desaturation and elongation vs. controls</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mart&#237;nez-Sanz et al., 2022, Spain [<xref rid="B82-nutrients-15-01990" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acids</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53 participants:<list list-type="simple"><list-item><label>-</label><p>31 HIV-positive patients with NAFLD (<italic toggle="yes">HIV/NAFLD</italic>)</p></list-item><list-item><label>-</label><p>22 HIV-negative patients with NAFLD (<italic toggle="yes">NAFLD</italic>)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic>: M 87%, age 56 (46&#8211;61) years, BMI 27 (25&#8211;28) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">NAFLD</italic>: M 40%, age 60 (58&#8211;71) years, BMI 33 (31&#8211;36) kg/m<sup>2</sup></p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">HIV/NAFLD</italic>: 100% on cART, 100% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: Abdominal Ultrasound</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>No difference in overall FAs composition between <italic toggle="yes">HIV/NAFLD</italic> and <italic toggle="yes">NAFLD</italic>.</p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic> had higher concentrations of &#945;-Linolenic, trans-palmitoleic, and behenic acids vs. <italic toggle="yes">NAFLD</italic></p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/NAFLD</italic> had lower activity of the elongases ELOVL1 and ELOVL6 vs. <italic toggle="yes">NAFLD</italic></p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Almeida et al., 2021, Brazil [<xref rid="B83-nutrients-15-01990" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acids, Carbohydrates, Fibers </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">451 PWH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 40%, age 45 (IQR 36&#8211;53) years, BMI 25 (23&#8211;29) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 10 (5&#8211;17) years, 97% on cART, 84% with viral suppression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>HS: CAP</p></list-item><list-item><label>-</label><p>Liver fibrosis: LSM by TE</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High FAs intake was associated with 91% higher odds of NAFLD</p></list-item><list-item><label>-</label><p>Moderate monounsaturated FAs intake was associated with lower odds of NAFLD and liver fibrosis</p></list-item><list-item><label>-</label><p>Moderate intake of saturated FAs was associated with lower odds of liver fibrosis</p></list-item><list-item><label>-</label><p>Moderate n-6 polyunsaturated FAs intake was associated with lower odds of NAFLD but higher odds of liver fibrosis</p></list-item><list-item><label>-</label><p>High total carbohydrates intake was associated with lower odds of NAFLD</p></list-item><list-item><label>-</label><p>Moderate fiber intake was associated with lower odds of NAFLD</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kelly et al., 2017, Canada/U.S. [<xref rid="B84-nutrients-15-01990" ref-type="bibr">84</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, median FU 10 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">686 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F 100%, age 39.7 (&#177;6) years, BMI 26.1 (&#177;6), kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29% on cART</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Light (1&#8211;3 drinks/week) or moderate (4&#8211;7 drinks/week) alcohol intake was not associated with liver fibrosis progression</p></list-item><list-item><label>-</label><p>High alcohol intake (&gt;14 drinks/week) was associated with increased rates of fibrosis progression</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kirkegaard-Klitbo et al., 2020, Danmark [<xref rid="B85-nutrients-15-01990" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">453 PWH </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 86%, age 52.4 (46.8&#8211;61.0) years, BMI 24.7 (22.4&#8211;27.5) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 16 (8.3&#8211;23.1) years, 99% on cART, 97% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: computed tomography </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Moderate alcohol intake (&lt;14 alcoholic units/week for men and &lt;7 alcoholic units/week for women) and beer consumption were associated with lower odds of moderate-to-severe HS</p></list-item><list-item><label>-</label><p>No association between wine, liquor, sugar-sweetened beverages, coffee, fast food, type of meat product, and moderate-to-severe HS</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carrieri et al., 2014, France [<xref rid="B86-nutrients-15-01990" ref-type="bibr">86</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, median FU 3.3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee, chocolate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">990 HIV/HCV coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 70%, age 45 (42&#8211;48) years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91% on cART, 71% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High coffee (&gt;3 cups/day) and chocolate intake were associated with lower transaminases levels</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carrieri et al., 2017, France [<xref rid="B87-nutrients-15-01990" ref-type="bibr">87</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, median FU 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1028 HIV/HCV coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 70%, age 49 (46&#8211;52) years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.5% on ART, 82.5% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High coffee intake (&gt;3 cups/day) was associated with a 50% reduction in all-cause mortality risk</p></list-item><list-item><label>-</label><p>High coffee intake was associated with lower prevalence of advanced liver fibrosis</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carrieri et al., 2018, France [<xref rid="B88-nutrients-15-01990" ref-type="bibr">88</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">918 HIV/HCV coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: N/A Liver fibrosis: LSM by TE and FIB-4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Higher coffee intake was associated with lower liver fibrosis, with an inverse dose&#8211;response relationship</p></list-item><list-item><label>-</label><p>No association between coffee intake and HS</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yaya et al., 2018, France [<xref rid="B89-nutrients-15-01990" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1019 HIV/HCV coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 70%, age 47.8 (&#177;6.4) years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% on cART</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High coffee intake (&gt;3 cups/day) was associated with lower odds of advanced liver fibrosis</p></list-item><list-item><label>-</label><p>High coffee intake mitigated harmful effects of alcohol consumption on liver fibrosis</p></list-item><list-item><label>-</label><p>Among patients with low-risk alcohol consumption, high coffee intake was associated with lower prevalence of advanced liver fibrosis compared to low coffee intake</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Legend</bold>: Continuous variables are expressed as mean + standard deviation or median (interquartile range or range) and categorical variables are presented as percentages. Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; cART, combined antiretroviral therapy; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PWH, people with HIV; M, males; F, females; FAs, fatty acids; FU, follow-up; HS, hepatic steatosis; CAP, Controlled Attenuation Parameter; N/A, not assessed; LSM, liver stiffness measurement; TE, transient elastography; and FIB-4, Fibrosis-4.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="nutrients-15-01990-t002" orientation="portrait"><object-id pub-id-type="pii">nutrients-15-01990-t002_Table 2</object-id><label>Table 2</label><caption><p>Studies evaluating the role of micronutrients in hepatic steatosis and/or liver fibrosis in people with HIV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year, Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nutrients of Interest</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Cohort</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients&#8217; Characteristics (Sex, Age, BMI) </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HIV Features <break/> (Duration of HIV Infection, cART, Viral Suppression)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic <break/> Method for NAFLD/<break/>NASH/Liver Fibrosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sebastiani et al., 2020, Canada [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-center, open-label, single-arm, clinical trial, FU 4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin E </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 PWH with NASH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 81%, age 54 (51&#8211;59) years, BMI 28 (25&#8211;32) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 23 (15&#8211;29) years, 100% on cART, 100% with viral suppression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>NASH: CAP + cytokeratin 18 (100% of the cohort); liver biopsy (15% of the cohort)</p></list-item><list-item><label>-</label><p>Liver fibrosis: LSM by TE</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>24 months of vitamin E treatment improved liver inflammation, HS, and hepatocyte apoptosis</p></list-item><list-item><label>-</label><p>Good safety profile of vitamin E (800 IU/day for 24 months)</p></list-item><list-item><label>-</label><p>No improvement in BMI or liver fibrosis with vitamin E treatment</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guzman-Fulgencio et al., 2013, Spain [<xref rid="B106-nutrients-15-01990" ref-type="bibr">106</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">174 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 75%, age 40.8 (37.3; 44.6) years, </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86% on cART, 71% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: liver biopsy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High prevalence of vitamin D insufficiency and deficiency (75.3% and 15.5%, respectively)</p></list-item><list-item><label>-</label><p>Vitamin D deficiency was independently associated with liver fibrosis severity</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terrier et al., 2011, France [<xref rid="B107-nutrients-15-01990" ref-type="bibr">107</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">189 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 77%, Age 39.5 (&#177;4.8) years, BMI 22.7 (&#177;3.2) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 12 (0.5&#8211;18.5) years, 82% on cART, 70% with &lt;400 HIV-RNA copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: liver biopsy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High prevalence of vitamin D insufficiency and deficiency (63% and 23%, respectively)</p></list-item><list-item><label>-</label><p>Vitamin D deficiency was independently associated with liver fibrosis severity</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Milazzo et al., 2011, Italy [<xref rid="B108-nutrients-15-01990" ref-type="bibr">108</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237 patients<list list-type="simple"><list-item><label>-</label><p>144 HIV monoinfected (<italic toggle="yes">HIV</italic>)</p></list-item><list-item><label>-</label><p>93 HIV/HCV-coinfected (<italic toggle="yes">HIV</italic>/<italic toggle="yes">HCV</italic>)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">HIV</italic>: M 65%, age 44 (39&#8211;50) years, BMI 23.8 (21.5&#8211;26.2) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/HCV</italic>: M 74%, age 45 (43&#8211;48) years, BMI 23.27 (20.7&#8211;25.27) kg/m<sup>2</sup></p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">HIV</italic>: Duration HIV 11.5 (6&#8211;15) years</p></list-item><list-item><label>-</label><p><italic toggle="yes">HIV/HCV</italic>: Duration HIV 18 (13&#8211;22) years</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4, liver biopsy (20% of the cohort)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Vitamin D deficiency was low in <italic toggle="yes">HIV</italic> and <italic toggle="yes">HIV/HCV</italic> (7.46% and 4.3%, respectively)</p></list-item><list-item><label>-</label><p>Vitamin D insufficiency was high in <italic toggle="yes">HIV</italic> and <italic toggle="yes">HIV/HCV</italic> (63.8% and 59%, respectively)</p></list-item><list-item><label>-</label><p>In <italic toggle="yes">HIV/HCV,</italic> vitamin D deficiency was independently associated with advanced liver fibrosis</p></list-item><list-item><label>-</label><p>Vitamin D deficiency was not associated with HCV coinfection or cART</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mandorfer et al., 2015, [<xref rid="B109-nutrients-15-01990" ref-type="bibr">109</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 71%, age 38.7 (+9.6) years, BMI 23.2 (+4) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71% on cART</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: liver biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D deficiency was independently associated with liver fibrosis progression and higher portal pressure
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">El-Maouche et al., 2013 U.S. [<xref rid="B110-nutrients-15-01990" ref-type="bibr">110</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 63%, age 49.9 (46.5&#8211;53.3) years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64% on cART, 79% with &lt;400 HIV-RNA copies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: liver biopsy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>High prevalence of vitamin D deficiency (41%)</p></list-item><list-item><label>-</label><p>Vitamin D deficiency was not associated with liver fibrosis severity or low bone mineral density</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Milic et al., 2020, Italy [<xref rid="B111-nutrients-15-01990" ref-type="bibr">111</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">707 PWH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 76%, age 53.5 (&#177;8.2) years, BMI 24.6 (&#177;4.2) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% on cART, 99% with viral suppression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>HS: CAP</p></list-item><list-item><label>-</label><p>Liver fibrosis: LSM by TE</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D deficiency was associated with NAFLD with liver fibrosis
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nordmann et al., 2018, France [<xref rid="B112-nutrients-15-01990" ref-type="bibr">112</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">838 HIV/HCV-coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 70%, age 44.9 (44.5&#8211;45.4) years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92% on cART, 84% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: abdominal ultrasound</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daily cannabis use was independently associated with lower prevalence of HS
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Barr&#233; et al., 2021, France [<xref rid="B113-nutrients-15-01990" ref-type="bibr">113</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, FU 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">997 HIV/HCV-coinfected patients (ANRS CO13 HEPAVIH cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS: fatty liver index</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regular cannabis use was associated with a 55% lower risk of elevated fatty liver index
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fuster et al., 2021, Russia [<xref rid="B114-nutrients-15-01990" ref-type="bibr">114</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">248 PWH with high prevalence of alcohol abuse (93%) and HCV coinfection (88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 73%, age 33 (30&#8211;37) years, BMI 22.5 (20.8&#8211;24.5) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4, APRI, LSM by TE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabis use was not associated with advanced liver fibrosis
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kelly et al., 2016, USA [<xref rid="B115-nutrients-15-01990" ref-type="bibr">115</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, FU 11 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">575 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Entry visit</italic>: F 100%, age 40 (&#177;6) years, BMI 26 (&#177;6) kg/m<sup>2</sup><italic toggle="yes">Last visit</italic>: F 100%, age 51 (&#177;7) years, BMI 26 (&#177;7) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Entry visit</italic>: 6% on cART, 7% with viral suppression <break/><italic toggle="yes">Last visit</italic>: 63% on cART, 33% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis: FIB-4, APRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabis use was not associated with progression to significant liver fibrosis
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brunet et al., 2014, Canada [<xref rid="B116-nutrients-15-01990" ref-type="bibr">116</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, FU 2.7 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">690 HIV/HCV-coinfected patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 73%, age 43.9 (38.4&#8211;49.2) years, BMI 24.0 (21.2&#8211;26.8) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 18.0 (10.4&#8211;24.5) years, 54% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver fibrosis and cirrhosis: APRI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabis use was not associated with liver fibrosis progression or cirrhosis
</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Legend:</bold> Continuous variables are expressed as mean + standard deviation or median (interquartile range or range) and categorical variables are presented as percentages. Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; cART, combined antiretroviral therapy; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; FU, follow-up; PWH, people with HIV; M, males; CAP, Controlled Attenuation Parameter; HS, hepatic steatosis; ALT, alanine transaminase; FIB-4, Fibrosis-4; LSM, liver stiffness measurement; TE, transient elastography; and APRI, AST to Platelet Ratio Index.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="nutrients-15-01990-t003" orientation="portrait"><object-id pub-id-type="pii">nutrients-15-01990-t003_Table 3</object-id><label>Table 3</label><caption><p>Studies evaluating the role of lifestyle intervention in weight loss in hepatic steatosis in people with HIV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year, Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lifestyle Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Cohort</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients&#8217; Characteristics (Sex, Age, BMI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HIV Features <break/> (Duration of HIV Infection, cART, Viral Suppression)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic <break/> Method for NAFLD/<break/>NASH</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sebastiani et al., 2020, Canada [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24-week single-center, open-label, single-arm, clinical trial; FU 4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At baseline standardized dietary and physical activity recommendations plus a nutritional consultation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 PWH with NASH receiving vitamin E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M 81%, age 54 (51&#8211;59) years, BMI 28 (25&#8211;32) kg/m<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration HIV 23 (15&#8211;29) years, 100% on cART, 100% with viral suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NASH: CAP + cytokeratin 18 (100% of the cohort); liver biopsy (15% of the cohort)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard lifestyle recommendations with nutritional consultations were not associated to BMI changes, after 48 months of follow-up</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stanley et al., 2019, USA [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week, randomized, double-blind, multicenter trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nutritional counselling from clinical research nutritionists at baseline, 6 months, and 12 months</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61 PWH with NAFLD:<list list-type="simple"><list-item><label>-</label><p>Tesamorelin (n = 30)</p></list-item><list-item><label>-</label><p><italic toggle="yes">Placebo</italic> (n = 30) *</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Tesamorelin</italic>: M 77%, age 52 (&#177;8) years, BMI 30 (&#177;6) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">Placebo</italic>: M 80%, age 54 (&#177;7), BMI 33 (&#177;6) kg/m<sup>2</sup></p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Tesamorelin</italic>: duration HIV 16 (&#177;9), 100% on cART, 100% with viral suppression</p></list-item><list-item><label>-</label><p><italic toggle="yes">Placebo</italic>: duration HIV 18 (&#177;8), 100% on cART, 100% with viral suppression</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAFLD by HFF &#8805; 5% with MRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nutritional counselling was not associated with significant weight loss, waist circumference reduction, changes in daily caloric, macronutrient, and alcohol intake or hours of physical activity, after 48 months of follow-up</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Policarpo et al., 2021, Portugal [<xref rid="B180-nutrients-15-01990" ref-type="bibr">180</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-center, randomized control trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detailed tailored nutritional plan based on MD with a caloric deficit of 500 kcal driven by the nutritionist, plus exercise training counselling </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 PWH with NAFLD<list list-type="simple"><list-item><label>-</label><p>Standard of care (n = 28)</p></list-item><list-item><label>-</label><p>Lifestyle intervention (n = 27)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Standard of Care</italic>: M 71%, age 55.9 (&#177;11.7) years, BMI 28.1 (&#177;4.0) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">Lifestyle intervention</italic>: M 74%, age 52.6 (&#177;9.9) years, BMI 27.7 (&#177;4.9) kg/m<sup>2</sup></p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Standard of Care</italic>: Duration HIV 17.2 (&#177;7.1) years</p></list-item><list-item><label>-</label><p><italic toggle="yes">Lifestyle intervention</italic>: Duration HIV 18.4 (&#177;8.1) years</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAFLD by abdominal ultrasound</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Lifestyle intervention was significantly associated with weight loss compared to standard of care (&#8722;1.5 kg vs. +0.65 kg, <italic toggle="yes">p</italic> &lt; 0.001), after 5 months of follow-up</p></list-item><list-item><label>-</label><p>Lifestyle intervention with telemedicine follow-up mitigated the negative effects of lockdown on weight gain</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yarasheski et al., 2011, USA [<xref rid="B185-nutrients-15-01990" ref-type="bibr">185</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-center, randomized control trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exercise training program based on 1.5&#8211;2 h/day, 3 days/week, of supervised, progressive, combined aerobic conditioning and resistance training driven by a certified exercise trainer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39 PWH with insulin resistance and central adiposity:<list list-type="simple"><list-item><label>-</label><p>Pioglitazone (n = 20)</p></list-item><list-item><label>-</label><p>Pioglitazone + exercise training (n = 19)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Pioglitazone</italic>: M 85%, age 44 (&#177;2), BMI 29.1 (&#177;1.2) kg/m<sup>2</sup></p></list-item><list-item><label>-</label><p><italic toggle="yes">Pioglitazone + exercise training</italic>: M 89%, age 46 (&#177;2), BMI 28.3 (&#177;1.2) kg/m<sup>2</sup></p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p><italic toggle="yes">Pioglitazone</italic>: duration HIV 11 (&#177;1), 100% with viral suppression</p></list-item><list-item><label>-</label><p><italic toggle="yes">Pioglitazone + exercise training</italic>: duration HIV 13 (&#177;1), 95% with viral suppression</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HS by <sup>1</sup>H-MRS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Structured exercise training improved the beneficial effects of pioglitazone on peripheral insulin sensitivity</p></list-item><list-item><label>-</label><p>Pioglitazone plus exercise reduced liver lipid content more than pioglitazone alone (&#8722;2.6 &#177; 1.4% vs. &#8722;1.5 &#177; 1.3, <italic toggle="yes">p</italic> = 0.6)</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p>* One patient withdrew consent <bold>Abbreviations</bold>: HIV, human immunodeficiency virus; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; FU, follow-up; PWH, people with HIV; CAP, Controlled Attenuation Parameter; HFF, hepatic fat fraction; MRS, magnetic resonance spectroscopy; HS, hepatic steatosis; <sup>1</sup>H-MRS, proton magnetic resonance spectroscopy; and MD, Mediterranean diet.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="nutrients-15-01990-t004" orientation="portrait"><object-id pub-id-type="pii">nutrients-15-01990-t004_Table 4</object-id><label>Table 4</label><caption><p>Clinical trials evaluating the pharmacological treatment of NAFLD/NASH in people with HIV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year, Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic Method for NAFLD/NASH/Liver Fibrosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sebastiani et al., 2020, Canada [<xref rid="B105-nutrients-15-01990" ref-type="bibr">105</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24-week, single-center, open-label, single-arm trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 PWH with NASH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>NASH by CAP &#8805; 248 dB/m and cytokeratin 18 &gt; 130.5 U/L</p></list-item><list-item><label>-</label><p>Liver fibrosis by LSM at TE</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24-week vitamin E treatment decreased liver inflammation (with ALT &#8722;27 units/L), steatosis (with CAP &#8722;22 dB/m), and hepatocyte apoptosis (with cytokeratin 18&#8211;123 units/L)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matthews et al., 2015, U.S. [<xref rid="B186-nutrients-15-01990" ref-type="bibr">186</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week, randomized, double-blind, placebo-controlled trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pioglitazone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 HIV/HCV-coinfected patients with NAFLD:<list list-type="simple"><list-item><label>-</label><p>Pioglitazone (n = 6)</p></list-item><list-item><label>-</label><p>Placebo (n = 7)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAFLD by HFF &#8805; 5% with MRS </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week pioglitazone treatment significantly decreased hepatic fat from baseline (15.1% &#177; 7.0%) to week 48 (7.6% &#177; 3.9%), with a mean difference of &#8722;7.4% (<italic toggle="yes">p</italic> = 0.02), whereas placebo administration did not change hepatic fat content</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kamolvisit et al., 2021, Thailand [<xref rid="B187-nutrients-15-01990" ref-type="bibr">187</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week, randomized, placebo-controlled trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pioglitazone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98 PWH with prediabetes and MAFLD:<list list-type="simple"><list-item><label>-</label><p>Pioglitazone (n = 49)</p></list-item><list-item><label>-</label><p>Placebo (n = 49)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>MAFLD by CAP &#8805; 238 dB/m or by abdominal ultrasound</p></list-item><list-item><label>-</label><p>Liver fibrosis by LSM at TE</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week pioglitazone treatment decreased HS and liver fibrosis, with a significantly higher change in CAP and LSM compared to placebo (&#8722;23.5 dB/m vs. 10.2 dB/m, <italic toggle="yes">p</italic> &lt; 0.001 and &#8722;0.184 kPa vs. 0.554 kPa, <italic toggle="yes">p</italic> = 0.0016, respectively)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ajmera et al., 2019, U.S. [<xref rid="B188-nutrients-15-01990" ref-type="bibr">188</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12-week, double-blind, randomized, investigator-initiated, placebo-controlled trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aramchol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 PWH with NAFLD:<list list-type="simple"><list-item><label>-</label><p>Aramchol (n = 25)</p></list-item><list-item><label>-</label><p>Placebo (n = 25)</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>NAFLD by MRI- PDFF &#8805; 5%</p></list-item><list-item><label>-</label><p>Liver fibrosis by MRE and VCTE</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12-week Aramchol treatment did not reduce HS and liver fibrosis or change body fat and muscle composition</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stanley et al., 2019, U.S. [<xref rid="B178-nutrients-15-01990" ref-type="bibr">178</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week, randomized, double-blind, multicenter trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tesamorelin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61 PWH with NAFLD:<list list-type="simple"><list-item><label>-</label><p>Tesamorelin (n = 30)</p></list-item><list-item><label>-</label><p>Placebo (n = 30) *</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>NAFLD by HFF &gt; 5% with MRS</p></list-item><list-item><label>-</label><p>Liver fibrosis and NASH by liver biopsy</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week tesamorelin treatment reduced hepatic fat content by 37% and prevented progression of liver fibrosis, with a significantly lower rate of liver fibrosis progression in the tesamorelin group compared to placebo (10.5% vs. 37.5%, <italic toggle="yes">p</italic> = 0.04)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MASH study, 2020, UK [<xref rid="B189-nutrients-15-01990" ref-type="bibr">189</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week, multicenter, open-label, single-arm trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maraviroc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 PWH with NASH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NASH and liver fibrosis by liver biopsy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48-week maraviroc treatment did not change HS, liver fibrosis, or NASH features</td></tr></tbody></table><table-wrap-foot><fn><p>* 1 patient withdrew consent. <bold>Abbreviations</bold>: HIV, human immunodeficiency virus; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PWH, people with HIV; CAP, Controlled Attenuation Parameter; LSM, liver stiffness measurements; TE, transient elastography; ALT, alanine transaminase; U.S., United States; HS, hepatic steatosis; HFF, hepatic fat fraction; MRS, magnetic resonance spectroscopy; MAFLD, metabolic (dysfunction)-associated fatty liver disease; MRI-PDFF, magnetic resonance imaging-proton density fat fraction; MRE, magnetic resonance elastography; VCTE, vibration-controlled transient elastography; MASH, maraviroc add-on for steatohepatitis in HIV-infected patients; and UK, United Kingdom.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>